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Chapter 1
Introduction to the thesis
10 Chapter 1
The approval of imatinib mesylate (Gleevec™) in 2001 has added a new class of drugs to 
the systemic treatment of cancer: that of the tyrosine kinase inhibitors (TKIs). Imatinib 
inhibits autophosphorylation of specific proteins involved in oncogenesis such as the 
BCR-ABL fusion protein (expressed in Philadelphia chromosome positive chronic myeloid 
leukemia), c-KIT (expressed in gastrointestinal stromal tumors; GIST) and the platelet-
derived growth factor receptor (PDGFR; i.e. expressed in GIST and several sarcomas).1 
After a decade of therapeutic use, imatinib has proven to be a highly effective targeted 
agent with a median overall survival in advanced GIST patients close to 5 years.2 
Sunitinib malate (Sutent™) was developed in imatinib’s foot steps and in 2006 it be-
came the first anticancer drug that was simultaneously approved for two indications: as 
first-line treatment of locally advanced or metastatic renal cell carcinoma (mRCC) and as 
second-line therapy for GIST after disease progression or intolerance to imatinib ther-
apy.3 Recently, it was also registered for the treatment of advanced well-differentiated 
pancreatic neuroendocrine tumors, based on its proven efficacy.4 
Sunitinib is a multi-targeted TKI with inhibitory effects on drug targets such as KIT 
and PDGFR, FMS-like tyrosine kinase 3 (FLT3; i.e. expressed in acute myeloid leukemia), 
RET (expressed in thyroid cancer) but also vascular endothelial growth factor receptor 
(VEGFR).5 Activation of VEGFR will induce blood vessel growth in normal as well as in 
tumor tissue; a process called angiogenesis.6,7 With a median overall survival of ap-
proximately 2 years, sunitinib-induced antiangiogenesis has proven to be an effective 
treatment modality in advanced mRCC patients.8  
Both imatinib and sunitinib are orally administered drugs and show a large inter-
individual variability in systemic exposure.3,9 As clinical outcome may be correlated to 
exposure,10,11 the elucidation of mechanisms underlying this pharmacokinetic variation 
may be of utmost clinical importance to the individual patient. Imatinib and sunitinib 
are extensively metabolized in the liver, mainly by cytochrome P450 enzyme isoform 
3A4 (CYP3A4), to their active metabolites; CGP74588 and SU12662, respectively.12,13 
Biliary excretion accounts for the major part of imatinib and sunitinib clearance, with 
60 – 70 % of the dose recovered in faeces.12,14 Imatinib is a good substrate of several 
drug uptake and efflux transporters, making it a possible candidate for facilitated or 
active drug transport during absorption, distribution and elimination phases (Chapter 
2). On the other hand, data on the effects of drug transporters on sunitinib exposure are 
limited.15-18 
In the context of potential therapeutic relevance of imatinib plasma concentrations, 
it was the aim of the first part of this thesis to extensively analyse imatinib pharmacoki-
netics over time, and assess the possible contributing factors to the observed systemic 
exposure. Therefore, we analysed imatinib plasma concentrations in a long-term popu-
lation pharmacokinetic study (Chapter 3) and evaluated the biliary secretion of imatinib 
during severe hepatic dysfunction (Chapter 5). In addition, in an in vitro and clinical set-
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ting, we studied the role of an intestinally located solute carrier in imatinib transport and 
absorption (Chapter 4), in order to translate preclinical findings into clinical practice. 
In the second part of the thesis, the clinical relevance of genetic variation in pharmaco-
kinetic and pharmacodynamic pathways in sunitinib-treated patients was assessed. We 
therefore investigated single nucleotide polymorphisms in candidate genes involved 
in sunitinib exposure and therapeutic activity and assessed their association with drug 
related toxicities (Chapter 6 and 8) and survival (Chapter 7). 
Finally, we investigated the suppression of allergic rhinitis symptoms in sunitinib-
treated patients (Chapter 9), as this is a side-effect of sunitinib therapy that may hold 
therapeutic potential in inflammatory disorders like hay fever or asthma. 
In conclusion, this thesis entitled “Towards a pharmacologically guided individualiza-
tion of imatinib and sunitinib therapy” explores the pharmacokinetic, pharmacodynamic 
and pharmacogenetic factors that may clarify variability in outcome and toxicity in 
patients treated with either imatinib or sunitinib. The ultimate goal of these studies is to 
personalize dosing and treatment sequences of these rationally designed drugs in order 
to match an individual patient’s needs.
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AbSTRACT
Imatinib mesylate is approved for the treatment of chronic myeloid leukemia (CML) and 
advanced gastrointestinal stromal tumors (GIST). Unfortunately, in the course of treat-
ment, disease progression occurs in the majority of patients with GIST. Lowered plasma 
trough levels of imatinib over time potentially cause disease progression, a phenomenon 
known as “acquired pharmacokinetic drug resistance.”This outcome may be the result of 
an altered expression pattern or activity of drug transporters. To date, the role of both 
efflux transporters (ATP-binding cassette transporters, such as ABCB1 and ABCG2) and 
uptake transporters [solute carriers such as organic cation transporter 1 (OCT1) and 
organic anion transporting polypeptide 1A2 (OATP1A2)] in imatinib pharmacokinetics 
and pharmacodynamics has been studied. In vitro experiments show a significant role 
of ABCB1 and ABCG2 in cellular uptake and retention of imatinib, although pharma-
cokinetic and pharmacogenetic data are still scarce and contradictory. ABCB1 and 
ABCC1 expression was shown in GIST, whereas ABCB1, ABCG2, and OCT1 were found 
in mononuclear cells in CML patients. Several studies have reported a clinical relevance 
of tumor expression or activity of OCT1 in CML patients. Further (clinical) studies are re-
quired to quantify drug transporter expression over time in organs involved in imatinib 
metabolism, as well as in tumor tissue. In addition, more pharmacogenetic studies will 
be needed to validate associations.
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InTROduCTIOn
Imatinib mesylate (Gleevec, Novartis International AG) is the first approved rationally 
designed inhibitor of specific protein tyrosine kinases. The drug inhibits ABL and the 
BCR ABL fusion protein [expressed in Philadelphia chromosome–positive chronic 
myeloid leukemia (CML)], c-KIT [expressed in gastrointestinal stromal tumors (GIST)], 
and the platelet-derived growth factor receptor (PDGF-R; i.e., expressed in some sarco-
mas1-4). Imatinib has become the standard treatment for patients with chronic myeloid 
leukemia5,6 and GIST.7-10 Although response rates in imatinib-treated patients are high, 
ranging between 70 to 90% of patients with GIST as well as CML 9,11,12, nonresponse or 
disease progression after a certain period of time may occur. Genetic mutations or gene 
amplification of the drug targets are known mechanisms for this observed (acquired) 
drug resistance.12-15 Accumulating data, however, indicate a contributing role of phar-
macokinetics in imatinib efficacy, as well as for the initial therapeutic response, and for 
the time to progression. Drug uptake and efflux transporters are likely to be involved in 
imatinib absorption, distribution, and excretion, thereby influencing pharmacokinetics. 
Imatinib is almost completely absorbed (>97%)16 and is, then, extensively metabolized 
in the liver with CGP74588 as its most active metabolite, predominantly formed by 
cytochrome P450 isoform 3A4 and 3A5 (CYP3A4, CYP3A5) as shown in Fig. 1.17 This 
Figure 1. Scheme for the involvement of transporters in imatinib pharmacokinetics.   
 
Figure 1. Scheme for the involvement of transporters in imatinib pharmacokinetics
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metabolite is equipotent to its parental compound in vitro. Other cytochrome P450 
isoforms (CYP1A2, CYP2D6, CYP2C8, CYP2C9, and CYP2C19) also play a (minor) role 
in imatinib metabolism.17,18 At clinically relevant concentrations, imatinib is bound to 
plasma proteins, mainly albumin and a1-acid glycoprotein.16,19 Both imatinib and its 
active metabolite are excreted in feces and, to a lesser extent, in urine. Initial drug resis-
tance could be correlated with drug exposure. For instance, imatinib trough levels, the 
lowest drug concentration, right before administration of a new dose, in nonresponding 
patients are significantly lower (see Table 1) than in responding patients.20-22 Moreover, 
imatinib pharmacokinetics may also contribute to acquired drug resistance. This find-
ing was shown in a small-population pharmacokinetics study in patients with GIST.23 
After long-term treatment (>1 year), imatinib clearance increased by 33% and systemic 
exposure decreased by 42%, compared with the start of treatment, possibly suggest-
ing involvement of pharmacokinetics in the development of resistance. This change in 
pharmacokinetics is likely also related to the reduced side effects over time and may also 
explain why dose escalation of imatinib at first progression results in clinical benefit in 
subsets of patients with advanced CML and GIST.24-26 Despite a broad interpatient vari-
ability in imatinib plasma exposure27, more recent data suggest the clinical significance 
of keeping imatinib plasma concentrations within a therapeutic range. That is, in GIST 
and CML, a lower response rate and/or shorter time to progression may occur when 
imatinib plasma levels drop below approximately 1,000 ng/mL.21,28-30 As reported in the 
study with GIST patients, imatinib steady state trough levels were higher than men-
tioned in literature.31 Therefore, an association with clinical benefit may be biased by 
the overestimation of trough levels. Nonetheless, steady state plasma concentrations 
above 1,000 ng/mL are often easily reached with a daily dose of 400 mg imatinib. Yet, in 
a subset of patients, this plasma concentration is not reached with this standard dose. 
Understanding the causes for this variability may be of clinical importance. One of the 
patient factors that is likely to be relevant for the observed differences in imatinib phar-
macokinetics is the possible interpatient variability in drug transporter expression and 
activity. In this review, we give a detailed overview of the potential clinical relevance of 
recently characterized drug transporters for imatinib therapy. 
InTERACTIOn OF IMATInIb wITh dRug TRAnSPORTERS 
Efflux transporters. 
Imatinib is a substrate of ATP-binding cassette (ABC) transporters such as the ABC 
subfamily B member 1 (ABCB1; formerly known as P-glycoprotein or MDR132-38) and 
subfamily G member 2 [ABCG2; formerly known as breast cancer resistance protein 
(BCRP)37,39,40, which are involved in its excretion process. These drug transporters use 
Drug transporters and imatinib treatment 17
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the hydrolysis of ATP and subsequent phosphorylation of the transporter as an energy 
source, enabling active transport of substrates across various biomembranes.41,42 Stud-
ies have reported imatinib as an inhibitor of ABC transporters35,43,44, but there is growing 
consensus that ABC transporter inhibition by imatinib is dose dependent with inhibition 
only occurring at higher imatinib concentrations (Table 2).35,37,38 ABCB1 and ABCG2 are 
expressed in a variety of tissues, including liver (at the sinusoidal basolateral membrane, 
as well as the apical bile canalicular membrane of hepatocytes)1,37,45,46, intestine (at the 
apical membrane; see Fig. 1)45-47, kidney, placenta46,48, and the blood brain barrier.41,49 The 
role of these efflux transporters in acquired drug resistance has been investigated more 
intensively than the role of uptake transporters because of the evident physiologic role 
of efflux transporters as a defense mechanism against penetration of xenobiotics.
Uptake transporters. 
Meanwhile, more than one fourth of the present-day anticancer drugs are oral formula-
tions, stressing the possible relevance of intestinal absorption through uptake trans-
porters expressed on the apical membrane of enterocytes. These solute carriers (SLC) 
use electrochemical gradients of ions to transport substrates across a membrane. Mainly 
the role of organic cation transporter 1 (OCT1 or the SLC22A1 gene product) and to a 
lesser extent organic anion transporting polypeptide 1A2 (OATP1A2, the SLCO1A2 gene 
product) in imatinib uptake has been described.50,51 Furthermore, imatinib proved to be 
a good substrate for the solute carriers OATP1B3 (SLCO1B3 gene product) and OCTN2 
(SLC22A5 gene product), both expressed on the basolateral membrane of hepatocytes 
(Fig. 1).51 
dRug TRAnSPORTERS And IMATInIb PhARMACOKInETICS
Absorption
This knowledge raises the question whether altered pharmacokinetics can be (in part) 
the result of (over) expression of drug transporters. At duodenal pH 5 to 6, imatinib is 
mainly charged52, implying active intestinal transport; this renders intestinally located 
solute carriers such as OATP1A2 and OCTN2 as good candidates for intestinal imatinib 
uptake.53,54 However, to date, little is known about the influence of these uptake trans-
porters on imatinib pharmacokinetics. Another good candidate for systemic imatinib 
uptake is ABCC4, expressed on the basolateral membrane of hepatocytes.51 This efflux 
transporter could pump imatinib from the liver to the systemic circulation. As men-
tioned above, imatinib is absorbed very efficiently, which is somewhat surprising, con-
sidering the high affinity of imatinib for ABC transporters, expressed on the canalicular 
membrane of hepatocytes and on enterocytes. A possible explanation for this apparent 
Drug transporters and imatinib treatment 19
Table 2. Interaction between drug transporters and imatinib pharmacokinetics and pharmacodynamics 
Drug 
transporter
Study 
design
Effects on imatinib 
PK*
Effects on 
imatinib PD†
Transporter 
interaction
Effect on 
imatinib 
IUR‡ Reference
ABCB1 in vitro IUR‡ ↓ (34-35,39)
in vitro resistance ↑ (35)
in vivo systemic clearance ↑ (33,57)
in vitro inducer (32,40)
in vitro inhibitor (32,35,37)
in vitro substrate (37-38)
ABCG2 in vitro IUR‡ = (44)
in vitro IUR‡ ↓ (39)
in vitro no resistance (44)
in vivo 
(mice) systemic clearance ↑
(33,57)
in vivo 
(mice)
plasma 
concentration = 
(60)
in vivo 
(mice)
liver concentration 
=
(60)
in vitro inhibitor (37,43-44)
in vitro inducer (40)
in vivo 
(mice) no inducer
(60)
in vitro substrate (37-39)
OCT1 in vitro IUR‡ = (51)
in vitro IUR‡ ↑ (50,62)
in vitro resistance ↓ (50)
clinical 
(CML§) resistance ↓
(63,65-66)
substrate (50,62)
OATP1A2 in vitro substrate (51)
OATP1B3 in vitro substrate (51)
OCTN2 in vitro substrate (51)
Legend: * pharmacokinetics; † pharmacodynamics; ‡ intracellular uptake and retention; § chronic myeloid 
leukemia
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contradiction could be local substrate inhibition of efflux transporters by imatinib, bear-
ing in mind its dose-dependent interaction. Furthermore, absolute bioavailability could 
also be influenced by the balance between efflux and influx transport over the intestinal 
barrier, favoring active imatinib uptake.
Tissue distribution
Liver distribution. 
Imatinib is actively cleared from the blood into the liver, where it is metabolized ex-
tensively. Possible candidates for this active transport are OATP1B3, OCTN2, and OCT1, 
predominantly located at the basolateral membrane of hepatocytes (Fig. 1).16,51,55,56. 
However, in vivo or clinical data, supporting the role of solute carriers in imatinib clear-
ance, are not available.
Brain distribution. 
Systemic treatment of brain tumors (primary as well as metastases) is limited because 
of low penetration of drugs into the brain tissue. Distribution to the brain is primarily 
prevented by the blood-brain barrier formed by the endothelial cells of brain capillaries. 
These endothelial cells also express ABCB1 and ABCG241,49, which actively prevent xeno-
biotics from diffusing into the brain. This finding was illustrated in Bcrp and Mdr1a/1b 
(rodent analogs of ABCG2 and ABCB1, respectively) knockout mouse models, showing 
that imatinib brain penetration significantly increased in knockout mice compared 
with wild-type mice, with a greater difference in Mdr1a/1b knockout.57 Another study 
with a rodent model showed that combined Bcrp and Mdr1a/1b knockout proved to 
significantly increase brain penetration compared with individual Bcrp or Mdr1a/1b 
knockouts.33 These data suggest that inhibition of efflux transporters at the blood-brain 
barrier may provide more tools in the treatment of brain metastases in imatinib-treated 
patients. A few obstacles remain, however. For instance, Gardner and colleagues showed 
that inhibition of ABCB1 and ABCG2 in mice resulted in a proportional increase in 
systemic exposure to imatinib in plasma and brain, leaving the brain-to-plasma con-
centration ratio unaltered.58 This finding suggests that reduced systemic elimination of 
imatinib leads to the observed increase in imatinib exposure to the brain as a result of 
higher imatinib concentrations at the blood-brain barrier, rather than a modification of 
the barrier itself. Furthermore, it is still unclear if efflux inhibitors will increase imatinib 
levels in tumor cells located in the central nervous system, because these inhibitors may 
be merely increasing brain uptake of substrates but not necessarily uptake into brain 
tumors.59
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Excretion
Biliary secretion. 
Up until now, in vivo experiments on the importance of drug transporters for imatinib 
excretion have shown only minor effects. Systemic clearance of imatinib in Mdr1a/1b and 
Bcrp1 knockout mice was 1.3-fold and 1.6-fold lower than wild-type mice.57 A combined 
Mdr1a/1b/Bcrp1 knockout showed a 1.8-fold reduction in imatinib plasma clearance 
compared with wild-type mice when imatinib was administered intravenously.33 Inter-
estingly, no differences in pharmacokinetic parameters were found between Mdr1a/1b/
Bcrp knockouts and wild-type mice after oral administration of imatinib. Whether ABCB1 
and ABCG2 contribute to imatinib clearance in humans to a similar degree and, more 
importantly, whether there is a possible upregulation of these efflux transporters in 
excretory organs during imatinib treatment is unknown. These murine data, however, 
suggest a minor contribution of efflux transporters to imatinib clearance, compared 
with the hepatic metabolism. Indeed, an extensive first-pass metabolism of imatinib 
could contribute more substantially to systemic clearance than Mdr1a/1b and Bcrp1 
efflux. Furthermore, protein expression of Abcb1 and Bcrp1 in mice did not differ after 
long-term treatment with orally administered imatinib.60 After daily administration for 
4 consecutive weeks, no upregulation of Abcb1 and Bcrp1 in mouse liver and intestinal 
tissues was found. Also, no significant change in plasma and liver concentrations of 
imatinib was seen. Theoretically, however, the length of treatment required to induce 
upregulation of these drug transporters in mice might be longer or the activity of both 
efflux transporters over the course of time may change without a quantitative change 
in expression. 
Renal excretion. 
Although renal excretion accounts for less than 10% of imatinib excretion31,61, increased 
plasma exposure and decreased clearance in imatinib-treated cancer patients with 
impaired renal function, were seen.61 This finding may be due to increased levels of 
circulating uremic toxins. One such toxin inhibits OATP1B3 function in a rodent model55, 
supporting the possibility that uremic toxins can directly reduce hepatic uptake of 
imatinib by OATP1B3. Further elucidation of this mechanism is needed.
dRug TRAnSPORTERS And IMATInIb PhARMACOdynAMICS
Role of OCT1 in chronic myeloid leukemia blasts. 
There is substantial evidence that tumor OCT1 expression or activity determines thera-
peutic outcome in imatinib-treated CML patients. Thomas and colleagues were the first 
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to show that inhibition of OCT1 in peripheral blood leukocytes from 6 CML patients, 
decreased intracellular imatinib uptake.62 This finding was confirmed in another study, 
showing that imatinib uptake in aCMLcell line significantly correlated with OCT1mRNA-
expression.63 Furthermore, White and colleagues showed that in vitro sensitivity for 
imatinib strongly correlated with the intracellular uptake and retention of imatinib in 
mononuclear cells of untreated CML patients.50 When prazosin, an OCT1 inhibitor, was 
added to these cells, the concentration needed to inhibit molecular drug targets was 
significantly increased. Furthermore, it was also shown that only the activity of OCT1 
in mature CML blasts is associated with therapeutic outcome and not the OCT1 activity 
in immature CD34+ cells.64 This could imply that effective tumoral uptake of imatinib 
by OCT1 may be decisive for therapeutic response in CML patients. On the other hand, 
Huand colleagues showed that intracellular uptake of imatinib in (nonleukemic) cells 
overexpressing OCT1 was only minimally higher than in control cells.51 In a gene expres-
sion analysis, they showed that SLC22A1 is significantly interrelated with ABCB1, ABCG2, 
and SLCO1A2. Alternatively, SLC22A1 gene expression could, therefore, be a marker for 
expression and subsequent activity of other transporters involved in imatinib transport. 
SLC22A1 gene expression did prove to be a good predictor of clinical outcome in ima-
tinib-treated CML patients.63,65 Pretreatment OCT1 expression levels in 32 CML patients 
were 8 times higher in responders than in nonresponding patients.65 This result was 
confirmed in 70 CML patients, in which high baseline OCT1 RNA expression levels cor-
related with better cytogenetic response at 6 months and prolonged progression-free 
and overall survival.63 White and colleagues showed that chronic phase CML patients 
with low OCT1 activity showed clinical benefit from imatinib dose escalation, but they 
reported no correlation between clinical efficacy and OCT1 mRNA levels.66 
ABC transporter expression in gastrointestinal stromal tumor and chronic myeloid leukemia. 
ABCB1 and ABCC1 are expressed in approximately three quarters of GISTs, which is 2- to 
3-fold more than the expression in leiomyosarcomas.67-69 On the other hand, Western 
blot analysis of 21 GIST specimens showed no expression of ABCG2 .68 So, in contrast to 
the possible influence of ABCG2 on the intestinal uptake of imatinib33,40,57, there seems to 
be no role for ABCG2 on a tumoral level in GIST patients. Little can be said of the impact 
of ABCB1 and ABCC1 expression in stromal tumor cells on imatinib therapy in these GIST 
patients because only a very limited number of patients in these studies were treated 
with imatinib. Although preclinical data34-36 show that cellular (over) expression of 
ABCB1 leads to a reduced intracellular accumulation of imatinib, it is not clear whether 
long-term treatment with imatinib induces overexpression of this transporter in tumor 
cells. Mahon and colleagues examined various cell lines and found no upregulation 
of the expression of the ABCB1 gene by imatinib in time.70 In contrast, bone marrow 
mononuclear cells in CML patients resistant to imatinib showed an overexpression of 
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ABCB1 and ABCG2 (although not statistically significant)65. In addition, a gene expres-
sion analysis in CML patients showed that expression of ABCC3 in CML blasts was unique 
to patients with disease recurrence.71 More studies with larger populations are needed 
to elucidate the possible tumoral upregulation of efflux transporters during imatinib 
therapy and its pharmacodynamic effects.
InTEgRATIng KnOwlEdgE OF TRAnSPORTERS In IMPROvIng IMATInIb 
ThERAPy: PhARMACOgEnETIC STudIES
Pharmacokinetic impact of genetic variation in ABC transporters.
To date, pharmacogenetic association studies were predominantly done for ABCB1 and 
ABCG2 (Table 3). Associations between 2 single nucleotide polymorphisms, known to 
reduce the activity of ABCB1 and ABCG2, respectively, and steady state imatinib phar-
macokinetics in 82 patients with mainly GIST, have been investigated.72 Sixteen patients 
had a heterozygous variant (421 C > A) genotype for ABCG2 and 20 patients expressed a 
homozygous variant for ABCB1 3435C > T. No significant differences in imatinib pharma-
cokinetics were seen compared with the homozygous wild-type patients. On the other 
hand, Takahashi and colleagues recently showed that imatinib trough levels were sig-
nificantly higher in CML patients carrying an ABCG2 421A allele (in homozygous as well 
as heterozygous variant genotypes).73 Gurney and colleagues found that patients with 
a TTT haplotype in ABCB1 1236C > T, 2677G > T/A, and 3435 C > T loci had significant 
higher estimated imatinib clearances.74 This finding is contradictory to reports showing 
lower mRNA and protein levels when a homozygous T allele for ABCB1 3435C > T was 
present75, and to the findings of others who observed a decreased hepatic 99mTC-MIBI 
elimination rate, a phenotypic marker for ABCB1-mediated drug clearance, in patients 
with the TTT haplotype.76 In addition, in CML patients, a TTT-haplotype was associated 
with higher imatinib trough levels.77 
Clinical impact of genetic variation in ABC transporters.
Up until now, pharmacogenetic association studies assessing clinical efficacy were 
exclusively done in CML patients. A poor response was observed in CML patients who 
were homozygous for the G allele in ABCG2 34G > A.78 As for ABCB1, a 1236T allele was 
associated with better response, whereas a 2677G allele or a CGC haplotype for the 1236, 
677, and 3435 loci were associated with worse response in CML patients.77 However, 
Kim and colleagues observed a reduced overall survival in CML patients carrying a TT 
genotype for 3435C > T locus, when analyzed univariately.78 This finding was confirmed 
by another group, who observed more resistance in CML patients carrying T alleles at 
positions 1236 and 3435.79 All in all, data on the role of pharmacogenetics in response 
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Table 3. Studied single-nucleotide polymorphisms in patients involved in imatinib pharmacokinetics and 
pharmacodynamics
Transporter 
gene Polymorphism Effects on imatinib PK*
Effects on imatinib 
PD† No. of patients Reference
ABCB1 3435 T no 82 (72)
3435 T Cmin = § response = \\ 67 (73)
TTT haplotype‡ Cmin ↑§ 90 (77)
TTT haplotype‡ clearance ↑ 22 (74)
3435 T overall survival ↓# 229 (78)
3435 T resistance ↑ ¶ 52 (79)
1236 T resistance ↑ ¶ 52 (79)
1236 T response ↑\\ 90 (77)
1236 T Cmin = § response = \\ 67 (73)
2677 T/A Cmin = § response = \\ 67 (73)
2677 G response ↓\\ 90 (77)
CGC haplotype‡ response ↓\\ 90 (77)
ABCG2 421 A no 82 (72)
421 A Cmin ↑§ response = \\ 67 (73)
34 A response ↓** 229 (78)
ABCC2 -24 T Cmin = § response = \\ 67 (73)
SLC22A1 181 T SS†† imatinib plasma level = 73 (51)
1393 A SS†† imatinib plasma level = 73 (51)
181 T no 32 (80)
480 G response ↓‡‡ 229 (78)
480 G Cmin = § response = \\ 67 (73)
1022 T Cmin = § response = \\ 67 (73)
1222 G Cmin = § response ↑\\ 67 (73)
156 C Cmin = § response = \\ 67 (73)
SLCO1B3 334 G Cmin = § response = \\ 67 (73)
Legend: * pharmacokinetics; † pharmacodynamics; ‡ description haplotype: 1236C>T, 2677G>T/A, 
3435C>T; § imatinib plasma trough level; \\ major molecular response; #defined as the period from 
initiation of imatinib therapy until the date of death from any cause or the date of last follow-up; ¶  non-
response defined as absence of cytogenetic response; ** major or complete cytogenetic response; ††  
steady state; ‡‡ higher rate of loss of cytogenetic or molecular response 
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and survival in CML patients receiving imatinib therapy are scarce and poorly validated 
or reproduced.
Pharmacokinetic and clinical impact of genetic variations in solute carriers.
To date, studies assessing the possible role of genetic polymorphisms in solute carriers 
in imatinib therapy are limited to OCT1 and OATP1B3. Allelic variants of the SLC22A1 
gene (encoding for the OCT1 protein) with known reduced function showed no effect 
on steady stateimatinib plasma levels (181C > T and1393G > A), in a group of GIST and 
CML patients compared with the reference genotype.51 Furthermore, Zach and col-
leagues found no significant differences in response in patients heterozygous for the T 
allele in the SLC22A1 181C > T polymorphism.80 Also, no correlation between SLCO1B3 
334T > G polymorphism and imatinib exposure or clinical response was seen in CML 
patients.73 On the other hand, CML patients carrying a homozygous GG genotype for the 
SLC22A1 480C > G polymorphism showed a lower response rate.78 Furthermore, a higher 
response rate was seen in CML patients carrying a GG genotype for the 1222A >Glocus.73 
Unfortunately, imatinib trough levels did not significantly differ for these patients, carry-
ing a 1222GG genotype, as compared with the reference allele.
FuTuRE PERSPECTIvES
Although in vitro studies show that imatinib exposure leads to an upregulation of ABCB1 
and ABCG2 in human colon carcinoma cells40, currently no data are available on the 
expression of these drug transporters in human intestinal cells under imatinib therapy. 
Future studies should assess the possible correlation between their expression pattern 
in excretory organs over time with imatinib pharmacokinetics and clinical outcome. In 
order to study the role of these transporters in the observed decline in imatinib clear-
ance, a series of intestinal biopsies at different time points are needed. Current studies 
also show that the majority of GIST expresses both ABCB1 and ABCC1, but its clinical 
importance is not yet elucidated. Although tumoral expression of OCT1 in CML patients 
has already been correlated with therapeutic outcome, more data are needed on the 
expression pattern of drug transporters in tumor cells in both CML and GIST patients 
and their possible pharmacodynamic impact. At least a quantification of these trans-
porters over time should be made in GIST biopsies or mononuclear cells in CML patients 
in order to assess the possibility of an altered expression pattern of drug transporters 
as a mechanistic explanation for an altered sensitivity to the drug. Finally, pharmaco-
genetic association data will need to be validated or reproduced. At this point, no clear 
guidelines exist on the design of pharmacogenetic studies. Preventing selection bias, 
adequate power analysis, clear endpoints, correction for genetic and nongenetic covari-
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ates, and other factors are often poorly implemented. Therefore, more pharmacogenetic 
studies assessing the association with imatinib pharmacokinetics and/or pharmacody-
namics are desired, and study design will need to be uniform. In the present context of 
rapidly emerging promising compounds, the latter is of utmost importance if we want 
to personalize dosing and treatment sequences of rationally designed molecules to an 
individual patient’s needs.
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Correlations between imatinib plasma 
concentrations and clinical benefit in 
gastrointestinal stromal tumor (GIST) 
patients will be time point specific: 
results of a long-term prospective 
population pharmacokinetic study
Eechoute K., Fransson M.N., Reyners A.K., de Jong F.A., Sparreboom A., van der Graaf 
W.T.A., Friberg L.E., Schiavon G., Wiemer E.A.C., Verweij J., Loos W.J., Mathijssen R.H.J., 
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AbSTRACT
Purpose: Imatinib minimal (trough) plasma concentrations after 1 month of treatment 
have shown a significant association with clinical benefit in patients with gastrointes-
tinal stromal tumors (GIST). Considering a retrospective pharmacokinetic (PK) analysis 
has also suggested that imatinib clearance increases over time in soft tissue sarcoma and 
GIST patients, the primary aim of this study was to assess systemic exposure to imatinib 
at multiple time points in a long-term prospective population PK study. As imatinib is 
mainly metabolized in the liver, secondary aim was to elucidate the potential effects of 
the volume of liver metastases on exposure to imatinib. 
Patients and Methods: Full PK blood sampling was performed in 50 GIST patients on 
the first day of imatinib treatment, and after 1, 6 and 12 months. Additionally, on day 
14, and monthly during imatinib treatment, trough samples were taken. PK analysis was 
performed using a compartmental model. Volume of liver metastases was assessed by 
CT imaging. 
Results: After 90 days of treatment, a significant decrease in imatinib systemic expo-
sure of 29.3 % compared to baseline was observed (P < .01). For every 100 cm3 increase 
of metastatic volume, a predicted decrease of 3.81 % in imatinib clearance was observed 
(P < .01).
Conclusion: This is the first prospective PK study in GIST patients, demonstrating a 
significant decrease of ~30% in imatinib exposure after long-term treatment. This means 
that future “trough level  – clinical benefit” analyses should be time-point specific. GIST 
liver involvement has a marginal effect on imatinib clearance.
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InTROduCTIOn
After a decade of therapeutic use, imatinib mesylate has proven to be a highly effec-
tive targeted agent in the treatment of advanced gastrointestinal stromal tumor (GIST) 
patients, with a median overall survival close to 5 years.1 Imatinib mesylate is a small 
molecule that inhibits intracellular autophosphorylation of 2 tyrosine kinase receptors 
involved in the pathogenesis of GIST: mainly KIT and to a lesser extent platelet-derived 
growth factor receptor-α (PDGFR-α).2-3 While a vast majority of GIST patients will dem-
onstrate clinical benefit from imatinib therapy, approximately 10 – 15 % will experience 
progressive disease within 3 – 6 months after start of treatment.4-6 Mechanisms behind 
this so-called early progression are not entirely elucidated. Although a majority of non-
responding patients harbor mutations in the molecular drug targets,3,7-8 early resistance 
may also result from imatinib plasma levels that are below a minimal effective threshold 
level. Although not significant, GIST patients not responding to imatinib treatment dem-
onstrated lower imatinib plasma levels than responders.9-10 In addition, in a retrospective 
pharmacokinetic (PK) side-study of the pivotal phase II B2222 trial, a significant shorter 
time to progression was observed in patients that demonstrated 1 month imatinib 
steady-state trough levels below 1,100 ng/ml.10 Considering a retrospective PK analysis 
has also suggested that imatinib clearance increases over time in soft tissue sarcoma 
and GIST patients, the primary aim of this study was to assess systemic exposure to 
imatinib at multiple time points in a long-term prospective population PK study.11 
Imatinib is extensively metabolized and cleared by the liver with 68 % of the dose 
recovered in faeces.12 Its main metabolite CGP74588 is formed by hepatic oxidases 
from the cytochrome P450 superfamily (CYP) with isoforms 3A4 and 3A5 (CYP3A4 and 
CYP3A5, respectively) as its predominant members.13 As a secondary objective, we 
therefore studied the potential metabolic effects of liver metastatic involvement on 
exposure to imatinib.
METhOdS
Patients
Patients with histologically confirmed GIST were accrued at start of imatinib therapy 
for long-term imatinib PK assessment in two Dutch and two Italian medical centers. 
Patients treated with drugs known to show major interactions with cytochrome P450 
isoforms 3A4 and 3A5 (CYP3A4 and CYP3A5) were excluded from the study if no alter-
native medication was available or if the patient was unwilling to change medication. 
Imatinib systemic treatment was initiated at the Erasmus University Medical Center (n = 
31), University Medical Center Groningen (n = 14), San Giuseppe Hospital Empoli (n = 4) 
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and at the Santa Maria delle Croci Hospital Ravenna (n = 1). This study was approved by 
the medical ethics review boards and performed in accordance with the Declaration of 
Helsinki. This trial was registered at the International Standard Randomized Controlled 
Trials Number Register (ISRCTN63855172). 
Pharmacokinetic sample collection
Blood samples for imatinib PK evaluation were collected on the first day of imatinib 
treatment and after 1, 6 and 12 months. On these days blood samples were collected 
immediately prior to imatinib administration and 30 minutes, 1, 2, 3, 4, 6 and 24 hours 
after imatinib intake. Additionally, on day 14, and monthly during imatinib treatment, 
trough samples were taken to assess minimal imatinib plasma concentrations. The 
trough samples were taken just prior to the next day administration. 
Methods for blood sample processing and storage, as well as analytical imatinib quan-
tification, were described previously.14  A total of 1,820 imatinib plasma concentrations 
were considered for analysis. Ten samples were missing a concentration value (below 
the limit of quantification or assay error) and 67 trough samples were excluded since the 
time for sampling and/or the time for the preceding dose could not be determined ex-
actly. Of the 1,743 observations that remained for PK model building, 512 observations 
from 69 occasions were in adjunction to measurements on volume of liver metastasis 
and on the metastasis/liver volume ratio. 
Population pharmacokinetic model 
Observed imatinib plasma concentrations were log transformed before being used for 
parameter estimation. Compartmental models with linear and non-linear processes 
were evaluated. As no intravenous data were available, the initial bioavailability (F) was 
set to 1, meaning that clearance and volume of distribution (V) should be interpreted as 
the clearance (CL/F) and apparent volume of distribution (V/F), respectively. 
The population PK analysis was performed using nonlinear mixed effect modelling in 
the NONMEM software (version 7.1.2, ICON Development Solutions, Ellicott City, MD). 
The ADVAN5 subroutine combined with the first order conditional estimation method 
with interaction between random effects was used in the model building procedure. 
Perl-speaks NONMEM (version 3.2.12, http://psn.sourceforge.net/) and the R-package 
Xpose (version 4.3.0, http://xpose.sourceforge.net/) were used to automate model runs 
and for graphical analysis. 
Presence of liver metastases was used as a dichotomous covariate (LIV) in the analysis. 
Time-dependency (TIME), body weight (WT), volume of liver metastasis (LIVM) and liver 
metastatic volume proportional to liver volume (LIVR) were evaluated as continuous 
covariates. Potential CYP-interactive drugs were highly restricted in this study. Hence, 
as major interactions were not expected, co-medication was not included as a covariate. 
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Recorded imatinib doses were used for modelling, and when information was missing it 
was assumed there was no change in the dosing until the next recorded dose.
Interindividual variability (IIV) for an individual (ind) was modelled exponentially, and 
the residual errors for observed concentrations (cobs) versus predicted concentrations 
(cpred) on the log scale were modelled using an additive error. 
The NONMEM objective function value (OFV), which is proportional to –2 x log likeli-
hood of the data, was used to evaluate different model structures. A difference in OFV 
of at least 6.63 (corresponding to P < .01) was used to discriminate between competing 
models. NONMEM standard errors were complemented with asymmetric confidence 
intervals by log-likelihood profiling (LLP) and a bootstrap (n=1,000, stratified on LIV) 
(http://psn.sourceforge.net/). A visual predictive check (VPC) was performed to evaluate 
the predictive performance of the model. The observed data was overlaid with a 90 % 
prediction interval based on 1,000 simulated data sets from the final model. The VPC 
was stratified on months of each 24-hour pharmacokinetic sampling in the following 
way; group 0 (day 1), group 1 (month 1, 2 and 3), group 2 (month 5 and 6) and group 3 
(months ≥ 11).
In addition, to assess imatinib metabolic ratios (AUCtau CGP74588 / AUCtau imatinib) 
at start of therapy and after 6 and 12 months of treatment, a non-compartmental 
analysis of our steady-state imatinib and CGP74588 PK data after 1, 6 and 12 months 
was performed, using WinNonlin software (Phoenix WinNonlin version 6.1, Pharsight 
Corporation, St. Louis, MO).
Computed tomographic (CT) – guided volumetric assessment of liver metastases
Original Digital Imaging and Communications in Medicine (DICOM) files were imported 
in the open source OsiriX Imaging Software for MacOS X (OsiriX Foundation, Geneva, 
Switzerland). All available CT scans at baseline, at 6 and 12 months of treatment were 
studied. Two regions of interest (ROI) were assessed per CT slice: total liver area and liver 
metastasis area. Total liver areas were manually outlined by using the closed polygon 
selection tool and liver metastases lesions were drawn with the pencil selection tool, 
which allows a more precise drawing (Figure 1A). Volumes of all three-dimensional 
structures were then automatically calculated (Figure 1b). For metastases visualized in 
only one CT slice, the area was multiplied with slice thickness (5 mm) to estimate the 
volume. The gallbladder and the inferior vena cava were excluded from the ROI; intra-
hepatic biliary and vascular structures were included. The ratio of metastasis volume to 
liver volume was then calculated based on the above described volumetric assessments.
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RESulTS
Patients
Twenty-nine male and 21 female patients were included in this population PK analysis. 
Median follow-up period was 366 days (range: 59 – 761 days); 26 patients (13 males, 
13 females) had evaluable liver metastases. Median volume of liver metastases was 5.8 
cm3 (range 0.68 to 1,800 cm3) and the median metastasis/liver volume ratio was 0.42 % 
(range 0.042 to 61 %). See Table 1 for clinical characteristics. 
Imatinib pharmacokinetics: time dependency
A 2-compartment model with linear elimination and 5 transit compartments to describe 
the absorption process (Figure 2) best fitted observed imatinib plasma concentrations. 
In addition, the relative bioavailability (F) and absorption rate (ka) were both found to be 
significantly (ΔOFV = -246.4) time-dependent according to:
F = 1 + θF * exp( −λ *TIME/24)
ka,ind = (1+θka *exp(−λ *TIME/24)) *ka,pop *exp (ηka,ind)
where TIME is the time in hours from first dose administration and λ the decay con-
stant, which was found to have the same value for both parameters. θF and θka were > 
0 indicating that F and ka,ind start at a value of 1+ θF and ka,pop*(1+θka), respectively, and 
A B 
Figure 1A: Digital Imaging and Communications in Medicine (DICOM) files were imported in OsiriX 
Imaging Software for MacOS X (OsiriX Foundation, Geneva, Switzerland). Metastatic liver lesions were 
then drawn as areas of interest with the pencil selection tool. 
Figure 1b:  Volumes of three-dimensional structures were automatically calculated by OsiriX Imaging 
Software.
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both decrease with time to values of 1 and ka,pop, respectively. Time-dependence on F 
and ka could be replaced with time-dependence on CL and ka (increasing CL with time) 
with an almost equally good fit (ΔOFV = +4.3). However, this model was not robust and it 
was highly sensitive to initial parameter estimates, and quantitative testing of covariate 
effects could not be performed. The predicted decrease in F and ka as function of time 
after treatment start are demonstrated in Figure 3
Figure 2: Imatinib population pharmacokinetic model.
A 2-compartment model with linear absorption and elimination and 5 transit compartments best fitted 
observed imatinib plasma concentrations.
Abbreviations: Tr1–5; transit compartments, ka; absorption (L/h), Q; inter-compartmental clearance (L/h), 
CL; total clearance (L/h), V; volume of distribution (L)
Time (days) 0 30 90 180 360 
Fa 1.482 1.224 1.048 1.005 1.000 
F%-ratio 100% 82.6% 70.7% 67.8% 67.5% 
ka (1/h) 1.52 1.08 0.781 0.707 0.699 
Figure 3:  Predicted reduction in the relative bioavailability, F, over time. 
Assuming that the true bioavailability is equal to 100% at day 1, the predicted decrease can be 
understood by looking at percentage ratio (F%-ratio) after 30, 90, 180 and 360 days.
Abbreviations: F; relative bioavailability, F%-ratio; bioavailability percentage ratio, ka; absorption (L/h), t; 
time (days)
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Table 1. Patient characteristics (N=50)
Characteristic No. %
Median age (years)  – range 61 (39 – 82)
   
Sex –  
   Male 29 58.0
   Female 21 42.0
Primary cancer site – 
   Stomach 28 56
   Rectum 9 18
   Small intestine 8 16
   Unknown 5 10
Disease – 
   Locally advanced 17 34
   Metastatic 31 62
      Liver 28 56
      Intraperitoneal 22 44
      Retroperitoneal 2 4
      Other 4 8
   Adjuvant setting 2 4
Histology – 
   Spindle cell 28 56
   Epitheloid 13 26
   Mixed 5 10
   Unknown 4 8
Imatinib dose – 
   400 mg per day at start 50 100
Dose escalation during treatment – 
   To 600 mg per day 1 2
   To 800 mg per day 13 26
Median ASAT (U/L) – range 24 (12 – 145)
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Non-compartmental analysis of our steady-state imatinib and CGP74588 PK data after 
1, 6 and 12 months, showed that the metabolic ratio (AUCtau CGP74588 / AUCtau imatinib) 
remained stable over time; (mean metabolic ratios ± S.D. at 1, 6 and 12 months: 0.72 ± 
0.12; 0.75 ± 0.11; 0.74 ± 0.11, respectively).
Imatinib pharmacokinetics: liver metastasis dependency
Covariates WT, LIV, LIVM and LIVR were tested on CL, Vcentral and F. LIVM on CL gave the 
largest drop in OFV (ΔOFV = -21.8), while the dichotomous covariate LIV was not signifi-
cantly correlated with CL (ΔOFV = -0.4). The effect of LIVM could not be associated with 
the parameters βF or λ, governing time-dependence on F. Combining the effect of LIVM 
in CL with an effect of LIVM also in F was not significant (ΔOFV = 0.0). LIVR on CL was also 
significant (ΔOFV = -11.0) but was not significant (ΔOFV = -2.3) when combined with 
LIVM. While including LIVM reduced the proportional residual error ε from 35.4 % to 35.0 
%, it did not reduce the IIV in CL.
WT on CL gave a significant drop in OFV (ΔOFV = -13.9), but was omitted in the final 
model because of too much data imputation. 
The estimates of the final population PK model comprising the effect of LIVM on CL 
are presented in Table 2 together with NONMEM relative standard errors (RSEs), 95 % CIs 
from the LLP and the median and 2.5 – 97.5 percentiles from 993 bootstrap replicates. 
The predicted decrease in CL as function of LIVM is expressed as:
CLpop = 9.12 * (1− 0.000381 * LIVM)
This means that for every 100 cm3 increase in metastasis volume CL is decreased 
by 3.81 %. The effect is presented in Table 3 for the minimum, median and maximum 
metastasis volume of the study population. 
Median ALAT (U/L) – range 22 (5 – 274)
Median ALP (U/L) – range 91 (47 – 847)
Median GGT (UL) – range 32 (10 – 613)
Median total bilirubin (μmol/L) – range 9 (3 – 39)
Abbreviations: ASAT; Aspartate aminotransferase, ALAT; alanine aminotransferase, ALP; Alkaline 
phosphatase, GGT; Gamma-glutamyltransferase
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Validation of the final population pharmacokinetic model
NONMEM RSEs, LLP 95 % CIs and bootstrap 2.5 – 97.5 percentiles are in good agree-
ment for most parameters, the notable exception being the covariate parameter θLIVM 
Table 2. Parameter estimates for the final population pharmacokinetic model.
Parameter Estimate RSEa (%)
Log-likelihood 
profiling
Estimates based on 993 bootstrap 
replicates stratified on LIV = 0/1
95% CI Median 2.5–97.5 percentiles
CL (L/h) 9.12 7.5 7.94–10.5 9.13 7.76–10.6
Vcentral (L) 128 18 95.8–165 130 96.0–165
Q (L/h) 24.9 13 19.0–31.9 25.3 18.2–34.9
Vperiph (L) 197 15 145–265 202 142–276
ka (1/h) 0.699 20 0.510–0.942 0.710 0.502–1.05
ktr (1/h) 15.8 17 10.9–24.9 15.4 11.3–22.8
Residual error, ε (%) 35.0 6.4 33.6–36.5 34.5 30.3–39.2
θF 0.482 26 0.367–0.610 0.511 0.225–0.865
θka 1.18 28 0.72–1.82 1.15 0.525–1.97
λ (1/day) 0.0256 37 0.0181–0.0357 0.0258 0.0143–0.0565
θLIVM (1/cm
3) 0.000381 3.9 0.000290–0.000440 0.000383 -0.000300–0.00124
IIV CL (CV %)b 49.5 26c 39.6–64.3 49.0 36.8–63.4
IIV Vcentral-ka (CV %)
b 70.9 26c 50.7–104 70.4 46.9–97.0
IIV ktr (CV %)
b 160 25c 104–314 153 97.0–263
IIV Vperiph (CV %)
b 65.9 33c 39.9–107 67.1 34.6–97.6
a Relative Standard Error given by NONMEM
b Coefficient of Variation, calculated as (exp(ω2) – 1)0.5
c RSE is related to the corresponding variance term, ω2
Abbreviations: LIV; dichotomous covariate indicating presence or absence of liver metastasis, 95% 
CI; 95 percent confidence interval, CL; apparent oral clearance, Vcentral; volume of distribution for 
the central compartment, Q; inter-compartmental clearance, Vperiph; volume of distribution for the 
peripheral compartment, ka; absorption rate, ktr; absorption rate between transit compartments, θF; 
change in bioavailability relative start of treatment, , θka; change in absorption rate relative start of 
treatment, λ; decay constant, θLIVM  ; variability based on liver metastatic volume, IIV CL; inter-individual 
variability in apparent oral clearance, IIV Vcentral-ka; inter-individual variability in volume of distribution 
for the central compartment or absorption rate, IIV ktr; inter-individual variability in absorption rate 
between compartments, IIV Vperiph; inter-individual variability in volume of distribution of the peripheral 
compartment
Table 3. The effect of liver metastasis volume on the apparent oral clearance.
Population metastasisa Minimum Median Maximum
LIVM (cm3) 0 0.68 5.8 1800
CL (L/h) 9.12 9.12 9.10 2.87
a The effect of liver metastasis volume using the minimum, median and maximum values from the study 
population.
Abbreviations: LIVM; liver metastasis volume, CL; apparent oral clearance
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for which the bootstrap percentiles contain the 0-value, while this is not the case for the 
corresponding LLP CI. 
Visual predictive checks based on 1,000 simulations are shown in Figure 4. Observed 
imatinib plasma concentrations (in μmol/L) showed good agreement with the 95 % 
CIs for the 5th, 50th and 95th percentiles of the simulated predictions. Time after dose (in 
hours) was used as the independent variable.
Figure 4: Visual predictive checks (VPC) based on 1,000 simulations for imatinib plasma concentrations in 
μmol/L as function of time after dose in hours. 
The VPC was stratified on months after start of treatment for each 24-hour pharmacokinetic sampling 
in the following way; group 0 (day 1), group 1 (month 1, 2 and 3), group 2 (month 5 and 6) and group 3 
(months ≥ 11). Legend: dots = real imatinib observations; solid and dashed lines = the 50th, 5th and 95th 
percentiles for all real observations in each bin; red and blue shaded areas = the 95% CI the 50th, 5th and 
95th percentiles of the simulated data.
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dISCuSSIOn
This is the first prospective population PK study in GIST patients, analyzing imatinib PK 
over an extensive median follow-up period of one year. During this study period, the 
reached number of follow-up PK observations was several times larger than in previous 
retrospective imatinib population PK studies in GIST patients, expressing the validity of 
the current data.11,15 A multi-compartmental PK model was built by use of this PK data 
set, demonstrating a significant downward trend in systemic exposure to imatinib over 
time. From start of therapy up to 90 days, the initial imatinib exposure is reduced by ap-
proximately one third. From this time point on, the curve flattens, suggesting a further 
steady imatinib PK. Previous retrospective associations between imatinib trough levels 
at day 29 and clinical outcome benefit in GIST patients thus need to be put into this 
perspective.10 As the predicted decrease in imatinib exposure at this time point is ~ 17 
%, the distribution of patients in groups based on imatinib trough levels will differ from 
the distribution seen after 3 months, when predicted systemic exposure to imatinib 
has dropped by approximately 30 %. Within this 90-day period, significance of correla-
tions between PK-based groups and clinical benefit will fluctuate. However, provided 
the proposed clinically relevant imatinib threshold level of 1,100 ng/ml is accurate, a 
number of patients will experience a drop below the efficacious plasma level after day 
29 of imatinib therapy and may thus be underdosed when trough levels are only as-
sessed after the first month of therapy. On the other hand, the proposed threshold may 
only be a marker for the actual clinically relevant imatinib plasma concentration cut-off 
value which is reached after three months. This is highly relevant if therapeutic drug 
monitoring should be applied in future imatinib dosing. Imatinib plasma level monitor-
ing in GIST patients should therefore be time-point specific and repeated after the first 
quarter of the first year of imatinib treatment. This will have to be taken into account 
when designing randomized studies aimed to validate the use of imatinib plasma level 
monitoring, that up to that validation will have to be considered as investigational. Our 
data also provide a plausible explanation for the lack of decreased imatinib PK in GIST 
patients in a recent retrospective PK analysis, as the median time from start of therapy to 
first PK assessment in this study was 5.5 months.15 In light of our findings, a major drop 
in imatinib plasma levels has already occurred during this lag time.
Currently, literature on mechanisms that may drive these acquired PK phenomena in 
imatinib-treated patients is scarce.16 Visually, maximum imatinib plasma concentrations 
in our study population (Cmax) are lower and time to reach Cmax is longer after 3 months 
of dosing (Figure 4) as compared to the first 3 months of treatment. In addition, the 
final PK model fitted significantly better when adding a time-dependence in absorption 
rate as a covariate (OFV = -42.9). These observations suggest that the observed time-
dependent drop in imatinib exposure is located at the absorption phase. Hence, there 
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may be a change in activity or expression of drug transporters involved in facilitated or 
active transport of imatinib. However, drug uptake and efflux transporters have shown a 
limited effect on imatinib absorption and excretion, 16-17 and in vivo data showed no up-
regulation of drug efflux transporters after long-term treatment with imatinib.18 So, up 
until now, key mediators of imatinib transport during absorption and elimination have 
not been identified. On the other hand, as imatinib is extensively metabolized by CYP3A4 
to its main metabolite CGP74588,13 upregulation of liver enzymatic function may also (in 
part) account for the observed drop in imatinib plasma levels. This PK mechanism would 
possibly have a minor impact on imatinib efficacy as CGP74588 is equipotent to its 
parent compound and has a longer terminal elimination half-life.19 However, metabolic 
ratios (AUCtau CGP74588 / AUCtau imatinib) remained stable during the first year of treat-
ment, implying that upregulation of metabolic activity does not occur over time. Finally, 
increasing patient non-adherence to imatinib treatment over time may also be involved 
in the observed decline in systemic exposure. This is less likely to be of large influence on 
exposure though, as full PK time-profiles show limited accumulation (a limited effect of 
single imatinib trough levels on total exposure). Occasional dosing delays will therefore 
have a limited effect on imatinib exposure. Moreover, an observational study evaluating 
compliance in 28 imatinib-treated GIST patients at 2 time points, detected no significant 
difference in non-adherence rates after 90 days of imatinib use.20 
Secondary objective of this study was to evaluate if volume of liver metastasis in GIST 
patients is predictive for imatinib exposure. Liver metastasis volume appeared to have 
a minor effect on imatinib CL/F, rendering some clinical significance with massive liver 
involvement, as for every 100 cm3 increase of metastatic volume, a predicted decrease of 
3.81 % in CL/F is observed. This is in concordance with an earlier phase I side study that 
reported limited effect of liver dysfunction on imatinib exposure.21 These data together 
with our present results indicate that neither liver metastatic involvement nor routine 
liver function testing highly correlate with hepatic CYP activity in imatinib treated pa-
tients.
To conclude, this observational population PK study demonstrates that imatinib PK 
in GIST patients stabilizes after approximately 3 months of dosing with a significant de-
crease in systemic exposure of ~30 % compared to baseline, most likely due to reduced 
absorption. This means that future “trough level – clinical benefit” analyses should be 
time-point specific and need to incorporate relevant tumor biology and patient char-
acteristics in multivariate analyses. Such survival analyses based on imatinib PK should 
be performed in large (multicenter) patient populations and could, ultimately, lead to 
therapeutic fine tuning in which a minimal effective imatinib dose for an individual 
patient can be defined on accurate time points in a treatment course. Finally, volume of 
GIST liver metastases has a marginal effect on imatinib exposure. 
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AbSTRACT
Imatinib has an oral bioavailability >90% despite being monocationic under the acidic 
conditions in the duodenum. In vitro, we found that imatinib is transported by the in-
testinal uptake carrier OATP1A2, and that this process is sensitive to pH, rosuvastatin, 
and genetic variants.  In humans, however, imatinib absorption was not associated with 
OATP1A2 variants, and was unaffected by rosuvastatin.  These findings highlight the im-
portance of verifying drug-transporter interactions from in vitro tests in a clinical setting. 
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InTROduCTIOn
The bioavailability of orally administered imatinib is >90%, although the drug is mono-
cationic under the acidic conditions in the duodenum. In vitro, we found that imatinib 
is transported by the intestinal uptake carrier organic anion transporting polypeptide 
(OATP1A2) and that this process is sensitive to pH, rosuvastatin, and genetic variants. 
However, in a study in patients with cancer, imatinib absorption was not associated 
with OATP1A2 variants and was unaffected by rosuvastatin. These findings highlight the 
importance of verifying in a clinical setting the drug–transporter interactions observed 
in in vitro tests. Clinical use of the tyrosine kinase inhibitor imatinib is associated with 
a high interindividual pharmacokinetic variability. It was recently demonstrated that 
patients who do not respond to imatinib generally have lower systemic concentrations 
of imatinib as compared with those who do respond.1,2 Furthermore, plasma imatinib 
concentration levels below a certain threshold value are possibly associated with a 
reduced response and reduced survival.2,3 The results of previous studies indicate that 
imatinib is almost completely absorbed and has an oral bioavailability >90%.4 This is 
somewhat unexpected, considering the affinity of imatinib for several intestinal efflux 
transporters, such as ABCB1 (Pgp) and ABCG2 (BCRP),5,6 and the general assumption 
that, under the acidic conditions in the duodenum, imatinib is predominantly positively 
charged (~90% monocationic at pH 5–6).7 These conditions may facilitate the uptake of 
imatinib across the intestinal wall by one or more carriers. Using data from preclinical 
studies, we previously identified imatinib as a substrate of the organic anion transport-
ing polypeptide OATP1A2 (formerly OATP-A, OATP1, OATP),8 which is expressed in 
duodenal enterocytes.9 In the present study, we further characterized imatinib transport 
by OATP1A2 in vitro and explored the hypothesis that imatinib absorption in humans is 
affected by (i) common genetic variants in the gene encoding for OATP1A2, SLCO1A2, 
and (ii) concurrent administration of rosuvastatin, an inhibitor of OATP1A2.
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RESulTS
Quantitative PCR analysis confirmed that the descending portion of the human duode-
num showed the highest expression of OATP1A2 messenger RNA among all the tissues 
(including the tongue, stomach, small intestine, colon, and rectum) that are involved 
in the absorption of xenobiotics (Fig. 1a). Several other human tissues were found to 
express significant levels of OATP1A2, notably the spinal cord, intracranial artery, optic 
nerve, brain, lung, retina, uvula, and pituitary tissue (Fig. 1a). In Xenopus laevis oocytes 
expressing the human OATP1A2 or rodent Oatp1a4, but not rodent Oatp1a1, the uptake 
of imatinib at physiological pH was significantly higher than that observed in water-
injected control oocytes (Fig. 1b). As compared with values at pH 7.4 (1.5-fold vs. control; 
P = 0.0008), a substantially higher uptake of imatinib by human OATP1A2 was seen at 
pH 5 (2.4-fold; P = 0.0001); a similar pH-dependent transport was seen with the Oatp1a4 
complementary RNA (cRNA)-injected oocytes (Fig. 1b). When OATP1A2-expressing oo-
Figure 1  (A) Expression of the OATP1A2 gene SLCO1A2 in a panel of 48 human tissues. (b) Uptake of [3H]
imatinib by cRNA-injected Xenopus laevis oocytes at pH 7.4 (left) and 5 (right). * P = 0.01; ** P = 0.001; *** 
P = 0.0001. (C) Influence of rosuvastatin on OATP1A2-mediated transport of [3H]imatinib in Xenopus laevis 
oocytes.
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cytes were coincubated with a mixture of imatinib and rosuvastatin (Fig. 1c), significant 
inhibition of imatinib transport occurred at both pH 7.4 and pH 5 (P < 0.0001 at both 
pH values). The uptake of imatinib in HeLa cells transiently transfected with six known 
SLCO1A2 variants was reduced in four of the six variants, as compared to cells transfected 
with wild-type OATP1A2*1
(Fig. 2a). The uptake of imatinib uptake was completely abolished in HeLa cells ex-
pressing the OATP1A2*3, OATP1A2*5, and OATP1A2*6 variants. In the case of OATP1A2*7, 
imatinib accumulation was reduced in a pH-dependent manner, with 77% reduction 
at pH 7.4 (P = 0.0001) and 46% reduction at pH 5 (P = 0.033) relative to OATP1A2*1 at 
each respective pH value. As predicted from the in vitro data, the average steady-state 
Figure 2  (A) Uptake of [3H]imatinib in HeLa cells transfected with the OATP1A2 variants *2, *3, *4, *5, *6, 
and *7 at pH 7.4 (left) and pH 5 (right).  (b, C) Steady-state plasma concentrations of imatinib in a cohort 
of 94 white cancer patients, carrying OATP1A2 variants (Var) at the 38 (b) and 516 (C) nucleoside positions 
versus patients carrying two copies of the reference (Ref ) allele (left panels).  Each symbol represents an 
individual patient, and horizontal line denote the mean.  The closed symbols represent the patients being 
homozygous for the variant allele.
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concentration of imatinib in 94 white patients was not significantly associated with the 
OATP1A2*2 variant (38T>C) (Fig. 2b). However, it is noteworthy that the only patient 
who carried two copies of this variant had a steady-state plasma concentration of 
imatinib that was less than 1,000 ng/ml, which was previously identified as a threshold 
level associated with response to treatment.3 Although OATP1A2*3 was associated with 
complete absence of imatinib transport in vitro, patients who carried this variant did not 
have altered levels of imatinib (Fig. 2c). Rosuvastatin significantly inhibited OATP1A2-
mediated transport of imatinib in vitro, but this was not observed in a clinical setting; the 
concomitant administration of rosuvastatin had no influence on the steady-state phar-
macokinetics of imatinib or its active metabolite CGP74588 in 12 patients (Fig. 3). There 
was a trend toward lower systemic concentrations of CGP74588 (P = 0.15) when imatinib 
was administered with rosuvastatin (Supplementary Table S1 online). As a result, a lower 
ratio of CGP74588-to-imatinib exposure was seen in almost all the patients; however, 
this difference did not reach statistical significance (P =0.065). Treatment-related toxic-
ity was generally mild (grade 2 edema and diarrhea were observed in one patient and 
grade 1 muscle cramps in two patients) and appeared to have no association with 
coadministration of rosuvastatin (data not shown).
dISCuSSIOn
Over the past few years, several studies have shown that, in the case of many drugs, 
transport across the intestinal epithelium may be mediated by solute carriers, includ-
ing the human organic anion transporting polypeptide OATP1A2. This protein is highly 
expressed in the intestine, kidney, cholangiocytes, the blood–brain barrier, and certain 
cancers;10 this pattern of localization suggests that OATP1A2 may be vitally important 
in the absorption, distribution, and excretion of a broad array of clinically important 
drugs. In this study, we evaluated the possible relevance of this uptake transporter in the 
intestinal absorption of imatinib, a known substrate of this carrier.8 The findings of this 
study complement previous knowledge on the interaction of imatinib with organic ion 
transporters and provide further insights into the possible mechanisms underlying the 
effect of these proteins on the pharmacokinetic profile of imatinib. Using transfected 
Xenopus laevis oocytes, we found that human OATP1A2, as well as its rodent ortholog 
Oatp1a4, transports imatinib in a pH dependent manner, with increasing activity taking 
place at acidic pH, as is found in the duodenum. This result is consistent with the finding 
that imatinib occurs mainly as a monocationic isomer at duodenal pH.7 A similar sensi-
tivity to extracellular pH has been previously reported in relation to the in vitro transport 
of methotrexate by OATP1A2.11 Using transfected HeLa cells, we also found that in vitro 
imatinib transport was completely absent or significantly reduced by several naturally 
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occurring protein variants of OATP1A2. Interestingly, the relevance of these genetic vari-
ants could not be confirmed from a pharmacogenetic association study in a group of 
94 white patients with cancer who were receiving treatment with imatinib. However, in 
view of the fact that relatively few individuals with each of the variant genotypes were 
studied, the observed lack of significant relationships between the studied SLCO1A2 
variants and the steady-state pharmacokinetics of imatinib may be attributable to the 
study’s limited statistical power. It is also theoretically possible that additional genetic 
variants or haplotypes of SLCO1A2 of importance to the pharmacokinetics of imatinib 
in this population are yet to be discovered and/or that larger numbers of patients are 
needed to more precisely quantify genotype–phenotype associations. Nonetheless, in 
conjunction with the previous observation that common variants in the ABCB1, ABCG2, 
CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and SLC22A1 genes have only a limited ef-
fect on the pharmacokinetics of imatinib,8,12,13 the findings of our study further support 
the possibility that intrinsic physiologic and environmental variables may have a more 
profound influence on the absorption and disposition of imatinib. On the basis of these 
considerations, and because recent data suggest that low circulating concentrations 
of imatinib may contribute to interindividual differences in clinical outcomes,1,2,14,15 it 
was felt that an improved understanding of the possible contribution of OATP1A2 to 
the effects of drugs on imatinib absorption is of potential clinical significance. In order 
Figure 3  Individual paired areas under the plasma concentration time curves (AUC) of imatinib (A), 
CGP74588 (b), and CGP74588/imatinib AUC ratios (C) in 12 white cancer patients receiving concomitant 
administration of rosuvastatin (closed circles) or imatinib given alone (open circles).  Average plasma 
concentration time profiles of imatinib (d) and CGP74588 (E) in the absence (open circles) and presence 
(closed circles) of rosuvastatin.
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to evaluate the impact of OATP1A2 inhibition on the pharmacokinetics of imatinib, a 
drug–drug interaction study was performed in patients concomitantly treated with 
imatinib and rosuvastatin. Unlike most statins, rosuvastatin is a hydrophilic compound16 
that undergoes limited metabolism and is mainly excreted into bile unchanged.17,18 After 
2 weeks of concomitant rosuvastatin use, no significant differences in imatinib pharma-
cokinetics or toxicity were observed. The collective results of this study illustrate the 
complications associated with translating preclinical pharmacological findings to the 
clinic. This recognition is particularly relevant in the context of the recent guidelines of-
fered by the International Transporter Consortium regarding preclinical criteria needed 
to be met in order to trigger the conduct of clinical studies to evaluate drug–transporter 
interactions.19 Theoretically, it is conceivable that the lack of a substantial effect of rosuv-
astatin on the steady-state concentrations of imatinib is the result of drug–drug interac-
tions simultaneously taking place on several transporters (Figure 4).8,20,21 For example, 
rosuvastatin is also known to interact with OATP1B3 transporters, which are expressed 
on the basolateral membrane of hepatocytes22 and are involved in the regulation, in 
part, of the hepatocellular uptake of imatinib.8 The combination of decreases in both 
intestinal and hepatic uptake transport by OATP1A2 and OATP1B3, respectively, could 
lead to a reduction in the oral bioavailability as well as the availability of imatinib for 
hepatic metabolism. These two mechanisms could balance out each other, thereby 
leaving systemic imatinib exposure unaltered. Indeed, we found a trend toward reduced 
Figure 4 Possible transporter interactions between imatinib and rosuvastatin.  Transporters involved 
in imatinib (red arrows) and rosuvastatin (blue arrows) pharmacokinetics are depicted, showing that 
imatinib and rosuvastatin share OATP1A2, ABCB1 and ABCG2 as a transporter at the intestinal level and 
OATP1B3, ABCB1 and ABCG2 at the hepatic basolateral and biliary membrane, respectively.  Due to their 
involvement in the absorption, metabolism and excretion of both drugs, these transporters may affect 
imatinib and/or rosuvastatin pharmacokinetics during concomitant use.
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concentrations of the main CYP3A4-mediated metabolite of imatinib after 2 weeks of 
rosuvastatin dosing. 
In conclusion, our results highlight the importance of verifying drug–transporter inter-
actions from in vitro tests in a followup clinical study. Our study indicates that, although 
imatinib is a substrate for OATP1A2, this transporter by itself is unlikely to contribute 
substantially to the absorption profiles of imatinib in humans. Further investigation is 
warranted to determine the individual and collective contributions of additional, poten-
tially redundant, intestinal carriers to the pharmacokinetics and pharmacodynamics of 
imatinib.
METhOdS
Tissue expression of SLCO 1A2. 
TissueScan Tissue qPCR Array plates (OriGene Technologies, Rockville, MD) were used to 
assess expression of SLCO1A2 in 48 human tissues with a TaqMan Gene Expression As-
say GEx probe 20× Mix for SLCO1A2 (BD Biosciences, Rockville, MD) on an 0020 Applied 
Biosystems 7900HT Detection System (Applied Biosystems, Carlsbad, CA). The cDNA 
samples were derived from a pool of at least five donors. Expression levels analyzed in 
triplicate were normalized to GAPDH. In vitro transport studies. Uptake studies were per-
formed in Xenopus laevis oocytes transfected with OATP1A2 cRNA, using [3H]imatinib as 
described8 at various pH values in the presence and absence of the OATP1A2 inhibitor 
rosuvastatin (1 mmol/l). The influence of SLCO1A2 variants at the 38T>C (*2), 516A>C 
(*3), 559G>A (*4), 382A>T (*5), 404A>T (*6), and 2003C>G (T668S, *7) loci on imatinib 
transport was evaluated in transiently transfected HeLa cells. These cells were grown 
in 12-well plates (0.8 × 106 cells/well), infected with vaccinia in serum-free Opti-MEM 
I medium, and allowed to adsorb for 30 min at 37 °C. The cells in each well were then 
transfected with 1 ìg of wild-type or variant SLCO1A2 cDNA packaged into a pEF6/V5-
His-TOPO or pSPORT vector, along with Lipofectin, and incubated at 37 °C for 16 h. The 
parental plasmid without any insert was used as vector control. 
Pharmacogenetic association studies. 
DNA for genotyping was available from 94 white patients undergoing treatment with 
daily oral imatinib. Pharmacokinetic parameters were determined at steady state, as 
described.12 Genotypes of interest23 were determined in each sample, using direct 
nucleotide sequencing of exon 1 (containing SLCO1A2 38T>C), exon 5 (containing SL-
CO1A2 502C>T and 516A>C), and exon 8 (containing SLCO1A2 968T>C and 1063A>G). 
The recorded genotype was termed “variant” if it differed from the reference sequence 
for the single nucleotide polymorphism position, as obtained from GenBank data. The 
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SLCO1A2 variants at the 559G>A (*4), 382A>T (*5), 404A>T (*6), and 2003C>G (T668S, 
*7) loci were previously shown to have an allele frequency of <0.5%; these were not 
analyzed in the samples.24,25 
Clinical drug interaction studies. 
Twelve patients with gastrointestinal stromal tumors were included in the interaction 
study. All of them had been treated with daily oral imatinib at a dose of 400 mg for 
at least 4 weeks (to guarantee steady-state conditions) before entering the study. With 
this sample size, the probability is 91% that a difference in oral drug availability caused 
by concurrent administration of the OATP1A2 inhibitor rosuvastatin will be detected 
at a two-sided 5% significance level, if the true difference is 0.3 units. This is based on 
a within-patient standard deviation of the response variable of 0.2 units. Additional 
eligibility criteria included age ≥18 years, World Health Organization performance ≤1, 
and adequate hematological, renal, and hepatic functions. The use of any medication 
or dietary supplement that could potentially inhibit or induce CYP3A4 or ABCB1 was 
prohibited. The study protocol was approved by the Erasmus University Medical Center 
review board, and all patients provided written informed consent before study entry. 
This clinical trial was registered with the Dutch trial registry (number NTR1504) and the 
European Clinical Trials Database (number 2008-002659-26). Blood samples for phar-
macokinetic evaluation of imatinib and CGP74588 were taken during two 24-h periods 
at steady state: one period in the absence of rosuvastatin (i.e., day 1) and one period 14 
days after the start of oral rosuvastatin at a dosage of 20 mg/day (i.e., day 16). Plasma 
was isolated and analyzed for imatinib and CGP74588 using a validated method based 
on liquid chromatography–tandem mass spectrometry.
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Biliary excretion of imatinib and 
its active metabolite CGP74588 
during severe hepatic dysfunction
Schiavon G., Eechoute K., Mathijssen R.H.J., de Bruijn P., van der Bol J., Verweij J., 
Sleijfer S., Loos W.J. 
Journal of Clinical Pharmacology 2011, May 20 [Epub ahead of print].
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InTROduCTIOn
Imatinib (STI571, Gleevec®) was the first approved rationally designed inhibitor of 
tyrosine kinases and is currently approved as standard care in patients with BCR-ABL-
positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).1 
Imatinib is rapidly absorbed after oral administration, with a bioavailability of 98%. It 
is mainly metabolized in the liver predominantly by cytochrome P450 isoforms 3A4 and 
3A5 (CYP3A4, CYP3A5) with CGP74588 as its most abundant (and equally active) metab-
olite.2-4 CGP74588 represents approximately 10% of the imatinib area under the plasma 
concentration-time curve (AUC). The elimination half-life of imatinib and CGP74588 are 
approximately 18 and 40 hours (h) respectively, and imatinib is highly bound to proteins, 
predominantly to albumin and α1-glycoprotein. In patients with normal liver function, 
imatinib shows linear pharmacokinetics (PK) between the dose range of 25 mg/day and 
1,000 mg/day.5,6 
Imatinib is actively secreted into the bile by several drug efflux transporters from the 
ATP binding cassette superfamily, mainly ABCB1 and ABCG2.3 In four healthy volunteers, 
an average of 80% of the radioactive dose of the drug was eliminated within 7 days 
(27% in 2 days). Approximately 67% of the dose was retrieved in feces and 13% in urine. 
In feces, 23% and 11% of the dose of unchanged imatinib and CGP74588 were found, 
respectively.7 Imatinib plasma exposure, as measured by the AUC, was studied in a large 
cohort by the National Cancer Institute Organ Dysfunction Working Group (NCI ODWG) 
(89 patients, 24 of them with severe liver dysfunction). In this study, no differences in 
exposure were seen between patients with normal liver function and those with liver 
dysfunction (LD).8 Despite these results, but based on dose-limiting toxicities occurring 
at an imatinib dose of 600 mg/day, the maximal recommended dose of imatinib for pa-
tients with mild LD was determined at 500 mg/day whereas for patients with normal liver 
function it is 800 mg/day. However, dosing guidelines for patients with moderate and 
severe LD could not be determined. Likewise, in two other phase-I/II pharmacokinetic 
trials with imatinib conducted in patients with impaired liver function and advanced 
hepatocellular carcinoma9 and in patients with advanced or metastatic hepatocellular 
cancer,10 no significantly different imatinib plasma PK was found compared to CML pa-
tients without liver disease. In the latter study an increased exposure to the metabolite 
was observed. However, in this study octreotide was co-administered and no control 
group (patients with normal function) was included. In addition, only patients with mild 
to moderate grade of LD were included in both studies (severe LD was an exclusion 
criterion). As a substantial number of GIST patients have liver enzyme disturbances and/
or LD and since liver metastases represent the most frequent metastatic site in these 
patients, it is important to get a better insight in how LD impacts imatinib clearance.
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To the best of our knowledge, a quantification of biliary excretion of imatinib has 
only been described in two patients so far; one patient with normal liver function and 
another with moderate LD.11 In the patient with normal liver function, who underwent 
imatinib therapy at a dose of 400 mg/day, biliary excretion was studied for 24h at steady 
state. Biliary excretion of imatinib and CGP74588 accounted for 17.7% and 2.1% of the 
administered daily dose, respectively. In the patient with disturbed liver enzymes, biliary 
excretion was quantitated following the first administration of 300 mg of imatinib. Dur-
ing the first 24h, biliary excreted imatinib and CGP74588 accounted for 1.8% and 0.2% of 
the dose, respectively.11 As for plasma exposure, biliary CGP74588 excretion represented 
approximately 10% of the biliary imatinib excretion in these two patients studied.
Here, we report on the biliary excretion of a patient with severe LD after 5 days of 
treatment with imatinib. The patient was sampled for plasma PK, as well as biliary PK for 
48h, during therapy.
PATIEnT And METhOdS
Patient and treatment
The patient was a 77-year-old caucasian man, who was treated with a total gastrectomy 
for a GIST of the stomach in 2006. Histological material showed a large epithelioid GIST 
(diameter 11 cm, MAI 6/10 HPF), with tumor involvement of the excision margins. Im-
munohistochemical and molecular analyses demonstrated weak CD117 positivity, CD34 
negativity and a deletion in PDGFR alpha gene exon 18. No oncogenic mutations in KIT 
gene exons 8, 9, 11, 13 and 17 and in PDGFR alpha gene exons 10 and 12 were found. In 
2008, this patient was referred to our hospital because of jaundice (bilirubin 166 µmol/L 
(Table 1)) and potbelly since one week. A computed tomography (CT) scan performed 
at admission showed the presence of multiple large liver metastases and signs of ob-
structed gall ducts. A Percutaneous Transhepatic Cholangiography (PTC) and complete 
biliary drainage were promptly performed, due to severe LD, defined according to the 
NCI ODWG Liver Function Classification.8 
The patient had the following comorbitities: arythmia (chronic atrial fibrillation/
flutter), rheumatoid arthritis and chronic obstructive pulmonary disease. There was no 
history of alcohol use or nicotine use, nor a positive serology for hepatitis B or C.
Imatinib-mesylate was started for the first time after biliary drain placement at a 
reduced dose of 200 mg/day (equivalent to 167 mg/day imatinib) for 4 days, which was 
increased to 300 mg/day (equivalent to 251 mg/day imatinib) from day 5 on. During 
the PK study, the patient was concomitantly treated with pantoprazole, prednisolone, 
metoprolole, furosemide, nadroparine and oxycodone. Methotrexate and folic acid were 
also administered for rheumatoid arthritis since 2004.
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Sample collection and bioanalysis
After written informed consent, blood samples for PK evaluation were collected daily 
prior to dosing from day 1 until day 14 via an indwelling intravenous catheter in the 
presence of lithium heparin as an anticoagulant. At day 1, 5 and 6 additional blood 
samples were collected at 0.5, 1, 2, 3, 4, 5, 6, 18 and 24 h after imatinib administration. 
Blood samples were centrifuged within 15 minutes after collection and the plasma 
supernatant was stored at T<-70°C until the analysis. Bile was quantitatively collected at 
days 5 and 6 at the same time-points as the blood samples. The volume of each portion 
was recorded and aliquots were stored at T<-70°C until analysis.
Imatinib and CGP74588 were quantitated by a validated liquid chromatography tan-
dem triple quadruple mass spectrometry (LC-MS/MS) assay. The analytes were extracted 
by liquid-liquid extraction from 25 µL aliquots of plasma with stable labeled imatinib-d8 
as internal standard. Multiple reaction monitoring settings (m/s) for the quantitation 
of imatinib, CGP74588 and imatinib-d8 were 494>394, 480>394 and 502>394, respec-
tively. Peak area ratios were a function of the concentration from 20.0 to 5,000 ng/mL for 
Table 1 Serum biochemical parameters, grade of liver dysfunction and biliary excretion of imatinib and 
GP74588 
Literature Case 1 1,3 Literature Case 2 2,3 Current Case
Serum biochemical parameters4 
ALT (U/L ) 53 (21-72) 43 (21-72) 143 (0-40)
AST (U/L) 52 (17-59) 68 (17-59) 213 (0-36)
total bilirubin (µmol/L) 15.4 (3.4-22.2) 54.7 (3.4-22.2) 166 (0-16)
alkaline phosphatase (U/L) 262 (38-126) 133 (38-126) 349 (0-119)
gamma-glutamyltransferase (U/L) − − 303 (0-49)
lactate dehydrogenase (U/L) − − 1157 (0-449)
creatinine (µmol/L) 61.9 (70.7-132.6) 97.2 (70.7-132.6) 87 (65-115)
BUN (µmol/L)
 
6.1 (3.2-7.1) 10 (3.2-7.1) 7.3 (2.5-7.5)
LD grade conform NCI ODWG Normal liver function Moderate LD Severe LD
Excretion data5
bile excreted (ml) 1365 500 819 (417/402)
Imatinib-mesylate dose/day (mg) 400 300 300
% imatinib excreted 17.7 1.8 0.22 (0.27/0.17)
% CGP74588 excreted 2.1 0.2 0.42 (0.56/0.27)
Ratio imatinib/CGP74588 excreted 8.4 9 0.52 (0.48/0.63)
1, patient with normal liver function (11); 2, patient with moderate LD (11); 3, Serum biochemical values 
for Literature Case 1 and 2 have been transformed from Conventional Unit to SI; 4, corresponding normal 
reference laboratory values of individual hospitals in parenthesis; 5, Excretion data are based on 24 h 
measurements for Literature Cases and 48 h measurements for Current Case. In parenthesis, 24h data for 
days 5 and 6 of the current case are presented.
Biliary secretion of imatinib during severe hepatic dysfunction 65
imatinib and CGP74588. For imatinib, a linear function was applied, while for CGP74588 
a non-linear quadratic regression model was used. The within and between-run preci-
sions at five tested concentrations were ≤12.6 and ≤3.7%, respectively, while the average 
accuracy ranged from 93.1 to 107.5%. Bile samples were processed following a 5-fold 
dilution in blank plasma.
RESulTS
Table 1 shows serum biochemical parameters, classification of liver function and biliary 
excretion data measured on the fifth and sixth day of imatinib treatment. 
Plasma concentration time curves of imatinib and CGP74588 are presented in Figure 
1A and 1B. Oral absorption on day 1 showed a long lag time, with imatinib detectable 
Figure 1 
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Figure 1 Plasma concentration time profiles of imatinib (circles) and CGP74588 (squares) in plasma (A and 
b) and in bile (C). Closed symbols in figure A and B represent trough concentrations, while open symbols 
represent concentrations observed during a 24h period. (d) Cumulative biliary excretion of imatinib 
(circles) and CGP74588 (squares) during day 5 and 6. The solid line represents the sum of imatinib and 
CGP74588. (E) Schematic illustration of the hypothesized processes in our patient with respect to imatinib 
metabolism and excretion. Abbreviations: ABC = ATP-binding cassette; CYP = cytochrome P450; MTX = 
methotrexate, OAT = organic anion transporting polypeptide; OCT = organic cation transporter.
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at 2h after administration and quantifiable (i.e., >20 ng/mL) after 3h of administration. 
CGP74588 was detectable at 4h and 6h after administration and only quantifiable after 
24h of administration.    
Imatinib trough levels between day 5 and 10 were approximately 700 ng/mL and 
subsequently slowly increased from day 11 on to 1600 ng/mL at day 14 (last day of PK 
sampling).
The patient experienced no severe toxicities besides some well-known side effects, in-
cluding grade 2-3 hypophosphatemia from day 5 and grade 1 fluid retention (according 
to Common Terminology Criteria for Adverse Events, version 4). Neither hematological 
toxicity nor other drug-related toxicities occurred.
In contrast to the plasma compartment, CGP74588 concentrations in bile at days 5 
and 6 were higher compared to imatinib concentrations (Figure 1C). As shown in Table 
1, a total of 819 mL of bile was collected through biliary drainage during the 48h study 
period, which is in the physiological range.12
Putting our findings into perspective to the previous report of two cases described re-
cently (Table 1)11, referred here as “Case 1” (patient with normal liver function) and “Case 
2” (patient with moderate LD) some striking differences were seen. In comparison with 
Case 1 much lower percentages of imatinib excreted in bile were observed (Table 1). 
Cumulative biliary excretion (Figure 1D) of unchanged imatinib in our patient accounted 
for only 0.22% of the total dose of 600 mg administered, while CGP74588 accounted 
for 0.42%. Overall, only 0.64% (3.2 mg as imatinib base equivalents) of the total dose 
administered to our patient was excreted through the bile as unchanged imatinib plus 
CGP74588. Even in comparison with Case 2, who was sampled for only 24h after the 
first administration, low percentages of the administered dose were excreted through 
the bile. In addition, the biliary excretion ratio of imatinib/CGP74588 was reversed com-
pared to both previously reported cases (Table 1).
In our patient, a CT scan after 4 weeks of imatinib therapy showed a minimal reduction 
in diameter of the largest liver metastasis, but hepatic function progressively worsened, 
leading to hypo-albuminemia and coagulation dysfunction. Treatment with imatinib 
was finally discontinued after 5 weeks of treatment due to deterioration of clinical 
performance.
dISCuSSIOn 
Here we report plasma and bile PK data of imatinib and its main metabolite CGP74588 
in a patient with metastatic GIST and severe LD. 
Although imatinib absorption showed a long lag time, with imatinib concentrations 
quantifiable after 3h of administration, imatinib and CGP74588 plasma trough concen-
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trations from day 5 and onward are within the range of values reported in the literature.5 
Our biliary data, however, appear to be in contrast. First of all, we observed low biliary 
excretion of imatinib as well as CGP74588 compared to the patient without LD, which 
was also at steady state therapy during the biliary drainage.11 This observation could 
potentially be explained by a significant down regulation of the expression of OCT1, 
both at mRNA and protein level, as reported in liver tissue samples from cholestatic 
patients,13 and in rats with induced cholestasis.14 Reduced hepatic uptake transport of 
imatinib by OCT1 may subsequently impair the availability of the compound for biliary 
secretion (unchanged and metabolized) (Figure 1E). Of note, imatinib and CGP74588 
bile excretion seems to decrease proportionally to liver function deterioration (Table 1). 
Also in comparison with the patient with moderate LD11, the dose excreted as imatinib 
and CGP74588 was low in our patient. Although the plasma trough concentrations from 
day 5 and further are in agreement with literature data,5 it cannot be excluded that the 
low percentage of the total dose of imatinib excreted via the bile is related to a low 
bioavailability in our patient. As shown (Figure 1A), a long lag time was observed after 
the administration on day 1 with peak plasma concentrations observed at 24h and a low 
oral availability is not unlikely. A combined effect of low oral availability and reduced 
hepatic uptake could balance each other out, resulting in plasma exposures of imatinib 
and CGP74588 comparable to the literature. Unfortunately, data on fecal excretion are 
not available. 
With respect to the inverted biliary ratio of imatinib to CGP74588, both the high grade 
of LD/cholestasis and co-medication could have played a role. Adaptive phenomena oc-
curring in the liver during cholestasis have been described, such as the activation of the 
Pregnane X receptor and Farnesoid X receptor.15 These receptors regulate the expression 
of numerous transporters and enzymes (especially CYP3A family) and have a major role 
in maintaining bile acid homeostasis and protecting against cholestatic hepatotoxic-
ity.16 Mouse models of liver induced cholestasis revealed that enhanced expression of 
Cyp3a11 (the murine ortholog of human CYP3A4) is the major defense mechanism to 
detoxify cholestatic bile acids.13-15,17 Based on this theory, enhanced enzymatic activity 
could therefore, at least partially, account for a higher proportion of imatinib metabolite 
in the bile of our patient.
In addition, the intake of potential competitive inhibitors for the ATP binding cassette 
transporters ABCB1 and ABCG2, the main efflux pumps for imatinib excretion, could 
have contributed to the low excretion and inverted ratio. The proton pump inhibitor 
(PPI) pantoprazole, for example, is an inhibitor of ABCB1 and ABCG218-21 and co-admin-
istration of benzimidazoles (e.g., anthelmintics as albendazole and PPIs) significantly 
inhibits ABCG2-mediated transport of methotrexate in vitro and reduces its clearance 
in vivo.22 Therefore, competitive inhibition of imatinib by pantoprazole or methotrexate 
at the ABCG2 transport site may have contributed to the reversed ratio in our study 
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patient. However, data on different transporter specificity of imatinib and CGP74588 
which could support this hypothesis are not available yet. 
In addition, although a pharmacogenetic analysis was not performed in our patient, 
potential genetic variations may not explain our biliary findings. In fact, up until now, 
functional polymorphisms in genes involved in imatinib metabolism (e.g. genes coding 
for ABCB1, ABCG2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and OCT1), have not 
shown a significant impact on systemic exposure to imatinib.3
In conclusion, biliary excretion of imatinib seems related to the severity of liver dys-
function. Tailored in vivo as well as clinical studies in patients with normal liver function 
and with different grades of cholestasis and liver involvement are warranted, to further 
elucidate the role of biliary excretion on the PK of imatinib.
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AbSTRACT
Purpose
To identify genetic markers in the pharmacokinetic and pharmacodynamic pathways of 
sunitinib that predispose for development of toxicities; thrombocytopenia, leukopenia, 
mucosal inflammation, hand-foot syndrome and any toxicity according to National 
Cancer Institute Common Toxicity Criteria higher than grade 2.
Patients and Methods
A multicenter pharmacogenetic association study was performed in 219 patients 
treated with single-agent sunitinib. A total of 31 single nucleotide polymorphisms in 
12 candidate genes, together with several nongenetic variants, were analyzed for a 
possible association with toxicity. In addition, genetic haplotypes were developed and 
related to toxicity.
Results
The risk for leukopenia was increased when the G-allele in CYP1A1 2455A/G (odds ratio 
[OR], 6.24; P = .029) or the T-allele in FLT3 738T/C (OR, 2.8; P = .008) were present or CAG 
in the NR1I3 (5719C/T, 7738A/C, 7837T/G) haplotype (OR, 1.74; P = .041) was absent. 
Any toxicity higher than grade 2 prevalence was increased when the T-allele of VEGFR-2 
1191C/T (OR, 2.39; P = .046) or a copy of TT in the ABCG2 (-15622C/T, 1143C/T) haplotype 
(OR, 2.63; P = .016) were present. The risk for mucosal inflammation was increased in the 
presence of the G-allele in CYP1A1 2455A/G (OR, 4.03; P = .021) and the prevalence of 
hand-foot syndrome was increased when a copy of TTT in the ABCB1 (3435C/T, 1236C/T, 
2677G/T) haplotype (OR, 2.56; P = .035) was present.
Conclusion
This exploratory study suggests that polymorphisms in specific genes encoding for me-
tabolizing enzymes, efflux transporters, and drug targets are associated with sunitinib-
related toxicities. A better understanding of genetic and nongenetic determinants of 
sunitinib toxicity should help to optimize drug treatment in individual patients.
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InTROduCTIOn
The oral, multitargeted tyrosine kinase inhibitor sunitinib (sunitinib malate; Sutent; Pfizer 
Pharmaceuticals Group, New York, NY) is known to inhibit vascular endothelial growth 
factor receptors (VEGFRs) 1, 2, and 3, platelet-derived growth factor receptor (PDGFR) α 
and β, KIT, Fms-like tyrosine kinase 3 receptor (FLT3), and the receptor encoded by the 
ret proto-oncogene (RET).1-4 Sunitinib is approved for first-line treatment of metastatic 
renal cell carcinoma (mRCC) and imatinib-resistant metastatic gastrointestinal stromal 
tumors (GIST).4-6 Targeted cancer therapies are generally considered to be less toxic than 
conventional chemotherapy since they specifically inhibit tyrosine kinase receptors that 
are frequently overexpressed or mutated in various types of tumor cells.7 Tyrosine ki-
nases, however, are also present in normal tissues and toxic effects are therefore difficult 
to eliminate. The 4 weeks on 2 weeks off dosing schedule of sunitinib was selected for 
the first phase I study on request of the health authorities to allow patients to recover 
from potential bone marrow and adrenal toxicity observed in animal models, indicating 
that toxicity was regarded as a serious problem.3, 8 Although the proportion of patients 
with grade 3 to 4 adverse events was relatively low in the recent phase III studies, a 
dose interruption appeared to be necessary in 38% of patients with mRCC and in 28% of 
patients with GIST whereas a dose reduction was required in 32% and 11%, respectively. 
Similar percentages were reported in other studies.2, 4, 9 Disease- and sunitinib-related 
toxicities can be distinguished based on results of a phase III trial in which the toxicity 
profile of sunitinib-treated patients has been compared with events in the placebo-
treated patients.2 Adverse events that preferentially occurred in the group treated with 
sunitinib were diarrhea, hand-foot syndrome, mucositis, vomiting, hypertension, leuko-
penia, neutropenia, and thrombocytopenia.2-4, 9-13 Less common, but specific toxicities 
related to sunitinib were cardiotoxicity and hypothyroidism.5, 14, 15
Sunitinib is used as palliative therapy with no standard therapeutic options available 
after failure of the therapy. It is therefore relevant for patients to adhere to sunitinib 
therapy while their quality of life is not unnecessarily reduced by drug toxicity. To date, 
it is not completely clear which patient characteristics render an individual patient at 
risk for sunitinib-induced toxicity. The aim of the present study is to identify genetic 
markers in sunitinib disposition, metabolism, and mechanism of action that predispose 
for development of common sunitinib related toxicities: thrombocytopenia, leukopenia, 
mucosal inflammation, hand-foot syndrome and any higher than grade 2 National Can-
cer Institute Common Toxicity Criteria for Adverse Events (CTCAE) toxicity.
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PATIEnTS And METhOdS
A total of 219 patients from five Dutch medical centers were analyzed in this study. The 
study was approved by the medical ethics review board. Patients were treated at the 
Erasmus University Medical Center (n=74), the Netherlands Cancer Institute (n=51), 
Leiden University Medical Center (n=37), VU University Medical Center (n=36), and the 
University Medical Center Groningen (n=21). The collection of DNA and patient data 
was performed between June 2004 and May 2008. A total number of 159 mRCC, 50 GIST, 
and 10 patients with other tumors were included in this study. Of them, 77 patients 
with mRCC and 26 patients with GIST were treated according to an expanded access 
programme of sunitinib. Eligible patients were those treated with single agent sunitinib 
for at least one treatment cycle (4 consecutive weeks of 50 mg per day followed by a 
two-week period of rest). 
Study design
Sunitinib toxicity was evaluated during the first treatment cycle by CTCAE version 3.0.16 
Toxicity scores were assessed by analysis of adverse events, physical examination and 
laboratory assessments carried out at baseline (before starting sunitinib), after 4 weeks 
of sunitinib therapy, and after 6 weeks (just before starting the second cycle). Demo-
graphic and clinical data of patients were reported on case record forms designed for 
data collection in this study. Patient characteristics considered relevant for experienc-
ing toxicity were: age, gender, ethnicity, body-surface area (BSA), Eastern Cooperative 
Oncology Group (ECOG) performance status, tumor type, renal, liver and bone marrow 
function (serum creatinine, total bilirubin, albumin, ALT, AST, hemoglobin, leukocytes 
and thrombocytes). Residual blood or serum samples taken for routine patient care 
were stored at -20ºC at the local hospital laboratory. Of each patient one whole blood 
or serum sample was collected from the participating centers. All samples were anony-
mized by a third party, according to the instructions stated in the Codes for Proper Use 
and Proper Conduct in the Self-Regulatory Codes of Conduct (www.federa.org). 
Definition of toxicity
All adverse events were graded by independent physicians of the participating medical 
centers. Four- and 6-week reported toxicities were compared to baseline conditions. The 
primary outcome measures of this study were thrombocytopenia, leukopenia, mucosal 
inflammation, hand-foot syndrome and any toxicity higher than grade 2. Toxicities were 
selected based on objectivity, clinical relevance and manageability of the symptoms. 
Thrombocytopenia and leukopenia were scored from blood cell counts and are thus 
objective endpoints. In case of any toxicity higher than grade 2, a dose interruption 
and, depending on the kind of toxicity, a resumed treatment with 25% dose reduction 
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is advised in the drug label of sunitinib. Moreover, mucosal inflammation and hand-foot 
syndrome are frequently reported and poorly manageable and therefore dose reduc-
tion is relatively soon considered. In addition, dose reduction of at least 25% according 
to the drug label (data complete for 187 patients) which is applied because of safety or 
tolerability issues, after cycle 1 to 3 was related to the toxicity outcomes.
Genetic Polymorphisms
Nineteen polymorphisms in seven genes involved in the pharmacokinetics and 12 poly-
morphisms in five genes involved in the pharmacodynamics of sunitinib were selected. 
Selection criteria for the polymorphisms were an allelic frequency higher than 0.2 in 
whites and an assumed clinical relevance based on previously reported associations 
or the assumption that nonsynonymous amino acid change leads to changed protein 
functionality. The selected polymorphisms are listed in Table 1. 
Genotyping of selected polymorphisms
Germline DNA was isolated from 1 ml of serum or EDTA-blood with the Magnapure LC 
(Roche Diagnostics, Almere, The Netherlands). DNA concentrations were quantified on 
the nanodrop (Isogen, IJsselstein, The Netherlands). Taqman assays were obtained from 
Applied Biosystems (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). 
All Single Nucleotide Polymorphisms (SNPs) were initially determined on the Biomark 
48.48 Dynamic Array (Fluidigm, San Fransisco, CA, USA) according to the manufacturer’s 
protocol. Failed samples were repeated on the TaqMan 7500 (Applied Biosystems), ac-
cording to standard procedures. For serum samples, a pre-amplification step was neces-
sary. Briefly, a dilution of all TaqMan assays in a total volume of 1.25 μL and 2.5 μL of 
pre-amplification mastermix (Applied Biosystems) was added to 1.25 μL of serum-DNA, 
and subsequently amplified by polymerase chain reaction. This mixture was 20 times 
diluted and 2.5 μL was used in the Biomark array according to the protocol. 
Genotyping assay validity
The overall average success rate of the assays and the individual samples was 98%. The 
lowest success rate in our study was 93.5%. As a quality control, all DNA samples were 
genotyped in duplicate for 12 of 31 SNPs, and three DNA samples were genotyped in du-
plicate for all 31 SNPs. No inconsistencies were observed. In addition negative controls 
(water) were used. The allelic frequencies of the 31 single nucleotide polymorphisms 
were tested for Hardy-Weinberg equilibrium (HWE). Six genotype assay results did not 
meet HWE. However, of four of these, frequencies were compared with allelic frequen-
cies as reported on the National Center for Biotechnology Information website (NCBI) for 
white population and found similar to the reported frequencies. Of the two remaining 
SNPs no frequencies were available on the NCBI website (www.ncbi.nlm.nih.gov). The 
76 Chapter 6
homozygotic wildtype frequencies of both SNPs exceed the HWE and were therefore 
allowed for the analysis. 
Table 1: Polymorphisms genotyped in the pharmacokinetic and pharmacodynamic pathway of sunitinib 
Gene Polymorphism rs-number
Pharmacokinetic pathway NR1I2 -25385C/T rs3814055
-24113G/A rs2276706
7635A/G rs6785049
8055C/T rs2276707
10620C/T rs1054190
10799G/A rs1054191
NR1I3 5719C/T rs2307424
7738A/C rs2307418
7837T/G rs4073054
CYP3A5 6986A/G rs776746
CYP1A1 2455A/G rs1048943
CYP1A2 -163A/C rs762551
ABCG2 421C/A rs2231142
34G/A rs2231137
-15622C/T *
1143C/T rs2622604
ABCB1 3435C/T rs1045642
1236C/T rs1128503
2677G/T rs2032582
Pharmacodynamic pathway PDGFRα 1580T/C rs35597368
-1171C/G rs1800810
-735G/A rs1800813
-573G/T rs1800812
VEGFR2 (=KDR) -604T/C rs2071559
-92G/A rs1531289
54T/C rs7692791
1191C/T rs2305948
1718T/A rs1870377
VEGFR3 (=FLT4) 1501A/G rs307826
RET 2251G/A rs1799939
FLT3 738T/C rs1933437
* No rs-number assigned yet
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Haplotype estimation 
Polymorphisms within a gene were tested to detect linkage disequilibrium (LD). If LD 
between SNPs was present, haploblocks (with several haplotypes) were determined. The 
uncertainty measure Rh
2 was calculated.  Rh
2 gives us information on the uncertainty in 
the prediction of common haplotypes from unphased SNP genotypes 17. A haplotype 
was considered to be present if the haplotype uncertainty measure Rh
2 was greater than 
0.98 as tested with the software program CHAPLIN 18. Haplotypes with an uncertainty 
measure Rh
2 ≤ 0.7 in CHAPLIN were not considered for further analysis since the data pro-
vided no information on haplotypes in our population. All  haplotypes with uncertainty 
(0.7 < Rh
2 ≤ 0.98 ) and without uncertainty (Rh
2 > 0.98) were computed and assigned 
per individual using gPLINK 19.  Rare haplotypes (< 2%) were combined into one group 
of other haplotypes in the association analysis. The haplotypes used in this study had 
no phase uncertainty (Rh
2 > 0.98). The VEGFR-2 gene had a large phase uncertainty (Rh
2 
≤ 0.7) indicating that in our population VEGFR-2 polymorphisms could not be defined 
as a haplotype. The following SNPs were combined for further analysis: ABCG2; 1143C/T 
and -15622C/T; PDGFRα; -573G/T, -1171C/G, -735G/A, 1580T/C; NR1I3; 5719C/T, 7738A/C, 
7837T/G; NR1I2 10620C/T, 10799G/A and ABCB1; 3435C/T, 1236C/T, 2677G/T. 
Statistical design and data analysis
For the analysis of toxicity, we used dichotomous end points expressed as increased 
toxicity (yes or no) or any toxicity higher than grade 2 (yes or no). All demographic and 
clinical variables were tested univariately against the selected primary outcomes using t 
test, the Mann-Whitney U test or the χ2 test, depending on the tested variables. A χ2 test 
was also used to detect linkage disequilibrium (LD). The polymorphisms were initially 
tested with 2 df. If the initial 2 df tests resulted in P ≤ .1, the polymorphisms were fitted 
and the most appropriate model (multiplicative, dominant, or recessive) was selected. 
The number of copies of each haplotype was used as parameter in the analysis. The 
polymorphisms and haplotypes were tested univariately against the selected primary 
outcomes using a χ2 test. Candidate variables with P ≤ .1 were selected for the multiple 
logistic regression analysis with toxicity as depending variable. All multivariate logistic 
regression analyses were corrected for age, gender and ECOG performance status. 
Additional patient characteristics were introduced in the multivariate analyses based 
on univariate tested results if P ≤ .1. Missing data were kept as missing data except for 
BSA and ECOG performance status. Missing BSA values (n=15) were replaced for the 
median BSA (1.93m2) and missing ECOG performance status (n=7) were replaced for 
the median ECOG performance status (1). To test this action, the multivariate analyses 
were performed with and without the replacement of the patients with missing BSA and 
ECOG performance status. Similar results were generated, indicating that the replace-
ment was legitimate. All statistical analyses were performed using SPSS 16.0 software 
78 Chapter 6
(SPSS, Chicago, IL, USA). With the sample size of our study, an increase in toxicity of 17% 
could be measured between two groups with a power of 80% and a confidence interval 
of 99%. All results from the multivariate analyses with P less than .05 were considered 
significant. Since this was an exploratory study, no correction for multiple testing was 
done. 
RESulTS 
Patients 
Nineteen out of 219 patients had to be excluded from analysis for several reasons in-
cluding progressive disease (PD) during the first treatment cycle resulting in early death 
(n=4), discontinuation of sunitinib in the first treatment cycle due to adverse events 
(hypertension grade 3, headache grade 3 and rash grade 3, respectively; n=3) and no ac-
ceptable genotyping success rate due to poor DNA quality (n=12). For toxicity analyses, 
a total of 200 patients were evaluable (Table 2). For the endpoint any toxicity higher than 
grade 2, the three patients who stopped therapy due to adverse events were included 
(n=203).
Toxicities
The hematological toxicities scored in this analysis were thrombocytopenia (40% any 
grade), leukopenia (59%, any grade). Non-hematological toxicities were primarily any 
toxicity higher than 2 (22%), mucosal inflammation (44%) and hand-foot syndrome 
(19%; Table 3). Dose reduction after cycle 1 to 3 was related to mucosal inflammation (P 
= .002) and any toxicity higher than grade 2 (P < .001)
Pharmacogenetic risk factors for sunitinib-induced toxicity
The results of the multivariate logistic regression analysis for the selected endpoints 
thrombocytopenia, leukopenia, mucosal inflammation, hand-foot syndrome and any 
toxicity higher than grade 2 are summarized in Table 4. For thrombocytopenia, an 
increase in age (P = .030) and ECOG performance status (P = .050) were independently 
significant in the multivariate logistic model. The factors associated with development 
of leukopenia were: CYP1A1 2455A/G; the presence of the G allele in an additive model 
was related to a 6.2-fold increase in the risk for leukopenia during the first treatment 
cycle (P = .029); the presence of the FLT3 738C allele (dominant model) was related to 
a 2.8-fold reduction in the risk for leukopenia (P = .008); the absence of the NR1I3 CAG 
haplotype was related to a 1.7-fold increased risk for leukopenia (P = .041) and 4); one 
grade increase in ECOG performance status, implicating a worse clinical condition, was 
related to a 1.8-fold reduction in the risk of leukopenia (P = .016). The presence of the 
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VEGFR-2 1191T-allele (additive model) was related to an increased risk of 2.4-fold for the 
development of any toxicity higher than grade 2 (P = .046), while the risk for this toxicity 
was 2.6-fold higher when 1 or 2 copies of TT in the ABCG2 haplotype were present (P = 
.016). For mucosal inflammation only CYP1A1 2455A/G was independently related; the 
G-allele (additive model) resulted in a 4.0-fold higher risk for mucosal inflammation (P 
= .021). The occurrence of hand-foot syndrome was related to the ABCB1 haplotype; 
the absence of copies of the TTT haplotype was protective and was related to a 2.6-fold 
lower risk to experience hand-foot syndrome as compared to patients with copies of 
the TTT haplotype (P=.035). The explained variance (R2) of the patient characteristics, 
without taking the polymorphisms into account, in the multivariate analyses was be-
tween the 2 to 10% of the total variance. After adding the selected polymorphisms the 
explained variance increased to 10 to 23% of the total variance.
dISCuSSIOn
To the best of our knowledge, this is the first study exploring the relationship between 
drug-induced toxicity and genetic polymorphisms in genes encoding for enzymes, ef-
flux transporters and targets involved in the pharmacokinetics and pharmacodynamics 
of sunitinib. 
Sunitinib is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP3A5. In addition, 
affinity of sunitinib for the ATP-binding cassette transporters ABCG2 and ABCB1 has 
also recently been reported.20 The transcription of CYP3A4 is regulated by members 
of the NR1I nuclear receptor subfamily.21 Metabolism through CYP1A1 and CYP1A2 is 
hypothesized since these enzymes appear to be involved in the metabolism of mul-
tiple tyrosine kinase inhibitors (eg, imatinib, erlotinib).22, 23 Both genes encoding the 
sunitinib targets, as well as genes encoding the enzymes (except for CYP3A4, in which 
no functional polymorphisms have been identified) and efflux transporters involved in 
sunitinib’s disposition and metabolism are highly polymorphic and may be related to 
the differential toxicity response in patients treated with sunitinib. 
Although the nature and incidence of adverse events related to sunitinib are cur-
rently well recognized and described, data regarding determinants of toxicity are still 
scarce.2, 4, 5, 14, 24, 25  So far, only one study has described factors (low BSA, high age, female 
gender) that are associated with the development of severe toxicities, defined as dose 
reduction or permanent discontinuation of sunitinib therapy.9 That study, however, was 
limited to patient characteristics and no genetic determinants were investigated. In our 
study, these patient characteristics, and another (performance status), were included as 
covariates in the data analysis. We should emphasize, however, that the definition of the 
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Table 2: Patient characteristics (N=203) 
Characteristic Value 
Age (years)
   Median (range) 60 (20-84)
Sex
   Male 129 (63.5%)
   Female 74 (36.5%)
Body Surface Area (square meters)
   Median (range) 1.93 (1.47-2.51)
ECOG performance status
   0 81 (39.9%)
   1 90 (44.3%)
   2 17 (8.4%)
   3
Missing
8 (3.9%)
7 (3.4%)
Ethnicity
   Caucasian 190 (93.6%)
   Blacks 6 (3.0%)
   Asian 2 (1.0%)
   Latin-American 2 (1.0%)
   Middle East 3 (1.5%)
Tumor types 
   Renal cell carcinoma 152 (74.9%)
   Gastrointestinal stromal tumor 46 (22.7%)
   Other 5 (2.5%)
Previous medical treatments
   Yes* 116 (57.1%)
   No 87 (42.9%)
First treatment regimen (N=116)*
   Interferon-alpha (INF-α) 46 (39.7%)
   Imatinib 46 (39.7%)
   Sorafenib 5 (4.3%)
   Others 19 (16.4%)
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Dose reduction after sunitinib cycle 1 – 3 
   Yes   Renal cell carcinoma 58 (28.6%)
            GIST 14 (6.9%)
            Other tumor 1 (0.5%)
   No    Renal cell carcinoma 94 (46.3%)
            GIST 32 (15.8%)
            Other tumor 4 (2.0%)
Baseline chemistry and hematology
   Creatinine (μM)
      Median (range) 96.0 (40-176)
   Total bilirubin (μM)
      Median (range) 7 (3-32)
   Albumine (gram/L)
      Median (range) 40 (23-52)
   ALT (units/L)
      Median (range) 18 (3-210)
   AST (units/L)
      Median (range) 24 (9-190)
   Hemoglobin (mM)
      Median (range) 7.6 (5.2-10.4)
   Leukocytes (*10^9/L)
      Median (range) 7.5 (3.6-56.5)
   Thrombocytes (*10^9/L)
      Median (range) 284.0 (92-864)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, Eastern Cooperative 
Oncology Group
CR, complete response ; PR, partial response; SD stable disease ; PD, progressive disease
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Table 4:  Factors relevant for sunitinib-induced toxicity, defined as thrombocytopenia, leukopenia, any 
toxicity > grade 2, mucosal inflammation or hand-foot syndrome
Data corrected for patient characteristics1 Uncorrected data1
Factor Genotype OR (95% CI) P-value OR (95% CI)* P-value
Thrombocytopenia Age 1.04 
(1.00–1.07)
.030
(n=177) Gender 1.93 
(0.97–3.85)
.063
ECOG 0.60 
(0.37–1.00)
.050
NR1I2 -24113 
G/A
GG vs 1 1
AG + AA 0.60 
(0.28–1.28)
.187 0.51 
(0.25–1.05)
0.067
CYP1A2 -163 
A/C
AA vs 1 1
AC + CC 0.67 
(0.34–1.32)
.251 0.65 
(0.34–1.23)
0.186
Table 3: Number (No) of patients (%) according to the distribution of increased toxicity grades 
Toxicity No/Yes Grade No (%)
Thrombocytopenia (n=198) No 118 (59.0)
Yes 1 58 (29.0)
2 14 (7.0)
3 7 (3.5)
4 1 (0.5)
Leukopenia (n=198) No 81 (40.5)
Yes 1 91 (45.5)
2 22 (11.0)
3 4 (2.0)
Any toxicity > 2 (n=203) 0, 1, 2 158 (77.8)
3, 4 45 (22.2)
Mucosal inflammation (n=199) No 112 (56.0)
Yes 1 57 (28.5)
2 25 (12.5)
3 5 (2.5)
Hand-foot syndrome (n=199) No 162 (81.0)
Yes 1 27 (13.5)
2 8 (4.0)
3 2 (1.0)
.
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ABCG2 421 
C/A
CC vs 1 1
CA + AA 2.09 
(0.88–4.96)
.096 1.93 
(0.85–4.42)
0.118
ABCG2 
haplotype ξ      
TT-TT + TT-
other vs
1 1
Other-other 1.93 
(0.96–3.86)
.065 1.77 
(0.91–3.46)
0.093
PDGFRα 
haplotype ψ
TGAT-TGAT + 
TGAT-other 
1 1
vs Other-other 0.44 
(0.17–1.18)
.103 0.36 
(0.14–0.92)
0.033
Leukopenia Age 1.01 
(0.98–1.04)
.423
(n=188) Gender 0.81 
(0.41–1.60)
.536
ECOG 0.57 
(0.36–0.90)
.016
VEGFR-2 
-92G/A
GG → GA → 
AA 
0.74 
(0.44–1.23)
.241 0.74 
(0.45–1.22)
.235
VEGFR-2 
1718 T/A
TT → AT → 
AA
1.49 
(0.84–2.66)
.172 1.47 
(0.83–2.60)
.188
CYP1A1 
2455A/G
AA → AG → 
GG
6.24 (1.20–
32.42)
.029 4.87 (1.06–
22.29)
.042
FLT 3 738T/C TT vs 1 1
CT + CC 0.36 
(0.17–0.77)
.008 0.41 
(0.20–0.85)
.016
NR1I3 
haplotype Ω 
CAG-CAG → 
CAG-other → 
other-other
1.74 
(1.02–2.96)
.041 1.81 
(1.07–3.04)
.026
NR1I3 
haplotype Ω
TCT-TCT → 
TCT-other → 
Other-other
0.54 
(0.27–1.06)
.074 0.55 
(0.28–1.06)
.075
Any toxicity > grade 2 Age 1.03 
(0.99–1.07)
.140
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(n=183) Gender 1.71 
(0.69–4.26)
.248
ECOG 1.31 
(0.79–2.19)
.299
BSA 0.22 
(0.02–2.49)
.220
VEGFR-2 
1191 C/T
CC → TC → TT 2.39 
(1.02–5.60)
.046 2.31 
(1.07–4.99)
.033
ABCG2 
haplotype ξ 
TT-TT + TT-
other vs
1 1
Other-other 0.38 
(0.17–0.83)
.016 0.40 
(0.19–0.84)
.016
Mucosal Inflammation Age 1.00 
(0.97–1.03)
.956
Gender 1.54 
(0.82–2.88)
.177
(n=193) ECOG 1.31 
(0.86–1.99)
.212
NR1I2  
-24113G/A
GG vs 1 1
AG + AA 0.58 
(0.30–1.13)
.110 0.55 
(0.29–1.04)
.064
CYP1A1 
2455A/G 
AA → AG → 
GG
4.03 (1.24–
13.09)
.021 4.15 (1.29–
13.36)
.017
ABCG2 
34G/A
GG → AG 2.45 
(0.74–8.17)
.144 2.41 
(0.75–7.76)
.140
NR1I3 
haplotype Ω
TCT-TCT → 
TCT-other → 
Other-other
0.78 
(0.42–1.44)
.420 0.77 
(0.42–1.42)
.404
Hand-Foot Syndrome Age 0.99 
(0.96–1.02)
.563
(n=182) Gender 1.22 
(0.56–2.68)
.612
ECOG 0.76 
(0.43–1.33)
.336
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity 85
endpoint severe toxicity is different in both studies as well as the observed study period 
(whole sunitinib treatment period v first treatment cycle in our study). 
To our knowledge, we report for the first time herein that the ABCB1 TTT haplotype 
was related to hand-foot syndrome. The TTT haplotype as well as the T genotype in 
3435C/T and the T polymorphism in 1236C/T separately have been associated with 
higher exposures to drugs transported by ABCB1 due to a decreased expression of the 
ABCB1 transporter.26-31 Also, for the other ABC-transporter investigated, ABCG2, the TT 
haplotype was related to the development of increased toxicity (eg, any toxicity > grade 
2). This haplotype has been associated with increased erlotinib exposure, a tyrosine 
kinase inhibitor that uses metabolic and predisposition pathways similar to those of 
sunitinib.32 Thus, our results concerning ABCB1 and ABCG2 are in line with previously 
reported functional consequences of the studied genetic variants and might lead to an 
increased systemic exposure to sunitinib resulting in dose-limiting toxicities. Certainly, 
to confirm our findings, further studies that relate pharmacogenetics to pharmacokinet-
ics and pharmacodynamics are required. 
Thus far, the extrahepatic CYP1A1 enzyme has not been described as being involved 
in the metabolism of sunitinib. For other receptor tyrosine kinase inhibitors, such as 
erlotinib, imatinib and gefitinib affinity for CYP1A1 has been demonstrated in in vitro 
studies.22, 23 Therefore, we also included genetic variants of CYP1A1 in the present study. 
The polymorphism studied in CYP1A1 resulting in an amino acid change of isoleucine 
462 Valine was found to be related to the occurrence of mucosal inflammation and leu-
kopenia. This suggests that CYP1A1 may also play a role in the metabolism of sunitinib 
in vivo. 
ABCB1 
haplotype ∞
TTT-TTT + 
TTT-other 
1 1
vs Other-other 0.39 
(0.16–0.94)
.035 0.39 
(0.16–0.92)
.032
ABCB1 
haplotype ∞
CTT-CTT → 
CTT-other →   
Other-other
0.38 
(0.11–1.32)
.126 0.36 
(0.10–1.27)
.114
Abbreviations: OR, odds ratio; CI, confidential interval; ECOG, Eastern Cooperative Oncology Group.
Multiplicative model is indicated with (→) between the genotypes
Dominant and recessive models are indicated with (vs) between the two groups of genotypes
1: All toxicity outcomes in the corrected analysis are corrected for; age, gender and ECOG performance 
status. Additional correction with body surface area (BSA) was done for Any toxicity > grade 2. Under the 
uncorrected data only the genotypes are included in the multivariate analysis. 
Description haplotypes: ξ = ABCG2 -15622C/T and 1143C/T; ψ = PDGFRα -573G/T, -1171C/G, -735G/A and 
1580T/C; Ω = NR1I3 5719C/T, 7738A/C and 7837T/G; ∞ = ABCB1 3435C/T, 1236C/T and 2677G/T
P-value < .05 is regarded as significant and printed bold.
Description of polymorphisms and rs-numbers: See table
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In addition, we investigated genetic polymorphisms in the NR1I3 gene, encoding the 
constitutive androstane receptor. This nuclear receptor plays an important role in the 
regulation of multiple drug detoxification genes, such as CYP3A4. The functionality of 
polymorphisms in NR1I3 is not yet fully elucidated, however we found a relationship 
between the absence of the CAG haplotype in this gene and an increased risk for leu-
kopenia33. Obviously, it would be interesting to relate this polymorphism with sunitinib 
exposure levels in future studies.  
The VEGFR-2 1191CT and TT genotypes were found to be predictive for the develop-
ment of coronary heart disease due to a lower binding efficiency of VEGF to the poly-
morphic VEGFR-2.34 In our study, these genotypes were related to the development of 
any toxicity higher than 2, which predominantly included fatigue, thrombocytopenia, 
and hypertension. The polymorphic receptor might therefore be involved in sunitinib-
induced cardiac toxicity and the development of hypertension.   
The importance of the FLT3 receptor has been described in relation to the develop-
ment of several subtypes of leukemia such as acute myeloid leukemia, acute lympho-
cytic leukemia, and chronic myeloid leukemia, in which FLT3 is frequently overexpressed 
and/or mutated.35, 36 However, the association between FLT3 738T/C polymorphism and 
a reduction in the risk of leukopenia has not previously been described. Since sunitinib-
induced leukopenia could be regulated strongly by this polymorphic receptor the clini-
cal relevance should be further investigated. 
In our study, a large number of candidate polymorphic loci were evaluated and 
multiple analyses of each genetic polymorphism were performed. This introduces the 
potential problem of multiple testing which increases the risk to find false-positive 
relations. However, our study was designed to explore associations that should be con-
firmed in an independent group of patients. The presented odds ratios and CIs facilitate 
comparisons of replicate studies with our data. 
The ECOG performance status was not consistently related to the occurrence of toxici-
ties in our study. The quantified performance status is multifactorial and is dependent 
on subjective interpretation of the physician. Moreover, in our study patients with poor 
performance status had relatively high baseline thrombocyte and leukocyte counts 
resulting in a small number of reported leukopenia and thrombocytopenia in this group 
in the first treatment cycle. 
Toxicities in the first treatment cycle of sunitinib were used as outcome measure. The 
rationale was that signs of clinical deterioration from disease progression in later cycles 
could be misinterpreted and would interfere with the drug-induced toxicity outcome. 
We hypothesized that patients that suffer from relatively mild (grade 1 or 2) toxicities in 
the first treatment cycle were at risk for developing more severe toxicity during further 
treatment cycles because the two weeks of rest would not be sufficient for patients to 
recover to baseline conditions. This cumulative effect is underscored by measured blood 
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cell counts and the observed dose reduction after cycle 1 to 3. Indeed, we found for 
leukocyte count and to a lesser extent also for thrombocyte count, that 91% and 73%, 
respectively, of the patients had not returned to baseline values (defined as > 90% of 
baseline counts) at cycle 2 day 1 (data not shown). In addition, we found that mucosal 
inflammation and any toxicity higher than grade 2 were strongly related to a dose reduc-
tion after cycle 1 to 3, indicating that these toxicities are regarded as clinically relevant 
to the treating physicians. 
Together, the genetic, clinical and demographic determinants in this exploratory 
study explain between 10 and 23% of the total variance in toxicity response. Although 
it indicates that the major part of the variability is left unexplained, it also shows that 
pharmacogenetics may make a greater contribution to explaining variability in sunitinib 
toxicity as compared to the nongenetic determinants in our study. From this study we 
cannot conclude whether the genetic variants are prognostic or predictive markers, due 
to the absence of a placebo-treated control group of patients. However in the future, 
pharmacogenetics may help to select patients which need a priori dose reduction to 
prevent toxicities. 
In conclusion, this study suggests a relationship between polymorphisms in the genes 
CYP1A1, ABCB1, ABCG2, NR1I3, VEGFR-2 and FLT3 and the development of sunitinib toxic-
ity. The next step will be to validate our data with the aim to better understand the 
determinants of sunitinib toxicity. 
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TRAnSlATIOnAl RElEvAnCE 
Currently, sunitinib is the most widely prescribed drug for the treatment of metastatic 
renal cell cancer. Unfortunately, only a part of treated patients will benefit from suni-
tinib therapy, despite the implementation of clinical prognostic criteria in the choice of 
therapy. As multiple systemic treatment modalities arise, a further refinement is needed 
to identify renal cell cancer patients who predispose to benefit from sunitinib treatment 
and patients who do not. One of the possible options to study the differential response 
to sunitinib treatment is to identify genetic polymorphisms related to the pharmacoki-
netics and pharmacodynamics of this drug. In the future, genetic variants may be added 
to the current prognostic criteria, enabling physicians to predict benefit from sunitinib 
in individual patients.   
AbSTRACT 
Purpose: The objective of this study was to identify genetic polymorphisms related to 
the pharmacokinetics and pharmacodynamics of sunitinib that are associated with a 
prolonged progression-free survival (PFS) and/or overall survival (OS) in patients with 
clear-cell metastatic renal cell cancer (mRCC) treated with sunitinib.
Experimental design: A retrospective multicenter pharmacogenetic association study 
was performed in 136 clear-cell mRCC patients treated with sunitinib. A total of 30 
polymorphisms in 11 candidate genes, together with clinical characteristics were tested 
univariately for association with PFS as primary and OS as secondary outcome. Candi-
date variables with P-value <0.1 were analyzed in a multivariate Cox regression model.
Results: Multivariate analysis showed that PFS was significantly improved when an 
A-allele was present in CYP3A5 6986A/G (Hazard ratio [HR], 0.27;P=0.032), a CAT copy 
was absent in the NR1I3 haplotype (5719C/T, 7738A/C, 7837T/G; HR, 1.76;P=0.017) 
and a TCG copy was present in the ABCB1 haplotype (3435C/T, 1236C/T, 2677G/T; HR, 
0.52;P=0.033). Carriers with a favorable genetic profile (n=95) had an improved PFS and 
OS as compared to non-carriers (median PFS and OS: 13.1 vs. 7.5 months and 19.9 vs. 
12.3 months). Next to the genetic variants, the Memorial Sloan-Kettering Cancer Center 
prognostic criteria were associated with PFS and OS (HR, 1.99 and 2.27;P <0.001). 
Conclusions: This exploratory study shows that genetic polymorphisms in three genes 
involved in sunitinib pharmacokinetics are associated with PFS in mRCC patients treated 
with this drug. These findings advocate prospective validation and further elucidation of 
these genetic determinants in relation to sunitinib exposure and efficacy.   
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InTROduCTIOn
For decades, the treatment options of metastatic renal cell cancer (mRCC) have been 
limited and systemic treatment primarily consisted of immunotherapy with cytokines. 
Increasing knowledge of the underlying biology of renal cell cancer (RCC), in particular 
the clear-cell subtype, has expanded the treatment options for patients with mRCC (1). 
RCC is characterized by an inactivated von Hippel-Lindau (VHL) tumor suppressor gene. 
Inactivated VHL leads to elevated protein levels of hypoxia-induced factor-α (HIF-1α) 
which upregulates vascular endothelial growth factor (VEGF) and platelet-derived 
growth factor (PDGF) genes and proteins. The development of targeted therapy against 
signaling of these proteins has significantly improved the perspectives of patients with 
mRCC. 
Currently, sunitinib is the most widely prescribed drug for the treatment of mRCC and 
has been registered as first-line and second-line therapy. Sunitinib is an oral tyrosine 
kinase inhibitor (TKI) which targets several receptors including VEGF receptors-1,-2,-3, 
platelet-derived growth factor receptors-α and –β, c-KIT and FLT-3. In a randomized 
controlled trial, sunitinib significantly prolonged the progression-free survival (PFS) and 
overall survival (OS) as compared to interferon-α (2,3). Although sunitinib can achieve 
partial response rates of up to 40% (3-5), approximately 35% of mRCC patients do not 
benefit from sunitinib treatment (4,5). Since sunitinib treatment may also result in un-
necessary toxicities (6,7), pre-treatment markers to identify mRCC patients with a favor-
able outcome to sunitinib treatment are warranted. 
Sunitinib efficacy may be dependent on its exposure which is regulated by efflux 
pumps and metabolizing enzymes. After oral administration, the systemic exposure of 
sunitinib is initially determined by its absorption in the gastrointestinal tract (Figure 1). 
This process may be regulated by active drug transport over the intestinal wall, as suni-
tinib may be a substrate for polyspecific efflux transporters, expressed on enterocytes 
(8,9). The efflux transporters ABCB1 (ATP binding cassette member B1, formerly known 
as P-glycoprotein or MDR1) and ABCG2 (ATP binding cassette member G2, formerly 
known as breast cancer-resistance protein [BCRP] or mitoxantrone resistant protein 
[MXR]) are expressed in the intestine and liver, and are involved in the oral absorption 
and biliary secretion of several anticancer drugs (10). Therefore, expression levels and 
functionality of these drug transporters may have important consequences for the ef-
ficacy of sunitinib.
The cytochrome P450 (CYP) 3A (CYP3A) family is the predominant drug metaboliz-
ing enzyme and CYP3A4 is thought to be the key enzyme for the biotransformation of 
sunitinib (11). CYP3A4 is predominantly found in the liver and its expression is regulated 
by the ligand-activated nuclear receptors NR1I2 (pregnane X receptor [PXR]) and NR1I3 
(constitutive androstane receptor [CAR]) (12). In addition, other enzymes of the cyto-
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chrome P450 family (CYP3A5, CYP1A1 and CYP1A2) may metabolize sunitinib, as these 
enzymes are known to be involved in the metabolism of other TKIs (13). 
Besides pharmacokinetic factors, pharmacodynamic factors may determine the ef-
ficacy of sunitinib. In RCC, sunitinib is thought to exert its major therapeutic effect by in-
hibition of the vascular endothelial growth factor receptor (VEGFR) on tumor-associated 
endothelium, leading to reduced tumor angiogenesis (14). In addition, inhibition of 
the platelet-derived growth factor receptor (PDGFR) might increase the antiangiogenic 
effects of sunitinib by targeting pericytes, which are able to protect endothelial cells 
from apoptosis (15). As the main targets for sunitinib are thought to be located in the 
microenvironment of tumor cells, the efficacy of sunitinib treatment may be related 
to the genetics of the surrounding microenvironment (16). Particularly, genetic varia-
tion in VEGFR-2 may affect sunitinib activity, since VEGFR-2 is expressed in the normal 
endothelium (17) and the tumor vasculature may develop from pre-existing vessels of 
the host (18).  
Single nucleotide polymorphisms (SNP) in genes encoding for efflux transporters, 
metabolizing enzymes, and drug targets may affect the efficacy of sunitinib in mRCC, as 
SNPs in specific genes have previously been associated with sunitinib-induced toxicities 
in patients with mRCC and gastrointestinal stromal tumors (19,20). Therefore, SNPs may 
be useful markers for personalized treatment planning and may be candidate markers 
for selecting mRCC patients for sunitinib treatment. The objective of the current study 
Figure 1 Schematic diagram of the pharmacokinetic and pharmacodynamic pathways that may be 
involved in the efficacy of sunitinib in mRCC. 
* NR1I2 and NR1I3 regulate CYP3A4 expression 
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was to identify SNPs involved in the pharmacokinetics and pharmacodynamics of suni-
tinib that are associated with a prolonged PFS and/or OS in mRCC patients.
PATIEnTS And METhOdS
Study population
In our previous study, 219 sunitinib-treated patients with various maligancies were 
included to investigate the association between SNPs and sunitinib-induced toxicities 
(19). In the present study, a subset of patients with histologically proven clear-cell RCC 
were selected for the analyses. A total of 136 consecutive mRCC patients who initiated 
sunitinib treatment between December 2005 and May 2008 were included. Sunitinib 
was administered orally at a dose of 50 mg daily, consisting of 4 weeks of treatment 
followed by a 2-week rest-period in cycles of 6 weeks. Dose reductions of sunitinib were 
allowed depending on the type and severity of adverse events according to the current 
guidelines (21). The study was approved by the medical ethics review board.
Study design
Demographic and clinical data of patients were reported on case record forms designed 
for data collection for this study. Patient characteristics considered relevant for PFS 
and OS analysis were age, gender, Eastern Cooperative Oncology Group (ECOG) per-
formance status, prior systemic therapy, prior radiotherapy, the number of metastatic 
sites, and the risk factors according to Memorial Sloan-Kettering Cancer Center (MSKCC) 
prognostic criteria, which is based on 5 risk factors including low Karnofsky performance 
status (< 80%), high lactate dehydrogenase (LDH, > 1.5 times the upper limit of normal), 
low hemoglobin level, high corrected serum calcium (> 10 mg/dL), and time from initial 
diagnosis to treatment < 1 year (22). Residual blood or serum samples taken for routine 
patient care were stored at -20ºC at the local hospital laboratory. Of each patient one 
whole blood or serum sample was collected from the participating hospitals. All samples 
were anonymized by a third party, according to the instructions stated in the Codes for 
Proper Use and Proper Conduct in the Self-Regulatory Codes of Conduct (www.federa.
org). 
Genetic Polymorphisms
Nineteen polymorphisms in 7 genes involved in the pharmacokinetics and 11 polymor-
phisms in 4 genes involved in the pharmacodynamics of sunitinib were selected (see 
Table 4).  Selection criteria for the polymorphisms were a minor allelic frequency > 0.2 in 
Caucasians and an assumed clinical relevance based on previously reported associations 
96 Chapter 7
Table 1. Patient characteristics
Characteristic No %
Median age, years 60
   Range 25-84
Sex 
   Male 83 61.0
   Female 53 39.0
Ethnicity 
   Caucasian 130 95.6
   Black 3 2.2
   Asian 1 0.7
   Latin-American 1 0.7
   Arab 1 0.7
ECOG performance status*
   0 66 48.5
   1 54 39.7
   2 10 7.4
   3 4 2.9
   Missing 2 1.5
Previous medical treatments 
   Yes         56 41.2
   No 80 58.8
Previous treatment regimen 
   Cytokine-based therapy 45 33.1
   Anti-angiogenic therapy 4 2.9
   Both 7 5.1
Previous nephrectomy 
   Yes 105 77.2
   No 31 22.8
Previous radiation therapy 
   Yes 34 25.0
   No 102 75.0
No. of metastatic sites 
   1 31 22.8
   2 47 34.6
   ≥ 3 58 42.6
Sites of metastases 
   Lung 100 73.5
   Liver 33 24.3
   Bone 46 33.8
   Lymph nodes 61 44.9
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or the assumption that non-synonymous amino-acid change leads to changed protein 
functionality. 
The 11 candidate genes were selected on their potential relation with the pharmaco-
kinetics and pharmacodynamics of sunitinib (Figure 1). First, the candidate genotypes 
were selected by literature review. If there was no available data in the literature review, 
we referred to the SNPs from the dbSNP database (http://www.ncbi.nlm.nih.gov/sites/
entrez). ABCB1, ABCG2, NR1I2, NR1I3, CYP3A5, CYP1A1 and CYP1A2 were selected for the 
pharmacokinetic pathways, whereas VEGFR-2, VEGFR-3, PDGR-α, and FLT-3 were selected 
for the pharmacodynamic pathways. The most common functional SNPs in human 
ABCB1 are the synonymous 3435C>T and 1236C>T changes and the non-synonymous 
2677G>T change. As functional studies have shown that the haplotype of these three 
SNPs is a silent mutation and alters the function of the efflux transporter including its 
substrate specificity (23), the haplotype of ABCB1, instead of the three individual SNPs, 
was included in the analysis. Although VEGFR-1 is a target of sunitinib, and CYP3A4 is 
an important enzyme for metabolism of sunitinib (11), no polymorphisms of VEGFR-1 
and CYP3A4 were analyzed, as no functional polymorphisms met the criteria for SNP 
selection. 
Methods for genotyping assay validation and haplotype estimation have been 
described previously (19). Briefly, germline DNA was isolated from 1 mL of serum or 
EDTA-blood with the Magnapure LC (Roche Diagnostics, Almere, The Netherlands). Poly-
morphic sites in genomic DNA were analyzed with TaqMan assays (Applied Biosystems, 
Nieuwerkerk aan den IJssel, The Netherlands).
Statistical design and data analysis
For PFS and OS, data collection was closed on August 31, 2009. The primary outcome 
measures of this study, PFS, was defined as the time between the first day of sunitinib 
and the date of progressive disease (PD) according to Response Evaluation Criteria in 
Solid Tumors (24), clear clinical evidence of PD or death due to PD within 12 weeks after 
the last response evaluation. If a patient had not progressed, PFS was censored at the 
   Brain 5 3.7
MSKCC risk factors**
   0 (favorable) 33 24.3
   1 – 2 (intermediate) 81 59.6
    ≥ 3 (poor) 22 16.2
* ECOG, Eastern Cooperative Oncology Group
** Risk groups according to Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic criteria 
[based on the 5 risk factors: low Karnofsky performance status (< 80%), high LDH 
(> 1.5 times the upper limit of normal), low serum hemoglobin, high corrected serum calcium (> 10 
mg/dL), and time from initial diagnosis to treatment < 1 year] (22)
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Table 2.  Univariate and multivariate analyses of progression-free survival in mRCC patients treated with 
sunitinib
univariate Analyses* Multivariate Analyses
Factors no Median PFS 
(months)
95% 
CI
P hR** 95% CI P
Clinical factors
MSKCC risk factors††
  0
  1-2  
  ≥ 3
33
81
22
24.3
8.7
7.0
11.3-
37.2
6.3-
11.2
0.0-
14.4
0.001 1.988 1.394-
2.837
< 0.001†
No. of metastatic sites    
  1
  2   
  ≥ 3
31
47
58
19.4
11.0
8.1
7.8-
31.0
5.1-
16.8
7.6-8.6
0.019 1.400 1.042-
1.880
0.025†
Age (HR = 1.024 per year 
increase)
1.000-
1.048
0.047 1.031 per 
year increase
1.003-
1.060
0.029
genetic factors 
pharmacokinetic 
pathway
CYP3A5 6986A/G   
  GG vs.   
  AG + AA
117
11
9.3
Not reached
6.9-
11.8
-
0.017
1
0.266 0.079-
0.892
0.032
NR1I3 haplotype‡    
  Other-other vs.
  CAT-other + CAT-CAT
75
60
13.3
8.0
7.9-
18.8
7.5-8.6
0.021
1
1.758 1.108-
2.790
0.017
NR1I2 8055C/T
  CC+ CT vs. 
  TT 
119
17
10.8
6.7
8.0-
13.6
3.6-9.9
0.025
1
1.638 0.187-
14.380
0.656
NR1I2 -25385C/T    
  CC + CT vs. 
  TT 
118
18
10.8
6.7
8.0-
13.6
2.8-
10.7
0.032
1
0.755 0.091-
6.273
0.795
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time of the last follow-up. If the PD date was unknown or a patient died due to PD later 
than 12 weeks after the last response evaluation, PFS was censored at the last adequate 
tumor assessment. OS was the secondary outcome and was defined as the time between 
the first day of sunitinib treatment and the date of death or the date at which patients 
were last known to be alive.
All patient characteristics were tested univariately against the primary outcome us-
ing Kaplan-Meier and Cox-regression analysis, depending on the tested variables. The 
polymorphisms and haplotypes were tested univariately against PFS and OS using the 
Kaplan-Meier method. For this initial analysis, the general model was used. Given the 
explorative nature of this study, variables with a P-value ≤ 0.1 were selected as candidate 
variabeles for multivariate Cox-regression analyses. Data were fitted to the most appro-
priate model (multiplicative, dominant or recessive) and tested in the multivariate Cox 
regression survival analysis with PFS and OS as depending variables. Additional patient 
characteristics were introduced in the multivariate analyses based on univariately tested 
results if P-value < 0.1. Hazard ratios (HR) were generated considering patients with the 
most common clinical factor or genotype as the reference group. Missing data were 
kept as missing except for factors in the MSKCC score and the ECOG performance status. 
Patients with missing performance status (n = 2), LDH (n = 2), hemoglobin (n = 1) and 
baseline calcium values (n = 2) were assumed to be part of the worse prognosis scores. 
Accordingly, MSKCC scores were increased with one risk factor in 5 patients and with 
ABCB1 haplotype‡‡
  Other-other vs.
  TCG-other
100
29
8.4
15.2
7.0-9.7
6.1-
24.3
0.072
1
0.522 0.287-
0.950
0.033
ABCG2 34G/A
  GG vs. 
  AG 
124
12
9.0
19.4
6.9-
11.2
0.0-
40.8
0.077
1
0.713 0.269-
1.891
0.497
* Only factors with P-value < 0.1 level are presented; factors with P-value < 0.1 in the univariate analyses 
were selected for multivariate analyses
** HR < 1.0 indicates that the factor associates with improved PFS, HR > 1.0 associates with worse PFS
† Multiplicative model, HR per increase in MSKCC class or number of metastatic sites class
†† Risk groups according to Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic criteria [based on 
the 5 risk factors: low Karnofsky performance status 
 (< 80%), high LDH (> 1.5 times the upper limit of normal), low serum hemoglobin, high corrected serum 
calcium (> 10 mg/dL), and time from initial diagnosis to treatment < 1 year] (22) 
Description haplotypes: ‡ = NR1I3 5719C/T, 7738A/C and 7837T/G; ‡‡ = ABCB1 3435C/T, 1236C/T and 
2677G/T
Abbreviations: 95% CI, 95% confidence interval; PFS, progression-free survival; HR, hazard ratio
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3.  Table Univariate and multivariate analyses of overall survival in mRCC patients treated with sunitinib
univariate Analyses* Multivariate Analyses
Factors no Median OS 
(months)
95% CI P hR** 95% CI P
Clinical factors
MSKCC risk factors        
  0       
  1-2
   ≥ 3
33
81
22
Not reached
14.8
10.9
-
11.8-17.7
7.2-14.7
< 
0.001 2.273 1.595-
3.238
< 
0.001†
No. of metastatic sites 
  1
  2
   ≥ 3
31
47
58
28.8
15.6
13.2
15.3-42.2
13.5-17.7
9.5-16.9
0.058
1.273 0.957-
1.693
0.097†
genetic factors pharmacokinetic 
pathway
NR1I2 -25385C/T 
  CC + CT vs.
  TT
118
18
17.1
10.2
12.9-21.2
7.4-13.1
0.017
1
1.490 0.834-
2.660
0.178
ABCB1 haplotype‡
  Other-other vs. 
  TCG-other
100
29
15.4
23.9
12.4-18.3
9.0-38.7
0.097
1
0.593 0.332-
1.061
0.078
ABCG2 34G/A 
  GG vs. 
  AG 
124
12
15.4
39.9
12.5-18.3
16.7-63.1
0.072
1
0.416 0.162-
1.070
0.069
genetic factors 
pharmacodynamic pathway 
PDGFR-α haplotype‡‡
  GCGT-GCGT vs.
  GCG-other + other-other 
78
56
24.2
14.8
17.2-31.2
11.6-17.9
0.002
1
1.458 0.920-
2.310
0.108
VEGFR-2 -1718T/A 
  AA + AT vs. 
  TT
125
8
16.3
9.4
12.4-20.2
7.2-11.7
0.022
1
2.907 1.224-
6.903
0.016
* Only factors with P-value < 0.1 level are presented; factors with P-value < 0.1 in the univariate analyses 
were selected for multivariate analyses
** HR < 1.0 indicates that the factor associates with improved OS, HR > 1.0 associates with worse OS
† Multiplicative model, HR per increase in MSKCC class or number of disease sites class
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two risk factors in one patient. As a result 3 patients were categorized into the interme-
diate risk group, whereas 3 other patients were categorized into the poor risk group. 
Patients with missing ECOG performance statuses (n = 2) were scored as ECOG = 1. To 
test these assumptions, the multivariate analyses were performed with and without the 
replacement of the patients with missing factors in the MSKCC score. Similar results were 
generated, indicating that the replacement was legitimate. All statistical analyses were 
performed using SPSS 16.0 software (SPSS, Chicago, IL). A 20% improvement (HR, 0 = 
0.44) in PFS at ~1 year in patients with sunitinib was judged to be clinically meaningful 
by the investigators designing the study. Forty-six events with disease progression were 
estimated to be needed to detect such an improvement using a two-sided, unstratified 
log-rank test with an overall significance level of 0.05 and power of 0.80. All results from 
the multivariate analyses with P-values < 0.05 were considered significant. Since this is 
an explorative study, no correction for multiple testing was made. 
RESulTS
Study Population 
The main patient characteristics are presented in Table 1. Thirty-one (22.8%) patients had 
one metastatic site, 47 (34.6%) patients had two metastatic sites and 58 (42.6%) patients 
had at least 3 metastatic sites. According to the MSKCC prognostic criteria most patients 
(59.6%) were categorized into the intermediate risk group, whereas 24.3% and 16.2% of 
the patients were categorized into the favorable and poor risk group, respectively. At the 
time of the analysis, 47 (34.6%) patients were alive and 92 (67.6%) patients had disease 
progression. Overall, the median PFS time was 10.0 months (range, 7.6-12.4 months) 
and the median OS time was 16.3 months (range, 13.5-19.2 months). Of the clinical 
characteristics, the MSKCC risk factors had the largest contribution to PFS and OS (P = 
0.001 and P < 0.001, respectively) (Tables 2 and 3). In addition, the number of metastatic 
sites, age and the ECOG performance status were prognostic for PFS (P = 0.019, 0.047 
and 0.049, respectively), whereas only the ECOG performance status and the number of 
metastatic sites were also prognostic for OS (P = 0.004 and 0.058, respectively). 
†† Risk groups according to Memorial Sloan-
Kettering Cancer Center (MSKCC) prognostic 
criteria [based on the 5 risk factors: low Karnofsky 
performance status (< 80%), high LDH (> 1.5 times 
the upper limit of normal), low serum hemoglobin, 
high corrected serum calcium (> 10 mg/dL), and 
time from initial diagnosis to treatment < 1 year] 
(22).
Description haplotypes: ‡ = ABCB1 3435C/T, 
1236C/T and 2677G/T; ‡‡ = PDGFR-α 1580T/C 
-1171C/G -735G/A -573G/T
Abbreviations: 95% CI, 95% confidence interval; 
OS, overall survival; HR, hazard ratio
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Baseline characteristics entered into the multivariate Cox models included the MSKCC 
risk factors, the number of metastatic sites, and age for PFS analyses, and the MSKCC 
risk factors and the number of metastatic sites for OS analyses. The ECOG performance 
status was excluded from the multivariate analyses due to co-linearity with the MSKCC 
prognostic criteria (22).
Table 4: Polymorphisms genotyped in the pharmacokinetic and pharmacodynamic pathways of 
sunitinib 
Gene Polymorphism rs-number
Pharmacokinetic pathway ABCG2 421C/A rs2231142
34G/A rs2231137
-15622C/T *
1143C/T rs2622604
ABCB1 3435C/T rs1045642
1236C/T rs1128503
2677G/T rs2032582
NR1I2 -25385C/T rs3814055
-24113G/A rs2276706
7635A/G rs6785049
8055C/T rs2276707
10620C/T rs1054190
10799G/A rs1054191
NR1I3 5719C/T rs2307424
7738A/C rs2307418
7837T/G rs4073054
CYP3A5 6986A/G rs776746
CYP1A1 2455A/G rs1048943
CYP1A2 -163A/C rs762551
Pharmacodynamic pathway VEGFR-2 (= KDR) -604T/C rs2071559
-92G/A rs1531289
54T/C rs7692791
1191C/T rs2305948
1718T/A rs1870377
VEGFR-3 (= FLT-4) 1501A/G rs307826
PDGFR-α 1580T/C rs35597368
-1171C/G rs1800810
-735G/A rs1800813
-573G/T rs1800812
FLT-3 738T/C rs1933437
* No rs-number assigned yet
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Pharmacogenetic Factors for Sunitinib and Progression-free survival  
Among the 30 studied polymorphisms, only polymorphisms related to the pharma-
cokinetics of sunitinib were predictive of PFS (Table 2). A prolonged PFS was found in 
the univariate analysis of patients with presence of the A-allele in CYP3A5 6986A/G (P 
= 0.017), absence of a CAT copy in the NR1I3 haplotype (P = 0.021), presence of the 
C-allele in NR1I2 8055C/T (P = 0.025), presence of the C-allele in NR1I2 -25385C/T (P = 
0.032), presence of a TCG copy in the ABCB1 haplotype (P = 0.072) and presence of the 
A-allele in ABCG2 (34G/A) (P = 0.077). Together with the MSKCC risk factors, the numbers 
of metastatic sites and age, these polymorphisms were entered with into the multivari-
ate Cox model. 
Multivariate analysis confirmed the following factors as significant (< 0.05) predictors 
of improved PFS: the MSKCC risk factors (HR: 1.988; 95%CI, 1.394-2.837), the number of 
metastatic sites (HR: 1.400; 95%CI, 1.042-1.880), age (HR: 1.031 per year increase; 95%CI, 
1.003-1.060), presence of the A-allele in CYP3A5 6986A/G (HR: 0.266; 95%CI, 0.079-0.892), 
absence of a CAT copy in the NR1I3 haplotype (HR: 1.758; 95%CI, 1.108-2.790), and a TCG 
copy in the ABCB1 haplotype (HR: 0.522; 95%CI, 0.287-0.950). 
Pharmacogenetic Factors for Sunitinib and Overall Survival 
In univariate analysis, polymorphisms related to the pharmacokinetics and pharmaco-
dynamics of sunitinib were predictive of OS (Table 3). Of the pharmacokinetic polymor-
phisms, presence of the C-allele in NR1I2 -25385C/T (P = 0.017), presence of a TCG copy 
in the ABCB1 haplotype (P = 0.097) and presence of the A-allele in ABCG2 34G/A (P = 
0.072) were associated with a prolonged OS. In addition, univariate analyses identified 
two pharmacodynamic polymorphisms including two GCGT copies in the PDGFR-α 
haplotype and presence of the A-allele in VEGFR-2 1718T/A as factors for a prolonged OS 
(P = 0.002 and 0.022, respectively).
Multivariate analysis confirmed the MSKCC risk factors (HR: 2.273; 95%CI, 1.595-3.238) 
and the presence of the A-allele in VEGFR-2 1718T/A (HR: 2.907; 95%CI, 1.224-6.903) as 
significant (< 0.05) predictors of a prolonged OS. In multivariate analysis, there was a 
trend towards an improved OS for patients with a TCG copy in the ABCB1 haplotype (HR: 
0.593; 95%CI, 0.332-1.061; P = 0.078) or presence of the A-allele in ABCG2 34G/A (HR: 
0.416; 95%CI, 0.162-1.070; P = 0.069).
Favorable Genetic Profiles and Outcome 
Polymorphisms that were associated with an improved PFS were combined in a predic-
tive model. Patients were categorized as carriers of the favorable genetic profiles when 
they had at least an A-allele in CYP3A5, a TCG copy in the ABCB1 haplotype or a missing 
CAT copy in the NR1I3 haplotype. Carriers with a favorable genetic profile (n = 95) had an 
improved PFS and OS as compared to non-carriers (median PFS: 13.1 vs. 7.5 months, P = 
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0.001 and median OS: 19.9 vs. 12.3 months, P = 0.009). Multivariate analysis including the 
clinical factors showed consistent predictive value of the model for PFS and showed a 
trend for OS (HR: 0.541; 95%CI, 0.340-0.860, P = 0.009 and HR: 0.667; 95%CI, 0.420-1.058, 
P = 0.085, respectively) (Figure 2). 
dISCuSSIOn
In mRCC patients treated with sunitinib, the MSKCC risk groups and the number of 
metastatic sites are clinical factors that are usually associated with PFS and OS (2,3,7). 
However, these clinical factors are prognostic criteria that are associated with the extent 
of the disease and do not necessarily predict antitumor efficacy of a specific drug. As an 
increasing number of drugs is currently available for the treatment of mRCC (25), tools 
are needed to identify patients who predispose to benefit from sunitinib treatment and 
to select individual mRCC patients for treatment with this drug. The efficacy of sunitinib 
may be influenced by multiple genes encoding for enzymes, efflux transporters and 
targets related to the pharmacokinetics and pharmacodynamics of sunitinib. Therefore, 
we analyzed whether SNPs in the pharmacokinetic and pharmacodynamic pathways 
of sunitinib were predictive of PFS and OS in patients with clear-cell mRCC. Our study 
showed that next to 3 clinical characteristics (MSKCC prognostic criteria, number of 
metastatic sites and age), 3 genetic variants in the CYP3A5, NR1I3 and ABCB1 genes 
were predictive factors for PFS. In addition, a role of an A-allele in VEGFR-2 1718T/A for a 
prolonged OS as a secondary outcome was found. 
Clinical benefit from sunitinib treatment may depend on systemic exposure to suni-
tinib. Sunitinib is metabolized primarily to the active N-de-ethylated metabolite SU12662, 
Figure 2 Favorable ( ____ ) and non-favorable genetic profile ( ----- ) in mRCC patients treated with 
sunitinib for progression-free (A) and overall survival (B) using multivariate Cox regression analysis. 
Patients were categorized as carriers of the favorable genetic profiles when they had at least an A-allele in 
CYP3A5, a TCG copy in the ABCB1 haplotype or a missing CAT copy in the NR1I3 haplotype.
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which reaches similar plasma concentrations and has equipotent biochemical activity as 
the parent compound (26). Thereafter, SU12662 undergoes a second N-de-ethylation 
step, which occurs at a slower rate, to the inactive metabolite SU14335.  Recently, a 
meta-analysis of pharmacokinetic data in 443 patients treated with sunitinib, showed 
that higher plasma levels of sunitinib and its active metabolite SU12662 were associated 
with a prolonged time-to-tumor progression and OS (27). Currently, it is not clear which 
underlying factors account for the observed inter-individual differences in plasma levels 
of sunitinib and its active metabolite SU12662. Inter-individual differences in sunitinib 
exposure may be the result of variations in sunitinib absorption, metabolism, distribu-
tion and excretion through metabolizing enzymes and transporter proteins. Concerning 
the pharmacokinetics of sunitinib, the present study identified variants in three genes 
(CYP3A5, NR1I3 and ABCB1) as predictive factors for PFS in mRCC patients treated with 
sunitinib. Although these polymorphisms were not predictive of OS, there was a trend 
towards a prolonged OS for patients with a TCG copy in the ABCB1 haplotype. Additional 
treatment after discontinuation of sunitinib treatment may explain the discrepancy 
between the results of the PFS and OS analyses, as 26% of patients were subsequently 
treated with at least one other agent, including sorafenib (22%), temsirolimus (2%) and 
everolimus (4%).
CYP3A4 is the major key enzyme for the biotransformation of sunitinib (11). How-
ever, no polymorphisms of CYP3A4 were analyzed in the present study, as there are no 
functional polymorphisms in CYP3A4 that meet our described criteria for SNP selection 
yet. The CYP3A5 enzyme is another important enzyme for the metabolism of several 
TKIs including erlotinib, gefitinib and imatinib (13). Similarly, the CYP3A5 enzyme may 
metabolize sunitinib and was therefore included in the analysis, though the sunitinib-
metabolizing capacity of CYP3A5 has to be confirmed. In the current study, presence of 
the A-allele in CYP3A5, a SNP which leads to the CYP3A5 expressor phenotype (28,29), 
was a predictive factor for a prolonged PFS. As the CYP3A5 expressor phenotype may 
lead to increased metabolism of sunitinib, these findings suggest that the prolonged 
PFS in patients with presence of the A-allele in CYP3A5 may be caused by increased 
levels of the active metabolite SU12662, which has a longer half-life than the parent 
compound (80-100 hours vs. 40-60 hours) (26). Furthermore, polymorphisms in other 
genes (NR1I2 and NR1I3) that regulate the expression of CYP3A4 (12) were identified as 
predictive factors for outcome in sunitinib-treated mRCC patients. 
The efflux transporters ABCB1 and ABCG2 play an important role in drug absorption, 
excretion, cellular accumulation and resistance (10). Consequently, polymorphisms in 
ABCB1 and ABCG2 may affect drug absorption and excretion of sunitinib. In the present 
study, the found associations between polymorphisms in the ABCB1 haplotype (a TCG 
copy) and the ABCG2 gene (presence of the A-allele), and improved outcome suggest 
that these polymorphisms may lead to reduced efflux transport of sunitinib into the 
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gastrointestinal lumen and bile, resulting in increased systemic exposure of sunitinib. 
In vitro studies have reported conflicting data on the affinity of sunitinib for ABCB1 and 
ABCG2 (8,9). Hu et al (8) found a moderate affinity of sunitinib for ABCB1 and a negligible 
transport of sunitinib in cells over-expressing ABCG2, whereas another study reported 
higher sunitinib affinity for ABCG2 compared with ABCB1 (9). Furthermore, sunitinib 
reversed ABCG2-mediated multidrug resistance by inhibiting the drug efflux function 
of ABCG2 (30). This inhibitory capacity of sunitinib on ABCG2 appeared to be sensitive 
for the ABCG2 1291T>C genotype (31). In addition, another SNP in ABCG2 (421C>A) was 
associated with increased sunitinib exposure (32). 
The ABC transporters may contribute to multidrug resistance in tumors by actively 
extruding drugs from cancer cells. In RCC, an increase in ABCB1 expression (33,34) and 
activity (35) has been reported, suggesting a contribution of ABCB1 to the resistance 
of RCC to some anticancer drugs. Although polymorphisms in ABCB1 and ABCG2 may 
be associated with the development of RCC (36,37), it is currently not known whether 
polymorphisms in ABCB1 and ABCG2 are associated with the expression and function of 
these transporters at the somatic level in renal cancer cells (38). Nevertheless, the role 
of efflux transporters in tumor cells may be limited for acquired resistance to sunitinib, 
which may develop after an initial response to sunitinib, as acquired resistance to suni-
tinib may be more related to physiological changes in the microenvironment of tumors, 
allowing reestablishment of angiogenesis during sunitinib treatment (16). 
Clinical efficacy of treatment with TKIs may also be related to specific mutations in 
drug targets, as was shown for imatinib and gefitinib (39,40). Currently, it is not known 
which targets in RCC predict response to sunitinib or whether the somatic polymor-
phisms of targets in RCC correlate with genetic polymorphisms obtained from germline 
cells. Of the studied pharmacodynamic polymorphisms of sunitinib, only a polymor-
phism of VEGFR-2 1718T/A was associated with a decreased OS in multivariate analysis, 
whereas the presence of two GCGT copies in the PDGFR-α haplotype was associated 
with a prolonged OS in univariate analysis. However, no significant association between 
these polymorphisms and PFS was found. These findings may suggest that polymor-
phisms in VEGFR-2 and PDGFR-α may be associated with the nature of the disease and 
may therefore be prognostic instead of predictive. However, prospective validation in an 
independent mRCC cohort that is not treated with sunitinib is necessary to determine 
whether the associated polymorphisms of the present study are predictive markers of 
sunitinib activity or prognostic markers of mRCC disease. 
In our previous study, several polymorphisms in genes involved in the pharmacokinetic 
and pharmacodynamic pathways of sunitinib were associated with sunitinib-induced 
toxicity (19). Polymorphisms of NR1I3 (absence of a CAG copy in the haplotype), ABCB1 
(presence of a TTT copy) and VEGFR-2 (T allele in 1191 C/T) were significantly related 
with an increased risk for leucocytopenia, hand-foot syndrome and any toxicity > grade 
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2, respectively (19). In the present study however, other genotypes or haplotypes in 
NR1I3, ABCB1 and VEGFR-2 were associated with clinical outcome. It is currently not clear 
how the different genotypes and haplotypes between these studies are related, but it 
is conceivable that severity and prevalence of some sunitinib-induced toxicities may 
basically depend on inhibition of a specific molecular pathway rather than variation in 
exposure, whereas other sunitinib-induced toxicities may mainly depend on exposure 
to the drug. In addition, the discrepancy between these two studies may be the result of 
different study populations, as patients with different malignancies were included in our 
previous study. Recently, Houk et al (27) have shown a relationship between sunitinib 
exposure and the probability of grade ≥ 1 fatigue, the absolute neutrophil count and the 
changes in diastolic blood pressure. However, these sunitinib-induced toxicities cannot 
be extrapolated to our previous toxicity study (19), as different toxicities and grades of 
toxicity were analyzed in both studies. 
A potential limitation of the study is the retrospective design. As a result, pharmaco-
kinetic data were not available to correlate polymorphisms of CYP3A5, NR1I3 and ABCB1 
with plasma levels of sunitinib and its active metabolite SU12662. If future studies reveal 
a relation between sunitinib exposure and presence of an A-allele in CYP3A5 6986A/G, 
absence of a CAT copy in the NR1I3 haplotype or presence of a TCG copy in the ABCB1 
haplotype, the sunitinib starting dose may be adjusted to dose-escalation of sunitinib 
> 50 mg/daily for patients without these genotypes and haplotypes. The non-beneficial 
genetic profile may be used to select patients who may be eligible for alternative dosing 
schedules with intensive monitoring of plasma levels of sunitinib and its active metabo-
lite SU12662. Before this genetic profile can be implemented, prospective validation in 
an independent patient population is necessary. 
In conclusion, pharmacokinetic but not pharmacodynamic polymorphisms were in-
dependent predictive factors for PFS in patients with clear-cell mRCC who were treated 
with sunitinib. Patients with an A-allele in CYP3A5 6986A/G, absence of a CAT copy in the 
NR1I3 haplotype or presence of a TCG copy in the ABCB1 haplotype had a prolonged PFS. 
These polymorphisms may be valuable factors to identify patients with reduced expo-
sure to sunitinib in order to improve treatment strategies in these patients. The findings 
of this study advocate more pharmacokinetic studies in patients treated with sunitinib 
to further elucidate the role of these genetic determinants in sunitinib exposure and 
efficacy.  
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AbSTRACT
Purpose: Hypertension is a common side-effect in patients treated with sunitinib. We 
investigated whether polymorphisms in genes involved in regulation of blood vessel 
tone can predict blood pressure change and hypertension during sunitinib treatment. In 
addition, possible association of hypertension with survival was evaluated in the subset 
of patients with metastatic renal cell cancer (mRCC). 
Patients and Methods: In 291 sunitinib-treated patients, single nucleotide polymor-
phisms in VEGFA (rs2010963, rs833061, rs3025039, rs699947), VEGFR-2 (rs1870377), ET-1 
(rs5370) and eNOS (rs2070744) were multivariately tested against the maximal change 
in systolic (SBP), diastolic (DBP) and mean arterial (MAP) blood pressure and hyperten-
sion grades during the first treatment cycle.  Overall survival (OS) was assessed in mRCC 
patients of the clear-cell type (n = 158) for a possible relation with hypertension.
Results: A higher rise in SBP and MAP was associated with presence of an ACG haplo-
type in VEGFA rs699947, rs833061 and rs2010963 (P = .014 and P = .036). Development 
of hypertension grade 3 was associated with the same haplotype and with a C allele in 
eNOS rs2070744 (P = .031 and P = .045; respectively). Mean OS in sunitinib-treated mRCC 
patients suffering from hypertension was prolonged with 7.2 months (P = .035; P = .026; 
for SBP and DBP, respectively).
Conclusion: Hypertension during sunitinib treatment in mRCC patients of the clear-
cell type is an independent factor for OS and is potentially suitable as a biomarker for 
outcome. Genetic polymorphisms in VEGFA and eNOS independently predict blood 
pressure rise and/or severe hypertension in sunitinib-treated patients. 
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InTROduCTIOn
Sunitinib is a multi-targeted tyrosine kinase inhibitor, known to inhibit autophosphory-
lation in several drug targets such as the vascular endothelial growth factor receptor 
(VEGFR) and KIT.1 VEGFR and its ligand VEGF play a key role in the regulation of angio-
genesis,2 which is essential for growth and metastatic spread of malignant tumors.3-4 The 
introduction of this agent in the clinic has improved the perspectives of several patient 
populations including patients with metastatic renal cell cancer (mRCC), advanced 
gastrointestinal stromal cell tumors (GIST) and neuroendocrine tumors.5-8 
Treatment with VEGF inhibitors, such as sunitinib, is associated with an increase in 
blood pressure in a substantial proportion of patients. Although hypertension induced 
by drugs targeting the VEGF pathway is usually manageable, a number of patients 
require dose reductions of these drugs or even treatment discontinuation. Recent stud-
ies, however, have shown that the development of hypertension during VEGF/VEGFR-2 
inhibition is associated with improved clinical outcome in mRCC patients.9-14 The exact 
mechanism by which VEGF inhibitors induce hypertension has not been completely 
clarified. Previous studies have shown that VEGFR-2 is involved in the regulation of 
vascular tone. Activation of VEGFR-2 via phosphoinositide 3-kinase (PI3K) and its down-
stream serine protein kinase Akt stimulates endothelium-derived nitric oxide synthase 
(eNOS), subsequently leading to the production of the potent vasodilator nitric oxide 
(NO) (Figure 1). In addition, decreased NO bioavailability favors the production and/or 
activity of endothelin-1 (ET-1) through the loss of inhibitory effects of NO on ET-1.15-16 
Indeed, plasma ET-1 concentrations have been described to increase in subjects treated 
with sunitinib.17-18 Consequently, it could be hypothesized that inhibition of VEGFR-2 
causes an imbalance between the vasodilator NO en the vasoconstrictor ET-1, favouring 
ET-1 and thereby resulting in the development of hypertension. 
Currently, predisposing factors for the development of hypertension during treatment 
with VEGF inhibitors have not been identified.19 Polymorphisms in genes that are associ-
ated with the regulation of blood pressure may be involved in the differential occur-
rence of this side-effect in individual patients. In a previous study in patients with mRCC 
and GIST, we have demonstrated that several single nucleotide polymorphisms (SNP) in 
specific genes encoding for metabolizing enzymes, efflux transporters and drug targets 
are associated with sunitinib-induced toxicities.20 Polymorphisms in VEGFA and VEGFR-2 
and down-stream mediators eNOS and ET-1 may be important factors in blood pressure 
changes, since inhibition of the VEGFR-2 signalling route may decrease the production 
of NO leading to peripheral vasoconstriction21-22 and subsequent development of hyper-
tension. The primary objective of the present study was to evaluate the predictive value 
of genetic polymorphisms in VEGFA, VEGFR-2, eNOS and ET-1 for the development of 
hypertension in patients treated with sunitinib. The secondary objective was to evaluate 
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the predictive value of hypertension for survival outcome in the subset of sunitinib-
treated mRCC patients of the clear-cell type in order to validate recent findings.
METhOdS
Patients
Patients were considered eligible when treated with sunitinib for at least four consecu-
tive weeks. DNA from 291 cancer patients was collected in six Dutch medical centers 
between June 2004 and October 2010 at the Erasmus University Medical Center (n = 
105), the Netherlands Cancer Institute (n = 49), Leiden University Medical Center (n = 47), 
VU Medical Center (n = 42), University Medical Center Groningen (n = 40) and Radboud 
University Nijmegen Medical Center (n = 8). Thirty-six of 291 patients had to be excluded 
from analysis due to lack of sufficient blood pressure measurements. For all endpoints, 
255 patients were available for analysis (See Table 1 for clinical characteristics). For the 
primary outcomes (change in SBP and DBP), the following baseline clinical characteris-
tics were entered into the multivariate linear regression analysis: weight, performance 
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Figure 1 Role of vascular endothelial growth factor receptor in blood vessel tone in patients (A) without or 
(B) with sunitinib-induced hypertension. 
Activation of VEGFR-2 via phosphoinositide 3-kinase (PI3K) and its downstream serine protein kinase Akt 
stimulates endothelium-derived nitric oxide synthase (eNOS), subsequently leading to the production 
of the potent vasodilator nitric oxide (NO). NO also exerts an inhibitory effect on the vasoconstrictor 
endothelin-1 (ET-1) (1A). In patients treated with sunitinib, inhibition of VEGFR-2 causes an imbalance 
between the vasodilator NO en the vasoconstrictor ET-1, favouring ET-1 and thereby resulting in the 
development of hypertension (1B).
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Table 1: Characteristics of evaluable patients (N=255)
Characteristic
No. (range)
%
Median age (years) 60 (20 – 89)
   
Sex – no. (%)
   Male 161 63.1
   Female 94 36.9
Ethnicity
   Caucasian 232 91
   Other 15 5.9
   Unknown 8 3.1
Tumor type
    Renal cell carcinoma 193 75.7
            Clear cell 167 65.5
            Non clear cell 22 8.6
            Unknown 4 1.6
    GIST 53 20.8
    Other tumor types 9 3.5
Median weight (kilograms) 77.0 (43.9 – 135.0)
ECOG performance status
   0 104 40.8
   1 123 48.2
   2 20 7.8
   3 7 2.7
   Unknown 1 0.4
Median glomerular filtration rate (milliliter/minute) 76.5 (21 – 176)
Antihypertensive therapy at baseline
Yes 110 56.1
   No 143 43.1
Unknown 2 0.8
Sunitinib dose during first treatment cycle
(milligrams)
   12.5 3 1.2
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status, SBP and DBP at start of therapy. For change in MAP, weight and SBP and DBP at 
start of therapy were tested in a multivariate linear regression analysis. For the second-
ary endpoint, hypertension grade 0-2 versus ≥ 3, no clinical characteristics were entered 
into a multivariate logistic regression. Due to a lack of proportionality among classes, 
performance status was recoded into dummy variables. This study was approved by 
the institutional medical ethics review boards and performed in accordance with the 
Declaration of Helsinki.
Study design
Residual blood or serum samples taken for routine patient care were stored at -20°C or 
lower temperature at the local hospital laboratory. At least one whole blood or serum 
sample was available for this study from each patient. All samples were anonymized by 
   25 1 0.4
   37.5 6 2.4
   50 242 94.9
   Unknown 3 1.2
Pre-existing hypertension
  Yes 76 29.8
  No 179 70.2
Pre-existing hypercholesterolemia
  Yes 17 93.3
  No 238 6.7
Pre-existing diabetes mellitus
  Yes 7 2.7
  No 248 97.3
Prexisting other cardiovascular event/disease
  Yes 39 15.3
  No 216 84.7
Median systolic blood pressure at start of therapy 135 (90 – 210)
  
Median
diastolic blood pressure at start of therapy
80 (43 – 105)
Abbreviations: GIST, gastrointestinal stromal tumor; ECOG, Eastern Cooperative Oncology Group
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a third party, according to the instructions stated in the Codes for Proper Use and Proper 
Conduct in the Self-Regulatory Codes of Conduct (www.federa.org). 
Office systolic (SBP) and diastolic blood pressures (DBP) were measured manually or 
electronically (with oscillometric devices) during the first treatment cycle with sunitinib 
at start of therapy (baseline), day 14 and day 28. Baseline patient characteristics that 
were considered relevant for the development of hypertension were: age, sex, ethnicity, 
tumor type, weight, Eastern Cooperative Oncology Group (ECOG) performance status, 
estimated creatinin clearance rate (Cockcroft-Gault formula), pre-existing hypertension, 
hypercholesterolemia and diabetes mellitus, a history of cardiovascular disease, and SBP 
and DBP at start of therapy. Mean arterial pressure (MAP) was estimated by using the 
formula: MAP ≈ 2/3 DBP + 1/3 SBP. Maximum change in blood pressure during the first 
treatment cycle measured either on day 14 or day 28 was calculated by subtracting SBP, 
DBP and MAP at baseline from the highest measured SBP, DBP and MAP, respectively, 
without initiation of antihypertensive therapy or dose modification of antihypertensive 
agents in use at baseline. In addition, hypertension during the first treatment cycle was 
assessed by using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE 
v3.0). 
Genetic polymorphisms
Seven polymorphisms in four genes were selected which were considered to be involved 
in blood pressure regulation possibly affected by sunitinib. Selection criteria were a 
minor allele frequency of more than 0.2 in a Caucasian population as found in literature 
or the dbSNP database (http://www.ncbi.nlm.nih.gov/snp) and an assumed clinical 
relevance based on previous literature.23-29 The selected polymorphisms are listed in 
Table 2. Detailed methods for genotyping assay validation and haplotype estimation 
have been described previously.20
Table 2: selected polymorphisms.
Gene
Polymorphism rs-number
VEGFA 405C>G rs2010963
-460C>T rs833061
936C>T rs3025039
-2578A>C rs699947
VEGFR-2 1718T>A rs1870377
EDN1 594G>T rs5370
eNOS -786T>C rs2070744
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Data analysis and statistical design
Primary endpoints for the pharmacogenetic association analysis were the maximal 
change in SBP, DBP and MAP in mmHg during the first treatment cycle. For the analysis 
of hypertension grades, dichotomous endpoints were used, expressed as grade 0-2 
versus ≥ grade 3. All demographic and clinical variables were tested univariately against 
the selected primary outcomes using a χ² test, t test or ANOVA test, depending on the 
tested variables. A χ² test was also used to detect linkage desequilibrium (LD). Polymor-
phisms were initially tested with 2 df. If the initial 2 df tests resulted in P ≤ .1, these 
polymorphisms were fitted into the most appropriate model (multiplicative, dominant, 
recessive). Polymorphisms were tested univariately against the primary outcomes, using 
a t test or ANOVA test for the change in SBP, DBP and MAP and by using a χ² test for 
the association analysis with hypertension grades. Genetic variables associated with 
the outcome variables (P value ≤ .1) were selected for a multivariate linear regression 
analysis with change in SBP, DBP and MAP or a multivariate logistic regression analysis 
with hypertension grades as depending variables. Post-hoc analysis showed that with 
the sample size in our study, a difference in SBP and DBP of 7.5 mmHg and 5.8 mmHg, 
respectively, could be detected with a power of 91%. All results from the multivariate 
analyses with P ≤ .05 were considered significant. Since this was an exploratory study, no 
correction was applied for multiple testing.
In our survival analysis, the occurrence of hypertension during the first cycle of 
sunitinib was univariately (Kaplan-Meier analysis) and multivariately (Cox-regression 
A B 
Figure 2 
Figure 2 Closed symbols represent patients that experience hypertension grade 3 during the first cycle 
of sunitinib treatment. Open symbols represent patients that experience hypertension grade 0–2. Systolic 
blood pressure values are expressed in mmHg.
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analysis) tested for association with progression-free and overall survival (PFS and 
OS, respectively). Baseline characteristics relevant for PFS were: age, Memorial Sloan-
Kettering Cancer Center (MSKCC) prognostic criteria and number of disease sites and 
for OS were: MSKCC risk groups and number of disease sites, as defined previously.30 
Hypertension as a depending variable was defined as a recorded SBP > 140 mmHg or 
DBP > 90 mmHg or MAP > 110 mmHg during first sunitinib treatment cycle. All results in 
this study are presented as mean values (± standard deviation), unless stated otherwise.
RESulTS
Sunitinib-induced blood pressure changes during the first treatment cycle 
Blood pressure values at start of sunitinib therapy (n = 255) were 135 ± 18 mmHg, 79 ± 
11 mmHg and 98 ± 12 mmHg for SBP, DBP and MAP, respectively. During the first cycle of 
sunitinib therapy, 166 patients (65%) showed an increase in SBP (25 ± 18 mmHg), while a 
rise in DBP (15 ± 9 mmHg) was measured in 186 (73%) and a rise in MAP (16 ± 11 mmHg) 
in 193 (76%) patients. Thirty-three patients (13%) developed hypertension grade 3 
during the first treatment cycle, while 222 patients (87%) showed hypertension grade 
0-2 (162, 27 and 33 patients with grade 0, 1 and 2, respectively). For the change in blood 
pressure during the first sunitinib cycle, following clinical characteristics were signifi-
cantly associated in a univariate analysis: SBP at baseline (P < .001) for change in SBP; 
and SBP and DBP at baseline for change in MAP (P < .001, P = .001, respectively). 
For patients with low blood pressure at baseline, the rise in both SBP and DBP during 
treatment was higher than for patients with higher blood pressures at baseline (ANOVA, 
P <.001 and P < .001, for SBP and DBP, respectively; see Figure 2). 
Pharmacogenetic risk factors for sunitinib-induced hypertension
Factors that were predictive for blood pressure change in the univariate and multi-
variate regression analyses are presented in Table 3. In a univariate analysis, an ACG 
haplotype in VEGFA rs699947 (-2578A>C), rs833061 (-460C>T) and rs2010963 (405C>G) 
was significantly associated with a higher increase in SBP during the first treatment cycle 
(P = .026). No significant associations were found between selected polymorphisms and 
DBP change during first cycle of sunitinib treatment. For change in MAP, presence of a 
VEGFA ACG haplotype in a dominant model was selected for multivariate analysis (P = 
.053). Presence of a VEGFA ACG haplotype was an independent predictor of change in 
SBP and MAP, indicating that the presence of an ACG copy increased the risk for higher 
rises in SBP and MAP. In order to confirm the independent prediction of blood pressure 
rise by presence of an ACG haplotype, further analysis showed that an ACG haplotype 
was not associated with higher baseline blood pressure or with higher incidence of 
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antihypertensive drug treatment at baseline (data not shown). Multivariate linear re-
gression analysis confirmed all selected clinical characteristics as inversely associated 
with change in SBP or MAP. 
Concerning the incidence of hypertension during the first treatment cycle, presence 
of an ACG haplotype in VEGFA or presence of a C-allele in eNOS rs2070744 (-786T>C), 
Table 3: Univariate and multivariate analyses of blood pressure in 255 evaluable study patients
Factor Univariate analyses Multivariate analyses
No. Genotype P OR* 95% CI P
Rise in systolic blood pressure
     
    Systolic blood pressure at start of 
therapy
255 N.A. <.001 N.A. N.A. <.001
     
    VEGFA haplotype** 182
65
ACG-ACG + ACG-other 
versus
Other-other .026 N.A. N.A. .014
     
Rise in mean arterial pressure 
      
    Systolic blood pressure at start of 
therapy  
255 N.A. <.001 N.A. N.A. .004
    Diastolic blood pressure at start 
of therapy
255 N.A. .001 N.A. N.A. <.001
    VEGFA haplotype 182
65
ACG-ACG + ACG-other 
versus
Other-other .053 N.A. N.A. .036
Hypertension CTCAE grade 3
    VEGFA haplotype 247 ACG-ACG → ACG-other 
→ other-other .083 0.59 0.34 – 1.03 .031
    eNOS rs2070744 101 TT versus 1
    153 CC + CT .051 2.62 1.08 – 6.35 .045
* OR < 1.0 indicates that the factor associates with lower incidence of hypertension grade 3 as compared 
to the reference genotype (most prevalent genotype or haplotype), OR > 1.0  indicates that the factor 
associates with higher incidence of hypertension grade 3 as compared to the reference genotype (most 
prevalent genotype or haplotype)
** Description haplotype: VEGFA rs699947 (-2578A>C), rs833061 (-460C>T), rs2010963 (405C>G)
Abbreviations: OR, odds ratio; 95% CI, 95 percent confidence interval; CTCAE, Common Terminology 
Criteria for Adverse Events; N.A, not applicable
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in a multiplicative or dominant model, respectively, was univariately associated with 
hypertension grade 3 (P = .083, and P = .051, respectively). When these polymorphisms 
were tested in a multivariate logistic regression analysis, an ACG haplotype significantly 
predicted grade 3 hypertension (OR: 1.69, confidence interval (CI) 0.97 – 2.94, P = .031). 
In addition, presence of a C-allele in eNOS -786T>C in a dominant model was indepen-
dently associated with grade 3 hypertension (OR 2.62, CI 1.08 – 6.35, P = .045). 
Blood pressure and survival in mRCC patients
To elucidate the possibly predictive value of high blood pressure during sunitinib 
treatment on survival in the subpopulation of 167 mRCC patients of the clear-cell type, 
outcome variables (PFS and OS) were compared between patients with and without 
hypertension during the first cycle of sunitinib, using Kaplan-Meier survival analyses 
(see Figure 3). Seven patients were excluded from analysis due to lack of sufficient 
survival data and/or data on clinical co-variables, resulting in 158 evaluable patients. No 
significant association with PFS was seen in patients with hypertension (see Table 4). 
Patients with a MAP, SBP or DBP above the defined threshold had a significant reduction 
in relative risk of death as compared to patients with blood pressure below the defined 
threshold (see Table 4). OS was prolonged with 7.2 months in patients suffering from 
A B C 
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Figure 3 
Figure 3 Kaplan-Meier survival curves for sunitinib-treated metastatic renal cell carcinoma patients 
according to blood pressure during first cycle of treatment. Dotted lines represent cumulative survival 
in patients with MAP >110 mmHg (3A/3D), or with SBP > 140 mmHg (3B/3E), or with DBP > 90 mmHg in 
(3C/3E). Continuous lines represent cumulative survival in patients with MAP ≤ 110 mmHg (3A/3D), or 
with SBP ≤ 140 mmHg (3B/3E), or with DBP ≤ 90 mmHg (3C/3F).
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high SBP or DBP (P = .035; P = .026; for SBP and DBP, respectively) and 6.3 months in 
patients suffering from high MAP (P = .037). Multivariate analysis confirmed that high 
MAP, SBP and DBP during the first cycle of sunitinib treatment are predictive markers for 
improved OS, independently of MSKCC criteria and number of disease sites (see Table 
4). 
Table 4: Survival in 158 sunitinib-treated clear-cell mRCC patients with or without hypertension
Factors Kaplan-Meier analysis Multivariate Cox-regression analysis*
No. (%) PFS 95% CI P HR 95% CI P 
MAP > 110 mmHg 68 (43) 22.6 13.2 – 20.3 .214 .756 .504 – 1.134 .177
         ≤ 110 mmHg 90 (57) 16.8 17.3 – 27.8
SBP > 140 mmHg 98 (62) 21.1 16.9 – 25.4 .363 .691 .457 – 1.045 .080
        ≤ 140 mmHg 60 (38) 17.1 12.6 – 21.7
DBP > 90 mmHg 65 (41) 22.3 16.9 – 27.6 .332 .828 .551 – 1.244 .363
        ≤ 90 mmHg 93 (59) 17.0 13.5 – 20.5
No. (%) OS 95% CI P HR 95% CI P 
MAP > 110 mmHg 68 (43) 29.1 24.1 – 34.1 .037 .644 .426 – .975 .038
         ≤ 110 mmHg 90 (57) 22.8 19.0 – 26.6
SBP > 140 mmHg 98 (62) 27.9 23.9 – 31.9 .035 .532 .349 – .810 .003
        ≤ 140 mmHg 60 (38) 20.7 16.6 – 24.8
DBP > 90 mmHg 65 (41) 29.9 24.8 – 35.0 .026 .633 .417 – .961 .032
        ≤ 90 mmHg 93 (59) 22.7 18.9 – 26.6
* Relevant baseline characteristics included in the multivariate analysis were: for PFS: age, Memorial 
Sloan-Kettering Cancer Center (MSKCC) risk groups, and number of disease sites and for OS: MSKCC risk 
groups and number of disease sites, as defined previously 
Abbreviations: PFS, mean progression-free survival in months; 95% CI, 95 percent confidence interval; HR, 
Hazard ratio; MAP, Mean arterial pressure; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; OS, 
Mean overall survival in months
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dISCuSSIOn
The present results demonstrate an increase in blood pressure in approximately 70% of 
patients treated with sunitinib, resulting in grade 3 hypertension in 13% of all treated 
patients. Persistent hypertensive disease can lead to serious cardiovascular events, and 
in rare cases malignant hypertension may be complicated by reversible posterior leuko-
encephalopathy.31-32 Prediction and adequate treatment of these adverse reactions are 
therefore clinically relevant. The aim of this study was to investigate if selected genetic 
differences in pathways involved in the regulation of blood vessel tone, are indepen-
dently predictive for the occurrence of high-grade hypertension or for the extent of 
blood pressure rise during sunitinib treatment. 
The current analysis shows that an ACG haplotype in VEGFA is a significant factor for a 
higher rise in SBP and MAP as well as for the incidence of hypertension grade 3 during 
the first cycle of sunitinib therapy. More than one out of five study subjects who were 
homozygous for the ACG haplotype developed hypertension grade 3 versus only 7.7% 
of patients who carried no copy of ACG. 
In addition, presence of an eNOS -786C allele is related to a 2.6-fold increase in the risk 
of hypertension grade 3 during the first cycle of sunitinib treatment. These pharmaco-
genetic associations demonstrate the clinical importance of polymorphisms in genes 
coding for VEGF and its downstream mediator NO during sunitinib treatment. Inhibition 
of VEGFR-2 pathways in these patients combined with possibly reduced VEGF levels and 
decreased NO production may enhance the development of hypertension. 
The biological effect of an ACG haplotype at position -2578, -460 and 405 is subject 
of debate as consensus has yet to be reached on the correlation between these SNPs 
and VEGF expression. In various patient populations -2578A, -460C and 405G carriers 
showed reduced circulating VEGF levels,33-35 while other studies reported no association 
between VEGF plasma levels and haplotypes including the -2578A and 405G alleles.34,36 
In contrast, clinical have shown a correlation of the ACG haplotype with ischemic heart 
disease and myocardial infarction37 and of the -2578AA genotype with coronary artery 
disease and atherosclerosis.38-39 All these conditions are closely related to pre-existing 
chronic hypertensive disease. 
Concerning the eNOS -786T>C polymorphism, there is accumulating evidence that 
presence of a C allele has functional consequences with reports on decreased transcrip-
tional activity and lowered NO plasma levels.40-44 In addition, a correlation has been 
found between the -786C allele and the incidence of diabetic retinopathy, coronary 
spasms and preeclampsia.45-46 The latter finding may also be complementary to our 
results as it was recently shown that sunitinib-induced hypertension ressembles part of 
a preeclampsia-like syndrome.18
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Early identification of patients at risk to develop hypertension on the basis of these 
genetic polymorphisms could yield specific monitoring methods, timely selection of 
antihypertensive agents and ultimately optimize sunitinib treatment. For instance, in 
our study population, an inverted association was observed between blood pressure at 
start of therapy and blood pressure increase during the first cycle of sunitinib treatment. 
This association may be explained by a phenomenon called “white-coat hypertension” 
in which (hospital / doctor-induced) stress-related factors may result in higher blood 
pressure at start of anti-cancer treatment compared to follow up measurements.47 
Alternatively, it may also reflect a physiological maximum in blood vessel tone due to 
VEGF inhibition. Thus, it can be concluded that patients with a high blood pressure at 
start of therapy are not at risk of developing higher increases in blood pressure dur-
ing sunitinib treatment than patients with blood pressure within the normal range. In 
contrast, in patients developing grade 3 hypertension during the first cycle of sunitinib, 
both the rise in blood pressure as well as blood pressure at start of therapy were higher 
as compared to patients with grade 0-2 hypertension (31 ± 17 vs 24 ± 19 mmHg, P = .032; 
and 20 ± 15 vs 13 ± 8 mmHg, P = .027; for change in SBP and DBP, respectively; and 140 
± 15 vs 128 ± 15 mmHg, P < .001; 82 ± 11 vs 76 ± 11 mmHg, P = .005; for baseline SBP 
and DBP, respectively; see Figure 2). Pharmacogenetic screening may therefore help 
to distinguish these patients among subjects with high baseline blood pressure who 
are predisposed for the development of severe hypertension requiring (adjustment of ) 
antihypertensive medication.
Interestingly, hypertension in mRCC patients treated with sunitinib has recently been 
correlated with survival benefit.12-13 In our study, mRCC patients who suffered from drug-
related hypertension after start of sunitinib treatment showed a significantly longer OS 
than patients with a lower blood pressure. In line with recent literature, the most signifi-
cant reduction in risk of death was seen in patients with high SBP.13 Hypertension in our 
population showed no significant associations with PFS. This is in accordance with Rini 
et al. who have demonstrated a much larger reduction in HR for the risk of occurrence 
of death than a reduction in HR for the occurrence of progressive disease when patients 
suffered from hypertension during sunitinib treatment.13 
In conclusion, genetic polymorphisms in VEGFA and eNOS independently predict blood 
pressure rise and/or severe hypertension in sunitinib-treated patients and may therefore 
be helpful in early diagnosis and initiation or adjustment of antihypertensive therapy. 
In addition, for Caucasian mRCC patients of the clear-cell type treated with sunitinib, we 
confirmed hypertension as an independent factor for OS and as a potential biomarker 
for outcome.
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Chapter 9
Suppressing effects of sunitinib 
on allergic rhinitis: previously 
undefined side effects with 
therapeutic potential
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InTROduCTIOn
We observed two female patients (51 and 59 years old, respectively) who were known 
with serious pollen allergy (hay fever) since childhood, expressed by rhino-conjunctivitis 
and asthma. For many years, these conditions were treated with antihistamines, β2 
agonists and pulmonary corticosteroids. In 2007, both patients were diagnosed with 
metastatic renal cell cancer for which they were treated with sunitinib mono-therapy 
since October and November 2007, respectively. Since the start of anti-cancer treatment 
allergic rhinitis related co-medication was not allowed, to prevent unwanted drug-drug 
interactions. To their surprise, and despite this prohibition, during the pollen season of 
2008 both patients experienced no allergic rhinitis complaints at all. In this study, we 
tried to elucidate the underlying mechanism for this remarkable observation.
Sunitinib malate is an anti-cancer drug, currently used in the palliative treatment of 
metastatic renal cell carcinoma and gastro-intestinal stromal cell tumors 1-2. Treatment 
regimens exist of once daily dosing of 50 milligram for four consecutive weeks, followed 
by two weeks of rest 3. Sunitinib acts as a multi-targeted tyrosine kinase inhibitor, known 
to inhibit the intrinsic tyrosine kinase activity of several specific proteins, including KIT, 
vascular endothelial growth factor receptor (VEGF-R) and the platelet-derived growth 
factor receptor (PDGF-R)4, resulting in reduced tumor vessel growth or carcinogenesis. 
Sunitinib-induced toxicities may be serious and quite diverse. They include hyperten-
sion, diarrhoea, hand-foot syndrome, mucositis, vomiting, leukopenia, cardiotoxicity, 
and hypothyroidism 5.
Of all these molecular targets inhibited by sunitinib, KIT is most likely to be involved 
in the pathogenesis of allergic rhinitis. KIT is encoded by the c-kit gene. It is a trans-
membrane protein, expressed on a variety of cells, including mast cells, haematopoietic 
progenitor cells, melanocytes, germ cells and gastro-intestinal pacemaker cells. Hetero-
zygous loss of function of KIT in mice results in macrocytic anaemia, hair depigmenta-
tion, sterility and reduced numbers of gastrointestinal pacemaker cells 6. Moreover, in 
mast cells, KIT acts as a receptor for the stem cell factor. Binding of stem cell factor on 
KIT is essential for the survival and differentiation, chemotaxis and functional activity of 
mast cells 7. Mast cells on their part play a vital role in the symptomatology of allergic 
rhinitis. 
Allergic reactions usually occur when an individual who has been sensitized to an al-
lergen (e.g. grass pollen), produces allergen-specific immunoglobulin isotype E antibod-
ies (IgE) and subsequently encounters this particular allergen again. The allergen will 
then trigger the activation of IgE-binding mast cells in the exposed tissue. As a result, 
these mast cells degranulate, releasing a variety of mediators causing clinical symptoms. 
Therefore, inhibition of mast cell activity could reduce allergic symptoms. 
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METhOdS
During all outpatient visits (usually at the beginning and at the end of a four-weekly 
treatment cycle), we measured total serum IgE and specific IgE antibodies in our study 
patients. The resting period was occasionally prolonged with a couple of days due to 
common sunitinib-related toxicity. These serological tests are used routinely in the 
diagnosis and management of allergic disease. Skin tests and nasal challenge tests 8 
with birch and/or grass pollen extract were used to characterise the allergic status of the 
patients. Myelosuppression as a mechanism of impaired immune response in our study 
patients was also investigated by measuring total white blood cell counts before start of 
therapy and during all consecutive courses of sunitinib treatment. 
Nasal provocation tests were performed at the beginning and at the end of one treat-
ment cycle to evaluate the nasal response to birch pollen (patient 1) or grass pollen 
(patient 2). Nasal provocation tests were performed according to standard protocol with 
three consecutive doses of 100, 1000 and 10.000 biological units per milliliter (BU/ml) of 
the allergen. Symptoms of rhinoconjunctivitis were scored after each dose according to 
Lebel (maximum total score 33) 8.
In order to assess the effects of sunitinib on the mast cell population, we measured 
serum tryptase levels. Total serum tryptase levels are used as indicators of mast cell 
number and activation 9. 
As sunitinib treatment was already given for several months to our two study patients, 
we could not measure tryptase concentrations from the start of therapy. As a result we 
cannot exclude that tryptase levels in these patients were already extremely low prior 
to the start of anti-cancer treatment. Therefore, in a separate cohort of patients with 
renal cell carcinoma, we measured tryptase levels before the start of their first sunitinib 
courses and during the successive courses. The non-parametric Friedman test was used 
to assess fluctuations in this cohort. The Wilcoxon signed ranks test was used for com-
parison between two time points (SPSS 15.0 for Windows). 
RESulTS
Total serum IgE levels were moderately elevated, but showed no significant changes 
during the four weeks treatment with sunitinib compared to the values measured 
straight after the two-week resting period (Table 1). Specific serum IgE antibodies (Table 
1) and skin tests (data not shown) fluctuated, but showed no significant alterations over 
the observed study period. White blood cell counts in our study patients were within the 
normal range before start of sunitinib treatment and during all the following treatment 
cycles. Table 1 depicts white blood cell counts during two treatment cycles.
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Surprisingly, the four nasal provocation tests (two per patient) were negative at three 
occasions and marginally positive (8 out of 33 points maximally) at one occasion. 
Also of interest: during the entire observation period of three months, total serum 
tryptase levels were extremely low (below threshold values) in both study patients. As 
shown in Table 1, tryptase levels in the separate cohort of control patients with renal 
cell carcinoma changed significantly from normal pre-treatment values to levels below 
the threshold, in most cases within the observation period of two treatment cycles 
(χ2 = 20.24; p<0.0001). A drop was already seen after one treatment cycle (p = 0.008). 
Table 1. Imatinib trough levels (Cmin) in imatinib treated chronic myeloid leukaemia and gastrointestinal 
stromal cell tumor patients with or without clinical response.
Patients Cycles studied
Study patient No 1
Start cycle 9 End cycle 9 Start cycle 10 End cycle 10 Start cycle 11
Tryptase (< 11.4 mg/La) <1.0d <1.0d <1.0d <1.0d <1.0d
Total IgEb (<100 u/mLa) 258 307 139 306 341
Birch pollen IgEb (<0.35 u/mLa) 80.5 >100e 87.0 >100e >100e
Grass pollen IgEb (<0.35 u/mLa) 14.5 29.0 28.5 33.7 32.1
Nasal provocation total scorec n.a.f 8 0 n.a.f n.a.f
WBCg (4.1-10.9x109/L) 5.4 8.4 4.8 5.8 3.9
Study patient No 2 Start cycle 9 End cycle 9 Start cycle 10 End cycle 10 Start cycle 11
Tryptase (< 11.4 mg/La) <1.0d <1.0d <1.0d <1.0d <1.0d
Total IgEb (<100 u/mLa) 200 329 288 398 211
Birch pollen IgEb (<0.35 u/mLa) 21.0 50.8 41.3 52.1 28.7
Grass pollen IgEb (<0.35 u/mLa) 11.7 21.5 17.9 21.9 12.9
Nasal provocation total scorec n.a.f 5 2 n.a.f n.a.f
WBCg (4.1-10.9x109/L) 4.3 n.a.f 7.6 5.0 5.2
Tryptase in control patients (< 
11.4 mg/La) 
Start cycle 1 End cycle 1 Start cycle 2 End cycle 2 Start cycle 3
Patient No 1 4.4 <1.0d 1.2 <1.0d <1.0d
Patient No 2 9.5 2.0 2.4 <1.0d n.a.h
Patient No 3 3.6 <1.0d 1.4 <1.0d n.a.h
Patient No 4 7.5 <1.0d n.a.h n.a.h n.a.h
Patient No 5 5.1 2.1 5.7 1.1 6.6
Patient No 6 4.9 <1.0d <1.0d <1.0d 2.7
Patient No 7 2.9 <1.0d 2.4 <1.0d 1.9
Patient No 8 6.4 <1.0d 4.6 <1.0d n.a.f
Patient No 9 4.3 1.9 5.3 1.9 4.4
aNormal values in microgram or units per (milli)liter; bImmunoglobulin type E; cAccording to standard 
protocol (total score may range between 0 and 33); dBelow threshold values; eAbove detectable values, 
fNot available; gWhite blood cell count; h Not available due to cessation treatment because of worsened 
clinical performance.
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Although these patients were not known for allergic rhinitis, we have no reason to sup-
pose another mechanistic effect on mast cells in the control patients. 
dISCuSSIOn
Up till now, the clinical benefit of mast cell inhibition through inhibition of KIT auto-
phosphorylation has been investigated in patients with systemic mastocytosis, where 
it showed little effect 10-11. However, this lack of effect is caused by a specific mutation in 
the catalytic domain, which is typical for the majority of neoplastic mast cells in human 
mastocytosis, making these cells refractory to tyrosine kinase inhibitors. Cell growth of 
human mast cells carrying wild type KIT is potently inhibited by inhibition of KIT 11. Also, 
preclinical data in a murine model with allergen-induced airway inflammation showed 
that both induced airway hyperresponsiveness and chronic airway inflammation were 
significantly inhibited when these mice were treated with sunitinib 12. These sunitinib-
treated mice showed a lower expression of KIT in the airways (measured in bronchoal-
veolar lavage fluid) compared to non-treated mice. The clinical benefit of KIT inhibition 
in the treatment of asthma was confirmed in thirty-three severe corticoid-dependent 
asthmatic patients, receiving masitinib, a KIT and PDGFR tyrosine kinase inhibitor 13. 
These patients showed a significant symptomatic relief as compared to eleven placebo-
treated patients. In this report the resolution of allergic symptoms in two cancer pa-
tients is correlated with a decreased mast cell population and activity, most probably 
through inhibition of KIT. This mechanism of reduced mast cell population and activity 
is confirmed in our sunitinib treated control patients. 
However, as sunitinib is a myelotoxic compound 5, 14, sunitinib-induced leukopenia 
may account for an impaired immune response in both our study patients, next to the 
above-mentioned mechanism. This is relevant because lymphocytic cell lines mediate 
the IgE response in allergic rhinitis. However, our study patients had normal white blood 
cell counts during the entire observation period. Moreover, recent data show that suni-
tinib may act as an immunomodulator that enhances T-lymphocytic function 15-16. These 
results plead against sunitinib-induced myelosuppression as a possible mechanism of 
reduced symptoms of allergic rhinitis in our patients.
Although the costs and unfavourable safety profile do not justify treatment of allergic 
disorders with sunitinib, further elucidation of this sunitinib-related mechanism on aller-
gic rhinitis may help to develop more effective medication for allergic disorders. For ex-
ample, locally produced KIT-ligand in the airways is responsible for the recruitment and 
adhesion of mast cells to the airway epithelium 17-18. Therefore, topical application of KIT 
inhibitors through inhalation or nasal spraying may be an efficient and safe treatment of 
local inflammation in allergic disorders. Furthermore, little is known about the threshold 
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dose of sunitinib, needed to effectively inhibit mast cell function. If lower dosages than 
those used in cancer treatment are sufficient to potently inhibit mast cell numbers, this 
could also improve the safety profile of sunitinib treatment in allergic disorders. In con-
clusion, along the known pathways responsible for allergic reactions, this observation 
suggests that sunitinib effectively inhibits mast cell proliferation and activity, resulting 
in a total absence of allergic rhinitis in our patients. This sunitinib-related mechanism 
may ultimately lead to the development of new therapeutic pathways in the treatment 
of (corticosteroid-resistant) allergic disorders. 
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IMATInIb STudIES
Most patients that suffer from an advanced or metastatic gastrointestinal stromal tumor 
(GIST) gain benefit from systemic treatment with imatinib. However, in 10% to 15% of 
patients, disease will progress within three to six months. Mechanisms behind this ´ early´ 
disease progression have not been entirely clarified. A majority of these non- responding 
patients harbor specific mutations in molecular drug targets.1-3 However, early drug resis-
tance may also result from imatinib plasma levels that drop below a minimally effective 
threshold level, a phenomenon called “acquired pharmacokinetic drug resistance”. GIST 
patients not responding to imatinib treatment appeared to demonstrate lower imatinib 
plasma levels than responders.4,5 In addition, in a retrospective pharmacokinetic side-
study of the pivotal phase II B2222 trial, median time to progression was approximately 
twenty months shorter in patients that demonstrated one month imatinib steady-state 
trough levels below 1,100 ng/mL.5
Therefore, in the first part of this thesis, an overview that focuses on the pharmacoki-
netic and pharmacodynamic relevance of drug transporters in imatinib therapy is given 
(Chapter 2). Although in vitro data indicate that imatinib is a good substrate of efflux 
transporters such as ABCB1 and ABCG2, and solute carriers such as OCT1, OATP1A2 and 
OATP1B3, clinical studies that investigate the impact of these transporters on imatinib 
pharmacokinetics and efficacy in humans are scarce. Pharmacogenetic studies assess-
ing associations between single nucleotide polymorphisms (SNPs) in ABCB1 and ABCG2 
genes with imatinib pharmacokinetics in GIST patients have generated contradictory 
findings. Furthermore, allelic variants in the SLC22A1 and SLCO1B3 gene (encoding for 
the proteins OCT1 and OATP1B3, respectively) had no clear effects on imatinib exposure 
compared to the reference allele. To date, the most prominent pharmacodynamic effects 
of drug transporters have been described in imatinib-treated chronic myeloid leukemia 
(CML) patients who demonstrated a correlation between OCT1 expression and activity 
in CML blasts and therapeutic outcome.
As stated earlier, minimal imatinib trough levels of approximately 1,100 ng/mL may 
be required to achieve therapeutic success in GIST patients. It is therefore of clinical im-
portance to assess acquired pharmacokinetic phenomena in imatinib-treated patients 
over time. Consequently, in Chapter 3, we designed a prospective population pharma-
cokinetic study in fifty GIST patients in order to assess systemic exposure to imatinib 
at multiple time points during a median follow-up period of one year. As imatinib is 
extensively metabolized by the liver, the secondary aim of this study was to evaluate 
the metabolic effects of GIST metastatic liver involvement on imatinib exposure. Full 
pharmacokinetic sampling was performed at start of therapy and after one, six and 
twelve months of therapy. In addition, at several time-points, trough samples were 
taken to assess minimal imatinib plasma concentrations. These data were analysed in a 
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compartmental pharmacokinetic model, which showed a significant downward trend in 
imatinib systemic exposure during the first three months of treatment to approximately 
thirty percent of the exposure at the beginning, with stabilization in imatinib pharma-
cokinetics from this time point on. Previous retrospective associations between imatinib 
trough levels at day 29 and clinical outcome benefit in GIST patients thus should be 
put into perspective.5 Concerning the secondary objective of this study, volume of liver 
metastasis had a minor impact on imatinib clearance as for every 100 cm3 increase in 
volume, a decrease of less than four percent clearance was observed.
Due to the discrepancy between previously reported results from imatinib in vitro 
transport assays and clinical studies, the aim of Chapter 4 was to translate preclinical 
findings concerning a specific solute carrier; the organic anion transporting polypeptide 
1A2 (OATP1A2), directly into clinical practice. Imatinib uptake in cells expressing human 
OATP1A2 or its rodent orthologue Oatp1a4, was significantly higher than in water-
injected control cells. In addition, as imatinib uptake transport by OATP1A2 was higher 
in an acidic environment as found in the jejunum, and as OATP1A2 messenger RNA 
expression in the descending part of the human duodenum was the highest among 
all tissues, OATP1A2 was a promising candidate for the intestinal uptake of imatinib. In 
order to translate this to clinical practice, we performed a drug-drug interaction study 
and a pharmacogenetic association study in imatinib-treated patients. Rosuvastatin 
significantly inhibited OATP1A2-mediated transport of imatinib in vitro but concomitant 
administration of imatinib and rosuvastatin in GIST patients had no effect on steady-
state pharmacokinetics of imatinib. Moreover, an allelic variant of the SLCO1A2 gene that 
was associated with complete absence of imatinib transport in vitro, had no effect on 
imatinib plasma levels in patients carrying this genotype. This study therefore indicates 
that, although imatinib is a substrate for OATP1A2, this transporter by itself is unlikely 
to contribute substantially to the absorption profiles of imatinib in humans. Further 
investigation is warranted to determine the individual and collective contributions of 
additional, potentially redundant, intestinal carriers to the pharmacokinetics and phar-
macodynamics of imatinib.
In Chapter 5 we (further) elucidated the role of liver dysfunction in imatinib clear-
ance by quantifying biliary secretion in the case of severe hepatic dysfunction. Full 
plasma pharmacokinetic sampling occurred at days one, five and six. In addition, trough 
samples were taken from days one to day fourteen of imatinib therapy. Bile was also col-
lected for pharmacokinetic analysis. The major finding of this study was that the biliary 
secreted imatinib dose was a mere fraction of previous reported concentration data and 
that the ratio of biliary imatinib to metabolite CGP74588 concentrations was inverted. 
On the other hand, imatinib plasma exposure was within the normal range as reported 
in literature. This indicates that, although biliary excretion of imatinib seems related to 
severe liver dysfunction, no major alterations in imatinib exposure were observed. This 
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may be due to adaptive phenomena, in which a low bioavailability and low systemic 
clearance balance each other out, resulting in normal imatinib plasma concentrations. 
Consequently, these data further support the need to investigate the collective contri-
bution of drug transporters to imatinib pharmacokinetics.  
SunITInIb STudIES
The second part of this thesis is dedicated to the inter-individual variability in sunitinib 
pharmacodynamics. Sunitinib is directed against multiple molecular drug targets, which 
are involved in normal physiological processes. Therefore, unlike imatinib, sunitinib 
has a broad toxicity profile, which will lead to a dose modification in one out of three 
patients.6 In addition, clinical response and survival in sunitinib-treated patients show 
a large variability.6 Accurate prediction of the appropriate sunitinib dose and/or pre-
diction of sunitinib’s proper place in the sequence of systemic treatment lines are thus 
highly relevant for the individual patient.
Therefore, in Chapters 6 and 7 we analysed potential genetic factors for sunitinib-
induced toxicity and survival. A total of 31 SNPs in twelve candidate genes involved 
in sunitinib metabolism and pharmacodynamics together with several non-genetic 
variables were tested for associations with toxicity and survival in 219 patients treated 
with single-agent sunitinib. An interesting finding of these analyses was that genetic 
factors for variation in sunitinib-induced toxicity and survival were mainly located in 
pharmacokinetic pathways. SNPs in genes encoding for drug efflux transporters (ABCB1 
and ABCG2), cytochrome P450 oxydases (CYP3A5 and CYP1A1) or nuclear receptors 
involved in cytochrome P450 regulation (NR1I3) proved to be independent factors for 
toxicity and/or survival in sunitinib-treated patients. The risk for leukopenia increased 
when the G allele in CYP1A1 2455A/G  or the T allele in FLT3 738T/C were present, or CAG 
in the NR1I3 (5719C/T, 7738A/C, 7837T/G) haplotype was absent. Any toxicity higher 
than grade 2 prevalence was increased when the T allele of vascular endothelial growth 
factor receptor 2 1191C/T or a copy of TT in the ABCG2 (-15622C/T, 1143C/T) haplotype 
were present. The risk for mucosal inflammation was increased in the presence of the 
G allele in CYP1A1 2455A/G and the prevalence of hand-foot syndrome was increased 
when a copy of TTT in the ABCB1 (3435C/T, 1236C/T, 2677G/T) haplotype was present. 
In metastatic renal cell carcinoma (mRCC) patients of the clear-cell subtype treated 
with sunitinib, multivariate analysis showed that progression-free survival was sig-
nificantly improved when an A-allele was present in CYP3A5 6986A/G, a CAT copy was 
absent in the NR1I3 haplotype (5719C/T, 7738A/C, 7837T/G) and a TCG copy was present 
in the ABCB1 haplotype (3435C/T, 1236C/T, 2677G/T). Carriers with a favorable genetic 
profile in these three genes involved in sunitinib pharmacokinetics had a significantly 
142 Chapter 10
improved progression-free (13.1 versus 7.5 months) and overall (19.9 versus 12.3 months) 
survival as compared to non-carriers.
Among sunitinib-induced toxicities, hypertension is a common side-effect. Approxi-
mately one third of patients treated with sunitinib will develop hypertensive disease 
and one third of this subgroup will need intensive medical treatment. In Chapter 8 we 
identified genetic factors for this rise in blood pressure and/or for the development of 
severe hypertension during sunitinib therapy. In addition, associations of hypertension 
with survival were assessed in the subset of mRCC patients. In almost three-hundred 
sunitinib-treated patients, single nucleotide polymorphisms in VEGFA (405C/G, -460C/T, 
936C/T, -2578A/C), VEGFR-2 (1718T/A), ET-1 (594G/T) and eNOS (-786T/C) were multivari-
ately tested against the maximal change in systolic, diastolic and mean arterial blood 
pressure and hypertension grades during the cycle of therapy.  Overall survival was 
evaluated in mRCC patients of the clear-cell type for a possible relation with hyperten-
sion. A higher rise in systolic blood pressure and mean arterial pressure was associated 
with presence of an ACG haplotype in VEGFA -2578A/C, -460C/T and 405C/G. Develop-
ment of hypertension grade 3 was associated with this haplotype and with a C allele in 
eNOS -786T/C. Mean overall survival in sunitinib-treated mRCC patients suffering from 
hypertension appeared more than seven months longer.
As stated earlier, sunitinib is a multitargeted agent, directed against several proteins 
that are involved in a diversity of (patho-)physiological processes. Among these drug 
targets, KIT is responsible for the proliferation and functional activity of mast cells, 
involved in allergic rhinitis.7 Consequently, in Chapter 9, inhibition of KIT activity in 
sunitinib-treated mRCC patients was investigated as a potential therapeutic pathway in 
inflammatory processes such as allergic rhinitis. Allergic reactions occur when an indi-
vidual who has been sensitized to an allergen such as grass pollen, produces allergen-
specific immunoglobulin isotype E antibodies (IgE) and subsequently encounters this 
particular allergen again. The allergen will then induce the activation of IgE-binding 
mast cells in the exposed tissue. As a result, these mast cells degranulate, releasing a va-
riety of mediators causing clinical symptoms. Metastatic RCC patients who were known 
with severe pollen allergy since childhood, showed complete absence of symptoms of 
allergic rhinitis during treatment with sunitinib. Total serum tryptase levels, which are 
used as indicators of mast cell number and activation, were below threshold values 
during the entire observation period of three months. Moreover, in a separate cohort of 
control mRCC patients serum tryptase changed significantly from normal pre-treatment 
values to levels below the threshold, in most cases within the observation period of two 
treatment cycles. No significant changes were observed in serum IgE levels. Hence, reso-
lution of allergic symptoms during sunitinib therapy is correlated to decreased mast cell 
activity, most probably through inhibition of KIT, as confirmed in a control population.
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COnCluSIOnS And PERSPECTIvES
Clinical research in this thesis extensively describes long-term imatinib pharmacokinet-
ics in GIST patients. A significant drop in imatinib exposure during the first year of therapy 
is observed, which may account for early tumor progression, a process called “acquired 
pharmacokinetic drug resistance”. Up until now, responsible alterations in imatinib phar-
macokinetic pathways are not fully elucidated. A change in drug transporter activity or 
expression may account for the observed descent in systemic exposure. We performed 
an in vitro and clinical study to assess the potential role of a solute carrier, OATP1A2, in 
imatinib pharmacokinetics, but found no significant impact on imatinib absorption in 
imatinib-treated patients. Future (pre)clinical studies that assess mediators of imatinib 
pharmacokinetics, will have to evaluate the involved pathways at a systemic level. Drug 
transporters and enzymes involved in imatinib absorption, metabolism and excretion, 
are most probably subject to a complex interplay with each other. Study design should 
therefore aim at evaluation of the collective contribution of potentially involved drug 
transporters and enzymes. This balance between drug transporters involved in imatinib 
absorption on the one hand and hepatic uptake and excretion on the other, could also 
explain why no major effect of liver dysfunction or liver metastases on imatinib expo-
sure was observed in GIST patients, although biliary excretion of imatinib seems to be 
affected by severe liver dysfunction. 
Clinical significance of these acquired pharmacokinetic processes should be assessed 
in “trough level – clinical benefit” analyses. These assessments should be time-point 
specific and need to incorporate relevant tumor biology and patient characteristics in a 
multivariate analysis in order to be able to define a minimal effective imatinib dose for 
an individual patient on accurate time points in a treatment course.
Genetic variation in genes involved in sunitinib pharmacokinetics proved to be an 
independent factor for toxicity and survival. Future clinical studies should therefore 
prospectively assess the correlations between these polymorphisms and sunitinib 
exposure. At present, a study that integrates genotypic and phenotypic data together 
with clinical characteristics and data on sunitinib pharmacokinetics, is being performed 
at our institution. 
This thesis also presents genetic factors for sunitinib-induced hypertension in a large 
cohort of patients and validates hypertension as a biomarker for survival in mRCC pa-
tients of the clear-cell subtype treated with sunitinib. 
Finally, along the pharmacodynamic pathways that are inhibited by sunitinib, KIT in-
hibition lead to downregulation of mast cell activity and consequently to the resolution 
of allergic symptoms. These findings should be validated in a prospective clinical study 
and may eventually hold therapeutic potential in inflammatory diseases such as asthma 
and allergic rhinitis.
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SAMEnvATTIng En COnCluSIES
Imatinib studies
Het merendeel van de patiënten die lijden aan een gevorderde of uitgezaaide gas-
troïntestinale stromale tumor (GIST) zullen een therapeutisch voordeel hebben van 
een behandeling met imatinib. Echter, in 10 tot 15% van deze patiënten zal er een 
ziekteprogressie optreden binnen drie tot zes maanden. De mechanismen achter deze 
zogenaamde “vroege” ziekteprogressie zijn niet geheel opgehelderd. Een meerderheid 
van deze niet-responderende patiënten zullen drager zijn van specifieke mutaties in de 
moleculaire doelen. Echter, vroege geneesmiddelenresistentie kan ook het resultaat zijn 
van imatinib plasmaspiegels die onder een minimaal effectieve drempelwaarde zakken, 
een fenomeen dat gekend is als “verworven farmacokinetische geneesmiddelenresistentie”. 
GIST patiënten die geen therapeutische respons vertonen op behandeling met imatinib 
lijken dan ook lagere imatinib plasmawaarden te vertonen dan responderende patiën-
ten. Daarenboven werd in een retrospectieve studie aangetoond dat de mediane tijd tot 
progressie ongeveer 20 maanden korter is in patiënten die na één maand behandeling 
een steady-state imatinib dalspiegel vertonen die lager is dan 1.100 ng/ml.
Om die redenen, wordt er in het eerste deel van dit proefschrift een overzicht gegeven 
van de farmacokinetische en farmacodynamische relevantie van drugpompen tijdens 
behandeling met imatinib (Hoofdstuk 2). Hoewel in vitro data aangeven dat imatinib 
een goed substraat is van effluxpompen zoals ABCB1 en ABCG2, en van opnamepom-
pen zoals OCT1, OATP1A2 en OATP1B3, zijn er weinig klinische studies die het effect van 
deze pompen analyseren. Bovendien hebben farmacogenetische associatie analyses in 
ABCB1 en ABCG2 tegenstrijdige bevindingen opgeleverd. Ook allelische varianten in het 
SLC22A1 en SLCO1B3 gen (die respectievelijk coderen voor OCT1 en OATP1B3) hadden 
geen duidelijke effecten op de systemische blootstelling aan imatinib.  
Op de achtergrond van mogelijk therapeutisch relevante imatinib dalspiegels, heb-
ben we in Hoofdstuk 3 een prospectieve opgezet om de systemische blootstelling aan 
imatinib te volgen over een mediane periode van 1 jaar. Omdat imatinib in hoge mate 
gemetaboliseerd wordt in de lever, was de secundaire doelstelling van deze studie de 
evaluatie van de eventuele metabole effecten van GIST levermetastasen op imatinib 
blootstelling. Alle farmacokinetische data werden geanalyseerd in een compartimenteel 
model, dat een significante neerwaartse trend liet zien in imatinib blootstelling gedu-
rende de het eerste kwartaal van de behandeling met daaropvolgend een plateaufase. 
Na 3 maanden behandeling is de blootstelling gedaald met ongeveer 30 procent. Wat 
betreft de secundaire doelstelling, werd een verwaarloosbaar effect van levermetasta-
sering gezien op de kinetiek van imatinib.
Omwille van de discrepantie tussen eerder gerapporteerde resultaten van imatinib in 
vitro transport assays en klinische studies, werd in Hoofdstuk 4 getracht om preklinische 
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bevinden rond een specifieke opnamepomp (OATP1A2) onmiddellijk te vertalen naar de 
kliniek. Opname van imatinib in cellen die het humane OATP1A2 of het ortholoog bij de 
rat (Oatp1a4) tot expressie brengen, was significant hoger dan in water-geïnjecteerde 
controlecellen. Daarenboven was imatinib opnametransport hoger in een zuur milieu 
zoals dat gevonden wordt in het proximale gedeelte van de darm, waar de expressie 
van OATP1A2 hoog is. Dit alles maakte OATP1A2 een goede kandidaat voor imatinib 
opnametransport in de darm. Om dit te vertalen naar de kliniek, hebben we een in-
teractiestudie en een farmacogenetische associatie-analyse uitgevoerd in patiënten 
behandeld met imatinib. Rosuvastatine liet een significante inhibitie zien van in vitro 
imatinib transport maar concomitante toediening van rosuvastatine en imatinib in GIST 
patiënten had geen effect op de steady-state farmacokinetiek. Daarenboven liet een 
allelische variatie in SLCO1A2 geen effect zien op imatinib plasmaconcentratie. Deze 
studie illustreert daarmee dat OATP1A2 waarschijnlijk weinig bijdraagt aan het absorp-
tieprofiel van imatinib in mensen. 
In Hoofdstuk 5 hebben we verder getracht de rol van leverdysfunctie op te helderen 
door biliaire secretie te kwantificeren in het geval van ernstige hepatische dysfunctie. 
Famacokinetische monsterafname en galverzameling gebeurden op dag 1, 5, 6 en 14. 
De belangrijkste bevinding van deze studie was dat de dosis imatinib die gesecreteerd 
werd in de gal, een fractie was van eerdere gerapporteerde bevindingen. Daarenboven 
was de verhouding van biliaire concentraties imatinib op de metaboliet CGP74588, om-
gekeerd. Dit wijst aan dat, hoewel biliaire secretie van imatinib gerelateerd lijkt te zijn 
aan leverdysfunctie, er geen belangrijke veranderingen gezien worden in de blootstel-
ling. Dit kan het gevolg zijn van adaptieve verschijnselen, waarbij de lage biologische 
beschikbaarheid en lage systemische klaring elkaar in evenwicht houden, wat resulteert 
in plasmaconcentraties binnen de normale range. 
Sunitinib studies
Het tweede deel van dit proefschrift is gewijd aan de inter-individuele variabiliteit in 
sunitinib pharmacodynamiek. Sunitinib is gericht tegen meerdere moleculaire doelen 
die betrokken zijn bij normale fysiologische processen. Sunitinib zal daarom, in tegen-
stelling tot imatinib, een breder toxisch profiel vertonen, dat zal leiden tot een dosisaan-
passing in ongeveer een derde van de patiënten. Daarnaast, wordt een grote variatie 
gezien in klinische respons en overleving. Een accurate voorspelling van de gepaste 
dosis sunitinib en/of voorspellen van de gepaste plaats van sunitinib in de sequentie 
van systemische behandelingenslijnen, zijn daarom hoogst relevant voor de individuele 
patiënt. 
In Hoofdstuk 6 en 7 hebben we dan ook potentiële genetische factoren geanalyseerd 
voor toxiciteit en overleving. Een interessante bevinding van deze analyses was dat de 
genetische factoren voor variatie in sunitinib-geïnduceerde toxiciteit of overleving, 
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voornamelijk gelokaliseerd waren in de farmacokinetische genen. Single nucleotide 
polymorfismen (SNPs) in genen die coderen voor effluxpompen (ABCB1 en ABCG2), 
leverenzymen (CYP3A5 en CYP1A1) en nucleaire receptoren (NR1I3) die betrokken zijn 
bij de regulatie van leverenzymen, bleken onafhankelijke factoren te zijn voor toxiciteit 
en overleving. Zo liet een multivariate analyse in patiënten met een uitgezaaid niercel-
carcinoom (mRCC) van het heldercellige subtype zien dat de progressievrije overleving 
significant beter was indien patiënten drager waren van een gunstig genetisch profiel in 
ABCB1, CYP3A5 en NR1I3 (13,1 versus 7,5 maanden). 
Hoge bloeddruk of hypertensie is gekende bijwerking van sunitinibtherapie. Eén 
derde van de patiënten, behandeld met sunitinib zal hypertensie ontwikkelen en 
ongeveer een derde van deze patiënten zal intensieve behandeling nodig hebben. In 
Hoofdstuk 8 hebben we dan ook geprobeerd om genetische factoren te identificeren 
voor bloeddrukstijging tijdens behandeling met sunitinib en om de potentiële predic-
tieve waarde van hypertensie voor overleving aan te tonen. Deze studie liet zien dat een 
haplotype in VEGFA (een gen dat codeert voor de ligand van het primaire therapeutische 
doel van sunitinib) en een SNP in eNOS (gen dat codeert voor een enzym betrokken 
bij bloeddrukregulatie) onafhankelijke factoren zijn voor ernstige hypertensie tijdens 
behandeling met sunitinib.  Wat betreft het secundaire doel van de studie, zagen we dat 
de algehele overleving in mRCC patiënten die hypertensie vertoonden tijdens behande-
ling met sunitinib meer dan 7 maanden langer was dan in patiënten zonder hypertensie. 
Zoals eerder gesteld, is sunitinib een geneesmiddel dat gericht is tegen meerdere ei-
witten die betrokken zijn bij diverse (patho)fysiologische processen. Onder deze doelen, 
is KIT betrokken bij de proliferatie en functionele activiteit van mestcellen, die betrokken 
zijn bij de pathofysiologie van allergische rhinitis of hooikoorts. In Hoofdstuk 9, wordt 
de inhibitie van KIT-activiteit in sunitinib-behandelde mRCC patiënten onderzocht als 
een potentiële therapeutische modaliteit bij inflammatoire processen zoals hooikoorts. 
Allergische reacties ontstaan wanneer een individu die gesensibiliseerd is voor een al-
lergeen, allergeen-specifieke immunoglobuline isotype E antilichamen (IgE) produceert 
en daaropvolgend opnieuw in aanraking komt met dit allergeen. Dit zal een activatie 
van de IgE-bindende mestcellen veroorzaken in het blootgestelde weefsel. De mestcel-
len zullen dan degranuleren wat een variëteit aan symptomen tot gevolg heeft. 
Tijdens onze observatie lieten mRCC patiënten die gekend waren met ernstige hooi-
koorts een complete afwezigheid van hooikoortssymptomen zien tijdens behandeling 
met sunitinib. Totale tryptase serumspiegels, die gebruikt worden als indicator van 
mestcelactiviteit en -aantal, waren onmeetbaar laag tijdens de gehele observatieperi-
ode van 3 maanden. Daarenboven werd in een tweede cohort van controlepatiënten 
gezien dat bij de meeste individuen tryptasespiegels significant daalden van normale 
waarden voor start van de behandeling naar onmeetbaar lage spiegels binnen twee 
behandelingscycli. Er werden geen significante veranderingen waargenomen in serum 
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IgE spiegels. De resolutie van hooikoortssymptomen tijdens behandeling met sunitinib 
is dus gecorreleerd aan een verlaagde mestcelactiviteit, meest waarschijnlijk door inhi-
bitie van KIT. 
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De bevindingen die in dit proefschrift beschreven staan, zijn het resultaat van klinisch 
onderzoek en dus het werk van vele mensen. In de eerste plaats dragen alle patiënten 
die, ondanks hun ernstige ziekte, deelnamen aan deze studies mijn dankbaarheid en 
bewondering.
Verder was dit werk niet mogelijk geweest zonder de dagelijkse inzet op zowel de klini-
sche afdelingen als in “ons” lab Translationele Farmacologie. Een aantal van de mensen die 
daar werken, wil ik graag in het bijzonder bedanken. 
Copromotor Dr. A.H.J. Mathijssen. Beste Ron, ik ben dankbaar voor de kans die je me 
bood om aan de medische wetenschap bij te dragen, toen ik als verdwaalde Belg op de 
Daniël den Hoed mee kwam kijken. Het lijkt al weer een eeuwigheid geleden toen we 
samen code geno samples uitzochten in het lab. Sinds die tijd heb ik een interessant 
parcours mogen afleggen met dit resultaat. 
Promotor Prof. Dr.  J. Verweij. Beste Jaap, dankzij jou zag ik hoe het was om op een 
internationaal niveau bezig te zijn. Een ervaring die ik koester.
Dr. W. Loos. Beste Walter, onze samenwerking is, samen met mijn waardering voor je, de 
afgelopen jaren alleen maar gegroeid. Ik wens je alle succes toe in de nieuwe uitdagingen 
die je tegemoet treed. Ing. P. de Bruijn. Beste Peter, je was een fijne collega. Dank voor de 
talloze keren dat je me vlot trok toen mijn labtechnische vaardigheden tekort schoten (of 
afwezig waren). Inge en Mei: ook jullie bijdrage aan het hier beschreven onderzoek was 
onmisbaar. Jullie zorgden steeds voor gezelligheid (en heerlijke koffie). Anne-Joy, Lisette, 
Jessica, Annemieke en Jacqueline: ik heb jullie als mede-promovendi zeer geapprecieerd. 
Vaak konden we informeel overleggen met elkaar of gezellig de batterijen opladen bij een 
bakje koffie. Dat zal ik zeker missen.
Per la dr.ssa Schiavon. Cara Gaia, desidero ringraziarti per tutto l’aiuto che hai dato alla 
stesura di questa tesi, in particolare per le splendide immagini e figure che hai prodotto. 
Ma soprattutto perchè sei un persona aperta ed entusiasta. Ti auguro il meglio a Londra.
Hooggeleerde leden van de promotiecommissie. U allen ben ik dankbaar voor uw 
bereidheid zitting te nemen in mijn commissie.
Beste Floris, al sinds onze studententijd ben je een constante. Na al die jaren heb je mij 
een oprechte vriendschap gegeven die over landgrenzen heen reikt. Hoewel we elkaar 
minder vaak zien, zowel door jouw als mijn drukke bestaan, hoeft een ontmoeting maar 
luttele seconden te duren om terug dat ongedwongen vertrouwde gevoel te op te wek-
ken. Je aanwezigheid vandaag als paranimf is voor mij een formele bevestiging van onze 
hechte vriendschap.
Beste Thieu, ook jouw betrokkenheid laat zich niet tegenhouden door enige landgren-
zen. Je staat steeds klaar voor advies en hulp en hoewel je kennis van de geneeskunst niet 
al te ver reikt, wou ik je toch graag als steunpilaar naast me op deze bijzondere dag.
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Lieve moeder, jij hebt al mijn gehele leven met heel je hart van me gehouden. Dat 
heeft me vaak gesterkt en soms ook wel zorgen gegeven toen het met jou minder goed 
ging. Dit proefschrift is mede aan jou opgedragen.
Lieve Janneke, al meer dan tien jaar delen we lief en leed, ben je mijn steun en toever-
laat. Dit proefschrift was er wellicht niet geweest zonder jouw toewijding. Lieve Kamiel, 
Sjors en Kaatje, sinds jullie er zijn, verveel ik me geen dag. Ik kan me geen zinvol leven 
meer voorstellen zonder jullie. 
En dan nu: NUNC EST BIBENDUM!
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